Bicyclic 5-alkylidene-penems as beta lactamases inhibitors

ABSTRACT

The present invention provides a compound of formula 1, pharmaceutical compositions and the use thereof for the treatment of bacterial infection or disease in a patient in need thereof.

[0001] This application claims priority from copending provisionalapplication Serial No. 60/377,052, filed May 1, 2002, the entiredisclosure of which is hereby incorporated by reference.

FIELD OF INVENTION

[0002] This invention relates to certain bicyclic 6-alkylidene penemswhich act as a broad spectrum β-lactamase inhibitors. β-Lactamaseshydrolyze β-lactam antibiotics, and as such serve as the primary causeof bacterial resistance. The compounds of the present invention whencombined with β-lactam antibiotics will provide an effective treatmentagainst life threatening bacterial infections.

BACKGROUND OF THE INVENTION

[0003] Penicillins and cephalosporins are the most frequently and widelyused α-lactam antibiotics in the clinic. However, the development ofresistance to β-lactam antibiotics by different pathogens has had adamaging effect on maintaining the effective treatment of bacterialinfections. (Coleman, K. Expert Opin. Invest. Drugs 1995, 4, 693;Sutherland, R. Infection 1995, 23 (4) 191; Bush, K, Cur. Pharm. Design1999, 5, 839-845) The most significant known mechanism related to thedevelopment of bacterial resistance to the β-lactam antibiotics is theproduction of class-A, class-B and class-C serine β-lactamases. Theseenzymes degrade the β-lactam antibiotics, resulting in the loss ofantibacterial activity. Class-A enzymes preferentially hydrolyzepenicillins where as Class-C lactamases have a substrate profilefavoring cephalosporin hydrolysis. (Bush, K.; Jacoby, G. A.; Medeiros,A. A. Antimicrob. Agents Chemother. 1995, 39, 1211). To date over 250different β-lactamases have been reported (Payne, D. J,: Du, W andBateson, J. H. Exp. Opin. Invest. Drugs 2000, 247.) and there is a needfor a new generation of broad spectrum β-lactamase inhibitors. Bacterialresistance to these antibiotics could be greatly reduced byadministering the β-lactam antibiotic in combination with a compoundwhich inhibits these enzymes.

[0004] The commercially available β-lactamase inhibitors such asclavulanic acid, sulbactam and tazobactam are all effective againstclass-A producing pathogens. Clavulanic acid is clinically used incombination with amoxicillin and ticarcillin; similarly sulbactam withampicillin and tazobactam with piperacillin. However, these compoundsare ineffective against class C producing organisms. The mechanism ofinactivation of class-A β-lactamases (such as PCI and TEM-1) has beenelucidated. (Bush, K.; Antimicrob. Agents Chemother. 1993, 37, 851;Yang, Y.; Janota, K.; Tabei, K.; Huang, N.; Seigal, M. M.; Lin, Y. I.;Rasmussen, B. A. and Shlaes, D. M. J. Biol. Chem. 2000, 35,26674-26682).

[0005] In 1981, the Beecham group disclosed 6-alkylidine penems ofgeneral structure 1 as inhibitors of β-lactamases. [N. F. Osborne, U.S.Pat. No. 4,485,110 (1984); N. F. Osborne, Eur. Pat. Appl. 81 301683.9,1981]

[0006] R₁ and R₂ are independently hydrogen or a C₁₋₁₀ hydrocarbon groupor mono heterocyclic, and R₃ represents a hydrogen or an organic group.Subsequently, the same group disclosed compounds of the general formula1, wherein R₁ comprises a 1,2,3-triazole moiety. [N. F. Osborne, Eur.Pat. Appl. 84301255.0]. The following year, the same group filed 3patents of the structure 1, wherein R₁ is an optionally substituted sixmembered or five membered mono aromatic ring system. [N. F. Osborne,Eur. Pat. Appl. 85100520.7; Eur. Pat. Appl. 85100521.5; Eur. Pat. Appl.85300456-2]. European patent applications No. 86305585.1 discloses thesynthesis and the utility of(Z)-6-(1−methyl-1,2,3-triazol-4-ylmethylene)-penem-3-carboxylate 2 as aclass-A and class-C β-lactamase inhibitor.

[0007] Eur. Pat. Appl. 86305584.4 disclosed the preparation of compoundsof general formula 1, wherein R₁=non-aromatic heterocyclic group and aPCT application [N. J. Broom; P. D. Edwards, N. F. Osborne and S.Coulton PCT WO 87/00525] disclosing R₁=fused bicyclic hetero-aromaticgroup was published. Similarly patent applications [N. J. Broom; G.Brooks; S. Coulton, Eur. Pat. Appl. 88311786.3; N. J. Broom; G. Brooks;B. P. Clarke, Eur. Pat. Appl. 88311787.1) described the preparation anduse of compounds of general structure 1, wherein R₁ is a substitutedfive membered hetero-aromatic ring. A process for the preparation ofcompounds of general formula 1 has been described by Coulton, et al [S.Coulton; J. B. Harbridge; N. F. Osborne and G. Walker Eur. Pat. Appl. No87300193.7]

[0008] In the year 1993, Beecham disclosed [A. V. Stachulski and R.walker, PCT WO 93/03042] the preparation and the use of compounds ofgeneral formula 1, in which R₁═(C₁₋₆) alkyl and R₂═CH₂X or COY whereinX=halogen or CONR₂.

[0009] During the last decade three patents have been filed by Beechamdescribing compounds of general formula 3. [N. J. Broom; F. P.Harrington, PCT WO 94/10178; K. Coleman; J. E. Neale PCT WO 95/28935; K.Coleman; J. E. Neale PCT WO 95/17184] wherein R₁=hydrogen or an organicgroup, and R₄ and R₅ may be both hydrogen or one or more substituentsreplacing hydrogen atoms in the ring system shown below.

DETAILED DESCRIPTION OF THE INVENTION

[0010] The present invention relates to novel, low molecular weightbroad spectrum β-lactam compounds, and in particular to a class ofbicyclic heteroaryl substituted 6-alkylidene penems which haveβ-lactamase inhibitory and antibacteria properties.

[0011] The compounds are therefore useful in the treatment ofantibacterial infections in humans or animals, either alone or incombination with other antibiotics.

[0012] In accordance with the present invention there are providedcompounds of general formula I or a pharmaceutically acceptable salt orin vivo hydrolyzable ester R₅ thereof:

[0013] and preferred compounds of the formula:

[0014] wherein:

[0015] One of A and B denotes hydrogen and the other an optionallysubstituted fused bicyclic heteroaryl group. The expression ‘fusedbicyclic heteroaryl group’ is used in the specification and claims tomean:

[0016] A group comprising two fused rings in which one has aromaticcharacter [i.e. Huckel's rule (4n+2)] and the other ring isnon-aromatic;

[0017] The fused bicyclic heteroaryl group contains one to sixheteroatoms selected from the group O, S, N and N—R₁;

[0018] The fused bicyclic heteroaryl group is bonded to the remainder ofthe molecule through a carbon atom in the aromatic ring as shown in theformula I;

[0019] The aromatic ring of the fused bicyclic heteroaryl group containsfive or six ring atoms (including bridgehead atoms) selected from CR₂,N, O, S or N—R₁. The aromatic ring of the fused bicyclic heteroarylgroup contains 0 to 3 heteroatoms selected from the group O, S, N andN—R₁;

[0020] The non-aromatic ring of the fused bicyclic heteroaryl groupcontains five to eight ring atoms (including bridgehead atoms) selectedfrom CR₄R₄, N, N—R₁, O, S(O)_(n) where n=0-2. The non-aromatic ring ofthe fused bicyclic heteroaryl group contains 0 to 4 heteroatoms selectedfrom N, N—R₁, O or S(O)_(n) where n=0 to 2.

[0021] X is O or S, preferably S;

[0022] R₅ is H, an in vivo hydrolyzable ester such as C1-C6 alkyl, C5-C6cycloalkyl, CHR₃OCOC1-C6 or salts such as Na, K, Ca; preferably R₅ is Hor a salt;

[0023] R₁ is H, optionally substituted —C1-C6 alkyl, optionallysubstituted -aryl, optionally substituted -heteroaryl or mono orbicyclic saturated heterocycles, optionally substituted —C3-C7cycloalkyl, optionally substituted —C3-C6 alkenyl, optionallysubstituted —C3-C6 alkynyl with the proviso that both the double bondand the triple bond should not be present at the carbon atom which isdirectly linked to N; optionally substituted —C1-C6 per fluoro alkyl,—S(O)_(p) optionally substituted alkyl or aryl where p is 2, optionallysubstituted —C=Oheteroaryl, optionally substituted —C=Oaryl, optionallysubstituted —C═O(C1-C6) alkyl, optionally substituted —C═O(C3-C6)cycloalkyl, optionally substituted —C═O mono or bicyclic saturatedheterocycles, optionally substituted C1-C6 alkyl aryl, optionallysubstituted C1-C6 alkyl heteroaryl, optionally substituted aryl-C1-C6alkyl, optionally substituted heteroaryl-C1-C6 alkyl, optionallysubstituted C1-C6 alkyl mono or bicyclic saturated heterocycles,optionally substituted arylalkenyl of 8 to 16 carbon atoms, —CONR₆R₇,—SO₂NR₆R₇, optionally substituted arylalkyloxyalkyl, optionallysubstituted -alkyl-O-alkyl-aryl, optionally substituted-alkyl-O-alkyl-heteroaryl, optionally substituted aryloxyalkyl,optionally substituted heteroaryloxyalkyl, optionally substitutedaryloxyaryl, optionally substituted aryloxyheteroaryl, optionallysubstituted C1-C6 alkyl aryloxyaryl, optionally substituted C1-C6 alkylaryloxyheteroaryl, optionally substituted alkyl aryloxy alkylamines,optionally substituted alkoxy carbonyl, optionally substituted aryloxycarbonyl, optionally substituted heteroaryloxy carbonyl. Preferred R₁groups are H, optionally substituted alkyl, optionally substituted aryl,—C═O(C1-C6)alkyl, C3-C6alkenyl, C3-C6alkynyl, optionally substitutedcycloalkyl, SO₂alkyl, SO₂aryl, optionally substituted heterocycles,—CONR₆R₇, and optionally substituted heteroaryl.

[0024] R₂ is hydrogen, optionally substituted C1-C6 alkyl, optionallysubstituted C2-C6 alkenyl having 1 to 2 double bonds, optionallysubstituted C2-C6 alkynyl having 1 to 2 triple bonds, halogen, cyano,N—R₆R₇, optionally substituted C1-C6 alkoxy, hydroxy; optionallysubstituted aryl, optionally substituted heteroaryl, COOR₆, optionallysubstituted alkyl aryloxy alkylamines, optionally substituted aryloxy,optionally substituted heteroaryloxy, optionally substituted C3-C6alkenyloxy, optionally substituted C3-C6 alkynyloxy, C1-C6alkylamino-C1-C6 alkoxy, alkylene dioxy, optionally substitutedaryloxy-C1-C6 alkyl amine, C1-C6 perfluoro alkyl, S(O)_(q)—optionallysubstituted C1-C6 akyl, S(O)_(q)-optionally substituted aryl where q is0, 1 or 2, CONR₆R₇, guanidino or cyclic guanidino, optionallysubstituted C1-C6 alkylaryl, optionally substituted arylalkyl,optionally substituted C1-C6 alkylheteroaryl, optionally substitutedheteroaryl-C1-C6 alkyl, optionally substituted C1-C6 alkyl mono orbicyclic saturated heterocycles, optionally substituted arylalkenyl of 8to 16 carbon atoms, SO₂NR₆R₇, optionally substituted arylalkyloxyalkyl,optionally substituted aryloxyalkyl, optionally substitutedheteroaryloxyalkyl, optionally substituted aryloxyaryl, optionallysubstituted aryloxyheteroaryl, substituted heteroaryloxyaryl, optionallysubstituted C1-C6alkyl aryloxyaryl, optionally substituted C1-C6alkylaryloxyheteroaryl, optionally substituted aryloxyalkyl, optionallysubstituted heteroaryloxyalkyl, optionally substitutedalkylaryloxyalkylamines. Preferred R₂ groups are H, optionallysubstituted alkyl, optionally substituted alkoxy, optionally substitutedheteroaryl, halogen, CN, hydroxy, optionally substituted heterocycle,—CONR₆R₇, COOR₆, optionally substituted aryl, S(O)_(q)-alkyl, andS(O)_(q)-aryl.

[0025] R₃ is hydrogen, C₁-C₆ alkyl, C₅-C₆ cycloalkyl, optionallysubstituted aryl, optionally substituted heteroaryl; preferred R₃ groupsare H or C1-C6 alkyl;

[0026] R₄ is H, optionally substituted C1-C6 alkyl, one of R₄ is OH,C1-C6 alkoxy, —S—C1-C₆ alkyl, COOR₆, —NR₆R₇, —CONR₆R₇; or R₄R₄ maytogether be ═O or R₄R₄ together with the carbon to which they areattached may form a spiro system of five to eight members with orwithout the presence of heteroatoms selected N, O, S═(O)n (where n=0 to2), N—R₁; preferred R₄ groups are H, C1-C6 alkyl, NR₆R₇ or R₄R₄ togetherwith the carbon to which they are attached may form a spiro system offive to eight members with or without the presence of heteroatoms;

[0027] R₆ and R₇ are independently H, optionally substituted C1-C6alkyl, optionally substituted aryl, optionally substituted heteroaryl,optionally substituted C1-C6 alkyl aryl, optionally substitutedarylalkyl, optionally substituted heteroarylalkyl, optionallysubstituted C1-C6 alkyl heteroaryl, R₆ and R₇ can be together to form a3-7 membered saturated ring system optionally having one or twoheteroatoms such as N—R₁, O, S═(O)_(n) n=0-2. Preferred R₆ and R₇ groupsare H, C1-C6 alkyl, arylalkyl, heteroarylalkyl or R₆ and R₇ togetherforming a 3-7 membered saturated ring system optionally having one ortwo heteroatoms.

[0028] Chemical Definitions

[0029] The term alkyl means both straight and branched chain alkylmoieties of 1-12 carbons, preferably of 1-6 carbon atoms.

[0030] The term alkenyl means both straight and branched alkenylmoieties of 2-8 carbon atoms containing at least one double bond, and notriple bond, preferably the alkenyl moiety has 1 or two double bonds.Such alkenyl moieties may exist in the E or Z conformations; thecompounds of this invention include both conformations. In the case ofalkenyl, hetero atoms such as O, S or N—R₁, should not be present on thecarbon that is bonded to a double bond;

[0031] The term alkynyl includes both straight chain and branchedalkynyl moieties containing 2-6 carbon atoms containing at least onetriple bond, preferably the alkynyl moiety has one or two triple bonds.In the case of alkynyl, hetero atoms such as O, S or N—R₁, should not bepresent on the carbon that is bonded to a double or triple bond;

[0032] The term cycloalkyl refers to a alicyclic hydrocarbon grouphaving 3-7 carbon atoms. The term perfluoroalkyl is used herein to referto both straight- and branched-chain saturated aliphatic hydrocarbongroups having at least one carbon atom and two or more fluorine atoms.Examples include CF₃, CH₂CF₃, CF₂CF₃ and CH(CF₃)₂. The term halogen isdefined as Cl, Br, F, and 1.

[0033] If alkyl, alkenyl, alkynyl, or cycloalkyl is “optionallysubstituted”, one or two of the following are possible substituents:nitro, -aryl, -heteroaryl, alkoxycarbonyl-, -alkoxy, -alkoxy-alkyl,alkyl-O—C2-C4alkyl-O—, -cyano, -halogen, -hydroxy, —N—R₆R₇, —COOH,—COO-alkyl, -trifluoromethyl, -trifluoromethoxy, arylalkyl, alkylaryl,R₆R₇N-alkyl-, HO—C1-C6-alkyl-, alkoxyalkyl-, alkyl-S—, —SO₂N—R₆R₇,—SO₂NHR₆, —CO₂H, CONR₆R₇, aryl-O—, heteroaryl-O—, —S(O)s-aryl (wheres=0−2), -alkyl-O-alkyl-NR₆R₇, -alkyl-aryl-O-alkyl-N-R₆R₇, C1-C6alkyl,alkenyl, alkynyl, cycloalkyl, alkoxy-alkyl-O—, R₆R₇N-alkyl-, and—S(O)-heteroaryl (where s=0-2); Preferred substitutents for alkyl,alkenyl, alkynyl, and cycloalkyl include: halogen, nitro, aryl,heteroaryl, —COOH, —COO-alkyl, alkoxycarbonyl-, alkoxy, -alkoxy-alkyl,-cyano, hydroxy, and —N—R₆R₇.

[0034] Aryl is defined as an aromatic hydrocarbon moiety selected fromthe group: phenyl, α-naphthyl, β-naphthyl, biphenyl, anthryl,tetrahydronaphthyl, fluorenyl, indanyl, biphenylenyl, acenaphthenyl,groups. The preferred aryl groups are phenyl and biphenyl.

[0035] Heteroaryl is defined as a aromatic heterocyclic ring system(monocyclic or bicyclic) where the heteroaryl moieties are selectedfrom: (1) furan, thiophene, indole, azaindole, oxazole, thiazole,isoxazole, isothiazole, imidazole, N-methylimidazole, pyridine,pyrimidine, pyrazine, pyrrole, N-methylpyrrole, pyrazole,N-methylpyrazole, 1,3,4-oxadiazole, 1,2,4-triazole,1-methyl-1,2,4-triazole, 1H-tetrazole, 1-methyltetrazole, benzoxazole,benzothiazole, benzofuran, benzisoxazole, benzimidazole,N-methylbenzimidazole, azabenzimidazole, indazole, quinazoline,quinoline, and isoquinoline; (2) a bicyclic aromatic heterocycle where aphenyl, pyridine, pyrimidine or pyridizine ring is: (a) fused to a6-membered aromatic (unsaturated) heterocyclic ring having one nitrogenatom; (b) fused to a 5 or 6-membered aromatic (unsaturated) heterocyclicring having two nitrogen atoms; (c) fused to a 5-membered aromatic(unsaturated) heterocyclic ring having one nitrogen atom together witheither one oxygen or one sulfur atom; or (d) fused to a 5-memberedaromatic (unsaturated) heterocyclic ring having one heteroatom selectedfrom O, N or S. Preferred heteroaryl groups are furan, oxazole,thiazole, isoxazole, isothiazole, imidazole, N-methylimidazole,pyridine, pyrimidine, pyrazine, pyrrole, N-methylpyrrole, pyrazole,N-methylpyrazole, 1,3,4-oxadiazole, 1,2,4-triazole,1-methyl-1,2,4-triazole, 1H-tetrazole, 1-methyltetrazole, quinoline,isoquinoline, and naphthyridine.

[0036] If aryl or heteroaryl is ‘optionally substituted’, one or two ofthe following are possible substituents: nitro, -aryl, -heteroaryl,alkoxycarbonyl-, -alkoxy, -alkoxy-alkyl, alkyl-O—C2-C4alkyl-O—, -cyano,-halogen, -hydroxy, —N—R₆R₇, -trifluoromethyl, -trifluoromethoxy,arylalkyl, alkylaryl, R₆R₇N-alkyl-, HO—C1-C6-alkyl-, alkoxyalkyl-,alkyl-S—, —SO₂N—R₆R₇, —SO₂NHR₆, —CO₂H, CONR₆R₇, aryl-O—, heteroaryl-O—,—S(O)_(s)-aryl (where s=0-2), -alkyl-O-alkyl-NR₆R₇,-alkyl-aryl-O-alkyl-N-R₆R₇, C1-C6alkyl, alkenyl, alkynyl, cycloalkyl,alkoxy-alkyl-O—, R₆R₇N-alkyl-, and —S(O)s-heteroaryl (where s=0-2);Preferred substituents for aryl and heteroaryl include: alkyl, halogen,—N—R₆R₇, trifluoromethyl, -trifluoromethoxy, arylalkyl, and alkylaryl.

[0037] Arylalkyl is defined as Aryl-C₁-C₆alky---; Arylalkyl moietiesinclude benzyl, 1-phenylethyl, 2-phenylethyl, 3-phenylpropyl,2-phenylpropyl and the like. The term ‘optionally substituted’ refers tounsubstituted or substituted with 1 or 2 substituents on the alkyl oraryl moiety as defined above.

[0038] Alkylaryl is defined as C1-C6alkyl-aryl-. The term ‘optionallysubstituted’ refers to unsubstituted or substituted with 1 or 2substituents on the aryl or alkyl moiety as defined above.Heteroaryl-C1-C6-alkyl is defined as a heteroaryl substituted alkylmoiety wherein the alkyl chain is 1-6 carbon atoms (straight orbranched). Alkyl heteroaryl moieties include Heteroaryl-(CH₂)₁₋₆— andthe like. The term ‘optionally substituted’ refers to unsubstituted orsubstituted with 1 or 2 substituents on the alkyl or heteroaryl moietyas defined above;

[0039] C1-C6 alkylheteroaryl is defined an alkyl chain of 1-6 carbonatoms (straight or branched) attached to a heteroaryl moiety, which isbonded to the rest of the molecule. Ex. C1-C6-alkyl-Heteroaryl--. Theterm ‘optionally substituted’ refers to unsubstituted or substitutedwith 1 or 2 substituents on the alkyl or heteroaryl moiety as definedabove;

[0040] Saturated or partially saturated heterocycles groups are definedas heterocyclic rings selected from the moieties; aziridinyl,azetidinyl, 1,4-dioxanyl, hexahydroazepinyl, piperazinyl, piperidinyl,pyrrolidinyl, morpholinyl, thiomorpholinyl, dihydrobenzimidazolyl,dihydrobenzofuranyl, dihydrobenzothienyl, dihydrobenzoxazolyl,dihydrofuranyl, dihydroimidazolyl, dihydroindolyl, dihydroisooxazolyl,dihydroisothiazolyl, dihydrooxadiazolyl, dihydrooxazolyl,dihydropyrrazinyl, dihydropyrazolyl, dihydropyridinyl,dihydropyrimidinyl, dihydropyrrolyl, dihydroquinolinyl,dihydrotetrazolyl, dihydrothiadiazolyl, dihydrothiazolyl,dihydrothienyl, dihydrotriazolyl, dihydroazetidinyl,dihydro-1,4-dioxanyl, tetrahydrofuranyl, tetrahydrothienyl,tetrahydroquinolinyl, and tetrahydroisoquinolinyl. Preferred saturatedor partially saturated heterocycles are aziridinyl, azetidinyl,1,4-dioxanyl, hexahydroazepinyl, piperazinyl, piperidinyl, pyrrolidinyl,morpholinyl, thiomorpholinyl, tetrahydroquinolinyl,tetrahydroisoquinolinyl, dihydroimidazolyl, and dihydroisooxazolyl.

[0041] C1-C6 alkyl mono or bicyclic saturated or partially saturatedheterocycles is defined as an alkyl group (straight or branched) ofC1-C6 attached to a heterocycles (which is defined before) through acarbon atom or a nitrogen atom and the other end of the alkyl chainattached to the rest of the molecule. The terms ‘optionally substituted’refers to unsubstituted or substituted with 1 or 2 substituents presenton the alkyl or heterocyclic portion of the molecule, as defined before;

[0042] Arylalkyloxyalkyl is defined as Aryl-C1-C6alkyl-O—C1-C6alkyl---.The term ‘optionally substituted’ refers to unsubstituted or substitutedwith 1 or 2 substituents present on the alkyl and/or aryl portions asdefined before;

[0043] Alkyloxyalkyl is defined as C1-C6 alkyl-O—C1-C6alkyl---. The term‘optionally substituted’ refers to unsubstituted or substituted with 1or 2 substituents present at the alkyl moiety as defined before;

[0044] Aryloxyalkyl is defined as Aryl-O—C1-C6 alkyl---. The term‘optionally substituted’ refers to unsubstituted or substituted with 1or 2 substituents present at the alkyl or aryl moiety as defined before;

[0045] Heteroarylalkyloxyalkyl is defined asHeteroaryl-C1-C6alkyl-O—C1-C6alkyl---. The term ‘optionally substituted’refers to unsubstituted or substituted with 1 or 2 substituents presenton the alkyl or heteroaryl moiety as defined before;

[0046] Aryloxyaryl is defined as Aryl-O—Ary---. The term ‘optionallysubstituted’ refers to unsubstituted or substituted withl or 2substituents present on the aryl moiety as defined before;

[0047] Aryloxyheteroaryl is defined as Aryl-O-Heteroaryl- or-Aryl-O-Heteroaryl; In this definition either the aryl moiety or theheteroaryl moiety can be attached to the remaining portion of themolecule; The term ‘optionally substituted’ refers to unsubstituted orsubstituted withl or 2 substituents present on the aryl moiety or on theheteroaryl moiety as defined before;

[0048] Alkyl aryloxyaryl is defined as Aryl-O—Aryl-C1-C6alkyl----; Theterm ‘optionally substituted’ refers to unsubstituted or substitutedwith 1 or 2 substituents present at the aryl moiety as defined before;

[0049] Alkylaryloxyheteroaryl is defined asHeteroaryl-O—Aryl-C1-C6alkyl--; The term ‘optionally substituted’ refersto unsubstituted or substituted with 1 or 2 substituents present on thearyl moiety or on the hetroaryl moiety as defined before;

[0050] Alkylaryloxyalkylamine is defined asR₆R₇N—C1-C6alkyl-O—Aryl-C1-C6alky---; The terms ‘optionally substituted’refers to unsubstituted or substituted with 1 or 2 substituents presenton the alkyl or aryl moiety as defined before; R₆ and R₇ as definedbefore;

[0051] Alkoxycarbonyl is defined as C1-C6alkyl-O—C═O—; The term‘optionally substituted’ refers to unsubstituted or substituted with 1or 2 substituents present on the alkyl portion of the alkoxy moiety asdefined before;

[0052] Aryloxycarbonyl is defined as Aryl-O—C═O—; The term ‘optionallysubstituted’ refers to unsubstituted or substituted with 1 or 2substituents present at the aryl moiety as defined before;

[0053] Heteroaryloxy carbonyl is defined as Heteroaryl-O—C═O—; The term‘optionally substituted’ refers to unsubstituted or substituted with 1or 2 substituents present at the heteroaryl moiety as defined before;

[0054] Alkoxy is defined as C1-C6alkyl-O—; The terms ‘optionallysubstituted’ refers to unsubstituted or substituted with 1 or 2substituents present at the alkyl moiety as defined before;

[0055] Aryloxy is defined as Aryl-O—; The term ‘optionally substituted’refers to unsubstituted or substituted with 1 or 2 substituents presentat the aryl moiety as defined before;

[0056] Heteroaryloxy is defined as Heteroaryl-O—; The term ‘optionallysubstituted’ refers to unsubstituted or substituted with 1 or 2substituents present at the heteroaryl moiety as defined before;

[0057] Alkenyloxy is defined as C3-C6 alkene-O—; Example allyl-O—,bute-2-ene-O like moieties; The term ‘optionally substituted’ refers tounsubstituted or substituted with 1 or 2 substituents present at thealkene moiety as defined before, with the proviso that no hetero atomsuch as O, S or N—R₁, is present on the carbon atom, which is attachedto a double bond;

[0058] Alkynyloxy is defined as C₃-C6alkyne-O—; Example CH triple bondC—CH₂—O— like moieties; The term ‘optionally substituted’ refers tounsubstituted or substituted with 1 or 2 substituents present at thealkyne moiety as defined before, with the proviso that no hetero atomsuch as O, S or N—R₁, is present on a carbon atom which is attached to adouble or triple bond;

[0059] Alkylaminoalkoxy is defined as R₆R₇N—C₁-C₆-alkyl-O—C₁-C₆-alky-,where the terminal alkyl group attached to the oxygen is connected tothe rest of the molecule; The terms R₆ and R₇ are defined above; Theterm ‘optionally substituted’ refers to unsubstituted or substitutedwith 1 or 2 substituents present at the alkyl moiety as defined before;

[0060] Alkylenedioxy is defined as —O—CH2—O— or —O—(CH2)₂—O—;

[0061] Aryloxyalkylamine is defined as R₆R₇N—C₁-C₆-alkyl-O-Aryl--, wherethe aryl is attached to the rest of the molecule; The term ‘optionallysubstituted’ refers to unsubstituted or substituted with 1 or 2substituents present at the alkyl or aryl moiety as defined before;

[0062] Arylalkenyl is defined as Aryl-C2-C8alkene--, with the provisothat no hetero atom such as O, S or N—R₁, is present on the carbon atom,which is attached to a double bond; The term ‘optionally substituted’refers to unsubstituted or substituted with 1 or 2 substituents presenton the alkene or aryl moiety as defined before;

[0063] Heteroaryloxyalkyl is defined as Heteroaryl-O—C1-C6alky---; Theterm ‘optionally substituted’ refers to unsubstituted or substitutedwith 1 or 2 substituents present at the heteroaryl moiety as definedbefore;

[0064] Heteroaryloxyaryl is defined as Heteroaryl-O-aryl---, where thearyl moiety is attached to the rest of the molecule; The term‘optionally substituted’ refers to unsubstituted or substituted with 1or 2 substituents present at the heteroaryl moiety or the aryl moiety asdefined before;

[0065] Alkoxy, alkoxyalkyl, alkoxyalkyloxy and alkylthioalkyloxy aremoieties wherein the alkyl chain is 1-6 carbon atoms (straight orbranched). Aryloxy, heteroaryloxy, arylthio and heteroarylthio aremoieties wherein the aryl and heteroaryl groups are as herein beforedefined. Arylalkyloxy, heteroarylalkyloxy, arylalkylthio andheteroarylalkylthio are moieties wherein the aryl and heteroaryl groupsare as herein before defined and wherein the alkyl chain is 1-6 carbons(straight or branched).

[0066] Aryloxyalkyl, heteroaryloxyalkyl, aryloxyalkyloxy andheteroaryloxyalkyloxy are substituents wherein the alkyl radical is 1-6carbon atoms. The terms monoalkylamino and dialkylamino refer tomoieties with one or two alkyl groups wherein the alkyl chain is 1-6carbons and the groups may be the same or different. The termsmonoalkylaminoalkyl and dialkylaminoalkyl refer to monoalkylamino anddialkylamino moieties with one or two alkyl groups (the same ordifferent) bonded to the nitrogen atom which is attached to an alkylgroup of 1-3 carbon atoms. Examples of fused bicyclic heteroaryl groupsare optionally substituted ring systems such as one of the following:

[0067] 4,5,6,7-tetrahydrothieno[3,2-c]pyridine, optionally substitutedby e.g., arylalkyl such as benzyl; by alkoxyarylalkyl such as4-methoxybenzyl; by C1-C6alkyl such as methyl; by heteroarylalkyl suchas pyridin-3-ylmethyl; by arylalkylCO— such as phenylacetyl; orheteroarylCO— such as pyridin-3-ylcarbonyl; e.g. by alkylCO—such asacetyl;

[0068] 5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine, optionally substitutede.g., by C1-C6alkyl such as methyl;

[0069] 5,6-dihydro-8H-imidazo[2,1-c][1,4]thiazine;

[0070] 6,7-Dihydro-5H-pyrrolo[1,2-a]imidazole

[0071] 5,6-Dihydro-8H-imidazo[2,1-c][1,4]oxazine

[0072] 5,6-Dihydro-4H-pyrrolo[1,2-b]pyrazole4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine

[0073] 6-oxo-5,6,7,8-tetrahydro-imidazo[1,2-a]pyrazine, optionallysubstituted e.g., by C1-C6alkyl such as methyl;

[0074] 6,7-Dihydro-4H-pyrazolo[5,1-c][1,4]thiazine;

[0075] 4H-5-thia-1,6a-diazapentalene;

[0076] 7H-Imidazo[1,2-c]thiazole;

[0077] 4-oxo-6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazine;

[0078] 6,7-Dihydro-4H-thieno[3,2-c]pyran;

[0079] 6,7-Dihydro-4H-thieno[3,2-c]thiopyran;

[0080] 6,7-dihydro-4H-thieno[3,2-c]pyridine, optionally substituted byC2-C7alkoxycarbonyl;

[0081] 6,7,8,9-tetrahydro-5H-imidazo[1,2-a]azepine;

[0082] 5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine, optionally substitutedby arylalkyl such as benzyl;

[0083] 5,5-Dioxo-4,5,6,7-tetrahydro-5λ⁶-pyrazolo[5,1-c][1,4]thiazine;

[0084] 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine;

[0085] 5,6-Dihydro-4H-cyclopenta[b]furan;

[0086] 4,5-Dihydro-6-thia-1,7a-diazaindene;

[0087] 5,6-Dihydro-8-H-imidazo[2,1-c][1,4]thiazine;

[0088] 4H-5-thia-1,6a-diazapentalene;

[0089] 2,3-Dihydropyrazolo[5,1-b]thiazole;

[0090] 2,3-Dihydropyrazolo[5,1-b]oxazole;

[0091] 6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazine;

[0092] 6,7-5H-Dihydropyrazolo[5,1-b]oxazine; and

[0093] 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine optionally substituted,e.g, by alkoxyalkylCO— such as 2-methoxyacetyl; or by alkyloxyalkylCO—such as methoxyacetyl.

[0094] Examples of bicyclic heteroarylgroup:

[0095] In formula 1-A Z1, Z2 and Z3 are independently CR₂, N, O, S orN—R₁, and one of Z1-Z3 is carbon and is bonded to the remainder of themolecule as shown in formula I. When one of Z's is CR₂ the other two Zscan be either two N or one N and O, S, N—R₁, in any combinations without disrupting the aromaticity; when two Z,s=CR₂ the other Z can beoptionally selected from one N, O, S or N—R₁, in any combination without disrupting the aromaticity;

[0096] W₁, W₂ and W₃ are independently CR₄R₄, S, SO, SO₂, O, N—R₁, C═O;with the proviso that no S—S or O—O or S-0 bond formation can occur toform the saturated ring system; t=1 to 4.

[0097] In formula 1-B Z1, Z2 and Z3 are independently CR₂, N, O, S orN—R₁ and one of Z1-Z3 is carbon and is bonded to the remainder of themolecule as shown in formula I.

[0098] When one of Z's=CR₂, then the other two Z's can be independentlyCR₂, N, O, S or N—R₁ in any combinations with out disrupting thearomaticity; When two Z's=N, then the other carbon in the ring is bondedto the penem portion of the molecule as shown in formula I.

[0099] W₁, W₂ and W₃ are independently CR₄R₄, S, SO, SO₂, O, N—R₁,

[0100] t=1 to 4;

[0101] Y₁ and Y₂═N or C; with the proviso that when the aromaticheterocycle is imidazole, the saturated ring may not contain a Sadjacent to the bridgehead carbon.

[0102] In formula 1-C Z1, Z2, Z3 and Z4 are independently CR₂ or N andone of Z1-Z4 is carbon and is bonded to the remainder of the molecule.

[0103] W₁, W₂ and W₃ are independently CR₄R₄, S, SO, SO₂, O, or N—R₁;with the proviso that no S—S or O—O or S—O bond formation can occur toform the saturated ring system; t=1 to 4.

[0104] Y₁ and Y₂ are independently C or N.

[0105] The more preferred embodiment of the formula 1-A:

[0106] 1. t=1 to 3.

[0107] 2. In formula 1-A Z1 is N, S, N—R₁ or O and one of Z2 or Z3 isCR₂ and the other of Z2 or Z3 is carbon and is bonded to the remainderof the molecule as shown in formula I.

[0108] 3. In formula 1-A Z3 is N, S, N—R₁, or O and one of Z2 or Z1 isCR₂ and the other of Z2 or Z1 is carbon and is bonded to the remainderof the molecule as shown in formula I.

[0109] 4. In formula 1-A Z2 is N, S, N—R₁, or 0 and one of Z1 or Z3 isCR₂ and the other of Z1 or Z3 is carbon bonded to the remainder of themolecule as shown in formula I.

[0110] 5. In formula 1-A Z1 is N, N—R₁, O or S and Z2 is N, O or S andZ3 is a carbon bonded to the penem portion of the molecule as shown informula I.

[0111] 6. In formula 1-A Z3 is N, N—R₁, O or S and Z2 is N, O or S andZ1 is a carbon bonded to the penem portion of the molecule as shown informula I.

[0112] 7. In formula 1-A Z1 is N, N—R₁, O or S and Z3 is N, O or S andZ2 is a carbon bonded to the penem portion of the molecule as shown informula I.

[0113] 8. In formula 1-A Z1 is N, S, N—R₁ or O and Z2 or Z3 is CR₂ andthe other of Z2 or Z3 is carbon and is bonded to the remainder of themolecule; W₁, W₂ and W₃ are independently CR₄R₄.

[0114] 9. In formula 1-A Z3 is N, S, N—R₁ or O and one of Z2 or Z1 isCR₂ and the other of Z2 or Z1 is carbon and is bonded to the remainderof the molecule; W₁, W₂, and W₃ are independently CR₄R₄.

[0115] 10. In formula 1-A Z2 is N, S, N—R₁, or O and one of Z1 or Z3 isCR₂ and the other of Z1 or Z3 is carbon and is bonded to the remainderof the molecule; W₁, W₂, and W₃ are independently CR₄R₄.

[0116] 11. In formula 1-A Z1 is N, N—R₁, O or S and Z2 is N, O or S; Z3is a carbon bonded to the penem portion of the molecule; W₁, W₂, W₃ areindependently CR₄R₄.

[0117] 12. In formula 1-A Z3 is N, N—R₁, O or S; Z2 is N, O or S; Z1 isa carbon bonded to the penem portion of the molecule; W₁, W₂, W₃ areindependently CR₄R₄

[0118] 13. In formula 1-A Z1 is N, N—R₁, O or S; Z3 is N, O or S; Z2 isa carbon bonded to the penem portion of the molecule; W₁, W₂, W₃ areindependently CR4R4.

[0119] 14. In formula 1-A Z3 is N, N—R₁, O or S; Z1 is N, O or S; Z2 isa carbon bonded to the penem portion of the molecule; W₁, W₂, W₃ areindependently CR4R4.

[0120] 15. In formula 1-A Z1 is N, S, N—R₁, or O; one of Z2 or Z3 is CR₂and the other of Z2 or Z3 is carbon and is bonded to the remainder ofthe molecule, t=1-3; one W₂ is N—R₁, O or S(O)_(n) n=0-2 and another W₂is CR4R4.

[0121] 16. In formula 1-A Z3 is N, S, N—R₁ or 0; one of Z2 or Z1 is CR₂and the other of Z2 or Z1 is carbon and is bonded to the remainder ofthe molecule, t=1-3; one W₂ is N—R₁, O or S(O)_(n) n=0-2 and anotherW₂═CR4R4.

[0122] 17. In formula 1-A Z2 is N, S, N—R₁, or O; one of Z1 or Z3 is CR₂and the other of Z1 or Z3 is carbon and is bonded to the remainder ofthe molecule; t=1-3; one W₂ is N—R₁, O or S(O)_(n) n=0-2 and another W₂is CR4R4.

[0123] 18. In formula 1-A when Z1=N, N—R₁, O or S and Z2=N, O or S andZ3=a carbon bonded to the penem portion of the molecule where t=1-3 thenone W₂═N—R₁, O or S(O)_(n) n=0-2 and other W₂═CR4R4.

[0124] 19. In formula 1-A Z3=N, N—R₁, O or S and Z2=N, O or S and Z1=acarbon bonded to the penem portion of the molecule where t=1-3 then oneW₂═N—R₁, O or S(O)_(n) n=0-2 and other W₂═CR4R4.

[0125] 20. In formula 1-A when Z1=N, N—R₁, O or S and Z3=N, O or S andZ2=a carbon bonded to the penem portion of the molecule where t=1-3 thenone W₂═N—R₁, O or S(O)_(n) n=0-2 and other W₂═CR4R4.

[0126] 21. In formula 1-A Z1=N, S, N—R₁, or O and Z2 or Z3=CR₂ and theother of Z2 or Z3 is carbon and is bonded to the remainder of themolecule; then W₁ and W₃═CH₂ or both hydrogens on the methylene linkagecan be substituted to form a spiro system with or without the presenceof hetero atoms selected from O, S═(O)_(n) (n=0 to 2), N—R₁, to formfive to eight membered cyclic system; t=1-3; one W₂═N—R₁, O orS(O)_(n)n=0-2 and other W₂═CR4R4.

[0127] 22. In formula 1-A Z3=N, S, N—R₁, or O and Z2 or Z1=CR₂ and theother of Z2 or Z1 is carbon and is bonded to the remainder of themolecule; then W₁ and W₃═CR4R4; where t=1-3 then one W₂═N—R₁, O orS(O)_(r) n=0-2 and other W₂═CR4R4.

[0128] 23. In formula 1-A Z2=N, S, N—R₁ or O and Z1 or Z3=CR₂ and theother of Z1 or Z3 is carbon and is bonded to the remainder of themolecule; then W₁ and W₃═CR4R4, where t=1-3 then one W₂═N—R₁, O orS(O)_(n) n=0-2 and other W₂═CR4R4.

[0129] 24. In formula 1-A when Z1=N, N—R₁, O or S and Z2=N, O or S thenZ3=a carbon bonded to the penem portion of the molecule; then W₁ andW₃═CR4R4, where t=1-3 then one W₂═N—R₁, O or S(O)_(n) n=0-2 and otherW₂═CR4R4.

[0130] 25. In formula 1-A Z3=N, N—R₁, O or S and Z2=N, O or S then Z1=acarbon bonded to the penem portion of the molecule; then W₁ andW₃═CR4R4, where t=1-3 then one W₂═N—R₁, O or S(O)_(n) n=0-2 and otherW₂═CR4R4.

[0131] 26. In formula 1-A when Z1=N, N—R₁, O or S and Z3=N, O or S thenZ2=a carbon bonded to the penem portion of the molecule; then W₁ andW₃═CR4R4; t=1-3; one W₂ is N—R₁, O or S(O)_(n) n=0-2 and another W₂ isCR4R4.

[0132] 27. In formula 1-A Z3 is N, N—R₁, O or S; Z1 is N, O or S; Z2 isa carbon bonded to the remainder of the molecule; W₁ and W₃ areindependently CR4R4; t=1-3; one W₂ is N—R₁, O or S(O)_(r) n=0-2 andanother W₂ is CR4R4.

[0133] The more preferred embodiments of the formula 1-B:

[0134] 28. In formula 1-B t=3.

[0135] 29. In formula 1-B Z1 and Z3 are N; Y1 is N; Y2 is C and Z2 iscarbon and is bonded to the remainder of the molecule as shown informula I.

[0136] 30. In formula 1-B Z2 and Z3 are N; Y1 is N; Y2 is C and Z1 iscarbon and is bonded to the remainder of the molecule as shown informula I.

[0137] 31. In formula 1-B Z1 is N, Y1 is N, Y2 is C, one of Z2 or Z₃ isCR₂ and the other of Z2 or Z3 is a carbon and is bonded to the remainderof the molecule as shown in formula I.

[0138] 32. In formula 1-B Z1 is N, Y1 is C, Y2 is N, one of Z₂ or Z₃ isCR₂ and the other of Z2 or Z3 is a carbon and is bonded to the remainderof the molecule as shown in formula I.

[0139] 33. In formula 1-B Z1 is N, Y1 is N, Y2 is C, one of Z₂ or Z₃ isCR₂ and the other of Z2 or Z3 is a carbon and is bonded to the remainderof the molecule as shown in formula 1, W₁ and W₃ are independentlyCR4R4; t=1-3; one W₂ is N—R₁, O, S═(O)_(n) (n=0-2), and another W₂ isCR4R4.

[0140] 34. In formula 1-B Z1 is N, Y1 is C, Y2 is N, one of Z₂ or Z₃ isCR₂ and the other of Z2 or Z3 is a carbon and is bonded to the remainderof the molecule as shown in formula I; W, and W₃ are independentlyCR4R4; t=1-3; one W₂ is N—R₁, O, S═(O)_(n) (n=0-2), and another W₂ isCR4R4.

[0141] 35. In formula 1-B Z3 is N; Y1 is N; Y2 is C; one of Z1 or Z2 isCR₂ and the other of Z₁ or Z₂ is carbon and is bonded to the remainderof the molecule as shown in formula I.

[0142] 36. In formula 1-B Z2 is N; Y1 is N; Y2 is C; one of Z1 or Z3 isCR₂ and the other of Z₁ or Z₃ is carbon and is bonded to the remainderof the molecule as shown in formula I.

[0143] 37. In formula 1-B Z1 and Z2 are N; Y1 is N; Y2 is C; and Z3 iscarbon and is bonded to the remainder of the molecule as shown informula I.

[0144] 38. In formula 1-B Z, Z2 and Z3 are independently CR₂; Y1 is C;Y2 is N; except one of Z1-Z3 is carbon and is bonded to the remainder ofthe molecule as shown in formula I.

[0145] 39. In formula 1-B Z1 and Z3 are N; Y1 is N; Y2 is C; Z2 iscarbon and is bonded to the remainder of the molecule as shown informula I; and t=1-3.

[0146] 40. In formula 1-B Z2 and Z3 are N; Y1 is N; Y2 is C; and Z1 iscarbon and is bonded to the remainder of the molecule; and t=1-3;

[0147] 41. In formula 1-B Z2 and Z3 are N, Y1 is C and Y2=N and Z1 iscarbon and is bonded to the remainder of the molecule and t=1-3;

[0148] 42. In formula 1-B Z2 and Z3 are N, Y1 is N; Y2 is C; Z1 iscarbon and is bonded to the remainder of the molecule; W₁ and W₃ areindependently CH₂ or both hydrogens on the methylene linkage can besubstituted to form a spiro system with or without the presence ofhetero atoms selected from O, S(O)_(n) n=0-2, N—R₁, to form five toeight membered cyclic system; t=1-3 and W₂ is CH₂, N—R₁, O, S(O)_(n)where n=0-2.

[0149] 43. In formula 1-B Z3 is N; Y1 is N; Y2 is C; Z1 is CR₂ and Z2 isthe carbon atom bonded to the remainder of the molecule.

[0150] 44. In formula 1-B Z3 is N; Y1 is N; Y2 is C; Z1 is CR₂; Z2 isthe carbon atom bonded to the remainder of the molecule; W₁, W₂ and W₃are independently CR4R4; t=1 to 3.

[0151] 45. In formula 1-B Z3 is N; Y1 is N; Y2 is C; Z1 is CR₂; Z2 isthe carbon atom bonded to the remainder of the molecule; W₁ and W₃ areindependently CR4R4; and one of W₂ is N—R₁, O or S(O)_(n), and anotherW₂ is CR4R4; t=1-3.

[0152] 46. In formula 1-B Z3 is N; Y1 is N; Y2 is C; Z1 is CR₂; Z2 isthe carbon atom bonded to the remainder of the molecule; W₁ and W₂ areindependently CR4R4; W₃ is N—R₁, O or S(O)_(n); and t=2.

[0153] 47. In formula 1-B Z3 is N; Y1 is N; Y2 is C; Z1 is CR₂; Z2 isthe carbon atom bonded to the remainder of the molecule; W₁ and W₃ areindependently CR4R4; W₂ is N—R₁, O or S(O)_(n); and t=1.

[0154] 48. In formula 1-B Z2 is N; Y1 is N; Y2 is C; Z3 is CR₂; Z1 isthe carbon bonded to the remainder of the molecule; W₁ and W₂ is CH₂ orboth hydrogens on the methylene linkage can be substituted to form aspiro system with or without the presence of hetero atoms selected fromO, S(O)_(n) n=0-2, N—R₁, to form five to eight membered cyclic system;W₃ is N—R₁, O or S(O)_(n); and t=3.

[0155] 49. In formula 1-B Z2 is N; Y1 is N; Y2 is C, Z3 is CR₂; Z1 isthe carbon bonded to the remainder of the molecule; W₁ and W₃ areindependently CH₂ or both hydrogens on the methylene linkage can besubstituted to form a spiro system with or without the presence ofhetero atoms selected from O, S(O)_(n) n=0-2, N—R₁ to form five to eightmembered cyclic system; and one W₂ is N—R₁, O or S(O)_(n) and another W₂is CR4R4; and t=2.

[0156] 50. In formula 1-B Z2 is N; Y1 is N; Y2 is C; Z3 is CR₂; Z1 isthe carbon bonded to the remainder of the molecule; W₁ and W₃ areindependently CH₂ or both hydrogens on the methylene linkage can besubstituted to form a spiro system with or without the presence ofhetero atoms selected from O, S(O)_(n) n=0-2, N—R₁, to form five toeight membered cyclic system; W₂ is N—R₁, O or S(O)_(n); and t=1.

[0157] 51. In formula 1-B Z2 is N; Y1 is N; Y2 is C; Z1 is CR₂; Z3 isthe carbon bonded to the remainder of the molecule; W₁ and W₃ areindependently CR4R4; one of W₂ is N—R₁, O or S(O)_(n) and another W₂ isCR4R4; and t=3.

[0158] 52. In formula 1-B Z2 is N; Y1 is N; Y2 is C; Z1 is CR₂; Z3 isthe carbon bonded to the remainder of the molecule; W₁ and W₃ areindependently CR4R4; one W₂ is N—R₁, O or S(O)_(n), and another W₂ isCR4R4; and t=2.

[0159] 53. In formula 1-B Z2 is N; Y1 is N; Y2 is C; Z1 is CR₂; Z3 isthe carbon bonded to the remainder of the molecule; W₁ and W₃ areindependently CR4R4; W₂ is N—R₁, O or S(O)_(n); and t=1.

[0160] 54. In formula 1-B Z1 and Z2 are N; Y1 is N; Y2 is C; Z3 iscarbon and is bonded to the remainder of the molecule; W₁ and W₃ areindependently CR4R4; one of W₂ is N—R₁, O or S(O)_(n) and another W₂ isCR4R4; and t=3.

[0161] 55. In formula 1-B Z1 and Z2 are N; Y1 is N; Y2 is C; Z3 iscarbon and is bonded to the remainder of the molecule; W₁ and W₃ areindependently CR4R4; one of W₂ is N—R₁, O or S(O)_(n) and another W₂ isCR4R4; and t=2. 56. In formula 1-B Z1 and Z2 are N; Y1 is N; Y2 is C; Z3is carbon and is bonded to the remainder of the molecule; W₁ and W₃ areindependently CR4R4; W₂ is N—R₁, O or S(O)_(n); and t=1

[0162] 57. In formula 1-B Z1 and Z2 are independently CR₂; Y1 is C; Y2is N; Z3 is carbon and is bonded to the remainder of the molecule; W₁and W₃ are independently CR4R4; one of W₂ is N—R₁, O or S(O)_(n);another W₂ is CR4R4; and t=3.

[0163] 58. In formula 1-B Z1 and Z2 are independently CR₂; Y1 is C andY2 is N and Z3 is carbon and is bonded to the remainder of the molecule;W₁ and W₃ are independently CR4R4; and one W₂ is N—R₁, O or S(O)_(n) andthe other W₂ is CR4R4; and t=2.

[0164] 59. In formula 1-B Z1 and Z2 are independently CR₂; Y1 is C; Y2is N; Z3 is carbon and is bonded to the remainder of the molecule; W₁and W₃ are independently CR4R4; W₂ is N—R₁, O or S(O)_(n); and t=1.

[0165] 60. In formula 1-B Z1 and Z3 are independently CR₂; Y1 is C; Y2is N; Z2 is carbon and is bonded to the remainder of the molecule; W₁and W₃ are independently CR4R4; one W₂ is N—R₁, O or S(O)_(n); anotherW₂ is CR4R4; and t=3.

[0166] 61. In formula 1-B Z1 and Z3 are independently CR₂; Y1 is C; Y2is N; Z2 is carbon and is bonded to the remainder of the molecule; W₁and W₃ are independently CR4R4; and one W₂ is N—R₁, O or S(O)_(n) andthe other W₂ is CR4R4; and t=2.

[0167] 62. In formula 1-B Z1 and Z3 are independently CR₂; Y1 is C; Y2is N; Z2 is carbon and is bonded to the remainder of the molecule; W₁and W₃ are independently CR4R4; W₂ is N—R₁, O or S(O)_(n); and t=1.

[0168] 63. In formula 1-B Z3 and Z2 are independently CR₂; Y1 is C; Y2is N; Z1 is carbon and is bonded to the remainder of the molecule; W₁and W₂ are independently CR4R4; one W₂ is N—R₁, O or S(O)_(n); anotherW₂ is CR4R4; and t=3.

[0169] 64. In formula 1-B Z3 and Z2 are independently CR₂; Y1 is C; Y2is N; Z1 is carbon and is bonded to the remainder of the molecule; W₁and W₃ are independently CR4R4; one W₂ is N—R₁, O or S(O)_(n); the otherW₂ is CR4R4; and t=2.

[0170] 65. In formula 1-B Z3 and Z2 are independently CR₂; Y1 is C; Y2is N; Z1 is carbon and is bonded to the remainder of the molecule; W₁and W₃ are independently CR4R4; W₂ is N—R₁, O or S(O)_(n); and t=1.

[0171] 66. In formula 1-B Z3 is N; Y1 is N; Y2 is C; one of Z1 and Z2 isCR₂ and the other is C; W₁ is CR4R4; W₂ is CR4R4; W₃ is CH₂, N—R₁ or 0;and t=1.

[0172] 67. In formula 1-B Z3 is N; Y1 is N; Y2 is C; one of Z1 and Z2 isCR₂ and the other is C; W₁ is CR4R4; W₂ is C═O; W₃ is N—R₁; and t=1.

[0173] 68. In formula 1-B Z3 is N; Y1 is N; Y2 is C; one of Z1 and Z2 isCR₂ and the other is C; W₁ is N—R₁; W₂ is C═O; W₃ is CR4R4; and t=1.

[0174] 69. In formula 1-B Z3 is N; Y1 is N; Y2 is C; one of Z1 and Z2 isCR₂ and the other is C; W₁ is C═O; W₂ is N—R₁; W₃ is CH₂; and t=1.

[0175] The more preferred embodiments of the formula 1-C are:

[0176] 70. In formula 1-C Z1, Z2, Z3 and Z4 are independently CR₂;one ofZ1-Z4 is carbon and is bonded to the remainder of the molecule; Y₁ andY₂ are C; t=1 to 3; and. W₁, W₂ and W₃ are independently CR4R4, S, SO,SO₂, O, or N—R₁.

[0177] 71. In formula 1-C Z1, Z2, Z3 and Z4 are independently CR₂ andone of Z1-Z4 is carbon and is bonded to the remainder of the molecule;Y₁ and Y₂═C or N; t=1 to 3; W₁, W₂ and W₃ are independently CR4R4, S,SO, SO₂, O, or N—R₁.

[0178] 72. In formula 1-C Z1, Z2, Z3 and Z4 are independently CR₂; Y₁and Y₂ are N; t=1 to 3; W₁, W₂ and W₃ are independently CR4R4, S, SO,SO₂, O, or N—R₁.

[0179] 73. In formula 1-C Z1 is N and Z2, Z3 and Z4 are independentlyCR₂; Y₁ and Y₂ are C; t=1 to 3; W₁, W₂ and W₃ are independently CR4R4,S, SO, SO₂, O, or N—R₁.

[0180] 74. In formula 1-C Z1 is N and Z2, Z3 and Z4 are independentlyCR₂; one of Z1-Z4 is carbon and is bonded to the remainder of themolecule; Y₁ is C; Y₂ is N; t=1 to 3; and W₁, W₂ and W₃ areindependently CR4R4, S, SO, SO₂, O, or N—R₁.

[0181] 75. In formula 1-C Z2=N and Z1, Z3 and Z4 are independently CR₂;one of Z1-Z4 is carbon and is bonded to the remainder of the molecule;Y₁ and Y₂ are C; t=1 to 3; and W₁, W₂ and W₃ are independently CR4R4, S,SO, SO₂, O, or N—R₁.

[0182] 76. In formula 1-C Z2 is N and Z1, Z3 and Z4 are independentlyCR₂; one of Z1-Z4 is carbon and is bonded to the remainder of themolecule; Y₁ is C; Y₂ is N; t=1 to 3; and W₁, W₂ and W₃ areindependently CR4R4, S, SO, SO2, O, or N—R₁.

[0183] 77. In formula 1-C Z3 is N; Z1, Z2 and Z4 are independently CR₂;one of Z1-Z4 is carbon and is bonded to the remainder of the molecule;Y₁ and Y₂ are C; t=1 to 3; and W₁, W₂ and W₃ are independently CR4R4, S,SO, SO2, O, or N—R₁.

[0184] 78. In formula 1-C Z3 is N and Z1, Z2 and Z4 are independentlyCR₂; one of Z1-Z4 is carbon and is bonded to the remainder of themolecule; Y₁ is C and Y₂ is N; t=1 to 3; and W₁, W₂ and W₃ areindependently CR4R4, S, SO, SO2, O, or N—R₁.

[0185] 79. In formula 1-C Z4 is N and Z1, Z2 and Z3 are independentlyCR₂; one of Z1-Z4 is carbon and is bonded to the remainder of themolecule; Y₁ and Y₂ are C; t=1 to 3; and W₁, W₂ and W₃ are independentlyCR4R4, S, SO, SO2, O, or N—R₁.

[0186] 80. In formula 1-C Z4 is N and Z1, Z2 and Z3 are independentlyCR₂; one of Z1-Z4 is carbon and is bonded to the remainder of themolecule; Y₁ is N; Y₂ is C; t=1 to 3; and W₁, W₂ and W₃ areindependently CR4R4, S, SO, SO2, O, or N—R₁.

[0187] 81. In formula 1-C Z1 is N and Z2, Z3 and Z4 are independentlyCR₂; one of Z1-Z4 is carbon and is bonded to the remainder of themolecule; Y₁ and Y₂ are C; t=1 to 3; and W₁, W₂ and W₃ are independentlyCR4R4, S, SO, SO2, O, or N—R₁.

[0188] 82. In formula 1-C Z1 and Z2 are N and Z3 or Z4 are independentlyCR₂; one of Z1-Z4 is carbon and is bonded to the remainder of themolecule; Y₁ is C; Y₂ is N; t=1 to 3; and W₁, W₂ and W₃ areindependently CR4R4, S, SO, SO2, O, or N—R₁.

[0189] 83. In formula 1-C Z1 and Z3 are N and Z2 or Z4 are independentlyCR₂; one of Z1-Z4 is carbon and is bonded to the remainder of themolecule; Y₁ is C; Y₂ is N; t=1 to 3; and W₁, W₂ and W₃ areindependently CR4R4, S, SO, SO2, O, or N—R₁.

[0190] 84. In formula 1-C Z1 and Z4 are N and Z2 or Z3 are independentlyCR₂; one of Z1-Z4 is carbon and is bonded to the remainder of themolecule; Y₁ is N; Y₂ is C; t=1 to 3; and W₁, W₂ and W₃ areindependently CR4R4, S, SO, SO2, O, or N—R₁.

[0191] 85. In formula 1-C Z1, Z2, Z3 are N and Z4 is carbon and isbonded to the remainder of the molecule; Y₁ is C; Y₂ is N; t=1 to 3; andW₁, W₂ and W₃ are independently CR4R4, S, SO, SO2, O, or N—R₁.

[0192] 86. In formula 1-C Z1, Z3 and Z4 are N and Z2 is carbon and isbonded to the remainder of the molecule; Y₁ and Y₂ are C; t=1 to 3; andW₁, W₂ and W₃ are independently CR4R4, S, SO, SO2, 0, or N—R₁.

[0193] 87. In formula 1-C Z1, Z2 and Z4 are N and Z3 is carbon and isbonded to the remainder of the molecule; Y₁ and Y₂ are C and t=1 to 3;and W₁, W₂ and W₃ are independently CR4R4, S, SO, SO2, O, or N—R₁.

[0194] 88. In formula 1-C Z2, Z3, Z4 are N and Z1 is carbon and isbonded to the remainder of the molecule; Y₁ and Y₂ are C and t=1 to 3;and W₁, W₂ and W₃ 30 are independently CR4R4, S, SO, SO2, O, or N—R₁.

[0195] More preferred compounds of the present invention are:

[0196] 1.(5R,6Z)-6-[(5-benzyl-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)methylene]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid.

[0197] 2. (5R), (6Z)-6-(7-Methyl-5, 6, 7,8-tetrahydroimidazo[1,2-a]pyrazin-2-ylmethylene)-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt.

[0198] 3. (5R),(6Z)-7-Oxo-6-(5,6,7,8-tetrahydroimidazo[1,2-a]pyrazin-2-ylmethylene)-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt.

[0199] 4. (5R,6Z)-6-{[5-(4-methoxybenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)]methylene}-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt.

[0200] 5. (5R),(6Z)-6-(5,6-dihydro-8H-imidazo[2,1-c][1,4]thiazin-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt

[0201] 6. (5R),(6Z)-6-(6,7-Dihydro-5H-pyrrolo[1,2-a]imidazol-2-ylmethylene)-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt.

[0202] 7. (5R),(6Z)-6-(5,6-Dihydro-8H-imidazo[2,1-c][1,4]oxazin-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt

[0203] 8. (5R),(6Z)-6-(5,6-Dihydro-4H-pyrrolo[1,2-b]pyrazol-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt

[0204] 9. (5R)(6Z)-7-Oxo-6-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-2-ylmethylene)-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt

[0205] 10. (5R),(6Z)-6-(7-Methyl-6-oxo-5,6,7,8-tetrahydro-imidazo[1,2-a]pyrazin-2-ylmethylene)-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid sodium salt

[0206] 11.(5R)(6Z)-6-(6,7-Dihydro-4H-pyrazolo[5,1-c][1,4]thiazin-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt

[0207] 12.(5R)(6Z)-7-Oxo-6-(4H-5-thia-1,6a-diazapentalen-2-ylmethylene)-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt

[0208] 13.(5R)(6Z)-6-(7H-Imidazo[1,2-c]thiazol-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt

[0209] 14.(5R,6Z)-7-oxo-6-[(4-oxo-6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-2-yl)methylene]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicAcid

[0210] 15.6-(6,7-Dihydro-4H-thieno[3,2-c]pyran-2-ylmethylene)-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid

[0211] 16.6-(6,7-Dihydro-4H-thieno[3,2-c]thiopyran-2-ylmethylene)-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid

[0212] 17.6-(5-Methyl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-2-ylmethylene)-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid

[0213] 18.2-(2-Carboxy-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-en-6-ylidenemethyl)-6,7-dihydro-4H-thieno[3,2-c]pyridine-5-carboxylicacid ethyl ester

[0214] 19.7-Oxo-6-(6,7,8,9-tetrahydro-5H-imidazo[1,2-a]azepin-2-ylmethylene)-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid

[0215] 20. (5R),(6Z)-6-(7-Benzyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazin-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid

[0216] 21.(5R,6Z)-7-oxo-6-{[5-(pyridin-3-ylmethyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)]methylene}-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid

[0217] 22.(5R,6Z)-7-oxo-6-{[5-(pyridin-3-ylcarbonyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)]methylene}-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid

[0218] 23.(5R,6Z)-7-oxo-6-{[5-(phenylacetyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)]methylene}-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid;

[0219] 24. (5R),(6Z)-6-(5,5-Dioxo-4,5,6,7-tetrahydro-5λ⁶-pyrazolo[5,1-c][1,4]thiazin-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt;

[0220] 25. (5R),(6Z)-7-Oxo-6-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylmethylene)-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt

[0221] 26.(5R)(6Z)-6-(5,5-Dimethyl-4H-1,6a-diazapentalen-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt 5,5-Dimethyl-2-piperidone;

[0222] 27. (5R),(6Z)-6-(5,6-Dihydro-4H-cyclopenta[b]furan-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt;

[0223] 28.(5R)(6Z)-6-(4,5-Dihydro-6-thia-1,7a-diazainden-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt;

[0224] 29.(5R),(6Z)-6-(6,6-Dimethyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrizin-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt;

[0225] 30. (5R),(6Z)-6-(5,6-Dihydro-8-H-imidazo[2,1-c][1,4]thiazin-3-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid;

[0226] 31.(5R)(6Z)-7-Oxo-6-(4H-5-thia-1,6a-diazapentalen-2-ylmethylene)-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt;

[0227] 32.(5R)(6Z)-6-(2,3-Dihydropyrazolo[5,1-b]thiazol-6-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt;

[0228] 33.(5R)(6Z)-6-(2,3-Dihydropyrazolo[5,1-b]oxazol-6-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt;

[0229] 34.(5R,6Z)-6-[(5-acetyl-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)methylene]-oxo-4-thia-1-azabicyclo[3.2.0.]hept-2-ene-2-carboxylicacid (E+Z Isomers mixture,Sodium salt);

[0230] 35.(5R,6Z)-6-(6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid;

[0231] 36.(5R)(6Z)-6-(6,7-5H--Dihydropyrazolo[5,1-b]oxazin-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt;

[0232] 37. (5R),(6Z)-6-[5-(3-carboxypropionyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylmethylene]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-carboxylicacid,disodium salt;

[0233] 38. (5R),(6Z)-6-[5-(2-methoxyacetyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylmethylene]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-carboxylicacid,sodium salt;

[0234] 39.(5R),(6Z)-6-[5-(2-methoxyacetyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylmethylene]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-carboxylicacid,sodium salt; and

[0235] 40. (5R),(6Z)-6-[5-(2-methoxyacetyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylmethylene]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-carboxylicacid,sodium salt.

[0236] Especially preferred compounds of the present invention include:

[0237] (5R),(6Z)-6-(5,6-dihydro-8H-imidazo[2,1-c][1,4]thiazin-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt;

[0238] (5R),(6Z)-6-(6,7-Dihydro-5H-pyrrolo[1,2-a]imidazol-2-ylmethylene)-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt;

[0239] (5R),(6Z)-6-(5,6-Dihydro-8H-imidazo[2,1-c][1,4]oxazin-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt; and

[0240](5R)(6Z)-7-Oxo-6-(4H-5-thia-1,6a-diazapentalen-2-ylmethylene)-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt.

[0241] The compounds according to the present invention have β-lactamaseinhibitory and antibacterial properties and are useful for the treatmentof infections in humans and animals. It should be noted that thecompounds of the present invention, when used in combination withβ-lactam antibiotics will result in the increased antibacterial activity(synergistic effect) against class-A and class-C producing organisms.β-Lactam antibiotics include penicillin antibiotics such aspiperacillin, amoxycillin, ticarcillin, benzylpenicillins, ampicillin,sulbenicillin, other known penicillins and cephalosporins such ascefatrizine, cephaloridine, cephalothin, cefazolin, cephalexin,cephradine, other known cephalosporins, aztreonam and latamoxef(Moxalactam). Most preferably compounds of this present invention areused with piperacillin or amoxicillin which has a broad spectrum ofactivity against Gram positive and Gram negative pathogens.

[0242] The compounds of the present invention may be provided prior to,simultaneously with, or subsequent to a β-lactam antibiotic(“co-administration”). By “provided”, it is intended to includeadministering the compound directly or in vivo, e.g. pro-drugs. When thecompounds of the present invention are co-administered with a β-lactamantibiotic, the ratio of the amount of the compound to the amount of theβ-lactam antibiotic may vary in a wide range. The ratio of β-lactamantibiotic to β-lactamase inhibitor may vary from 1:1 to 100:1.Preferably the ratio of the β-lactam antibiotic to β-lactamase inhibitoris less than 10:1. The composition of the present invention may be in aform suitable for oral (PO), intravenous (IV) or topical administration.The compositions of the invention may be in a form of tablets, capsules,creams, syrups, suspension, sterile solutions suitable for injection orinfusion. Preferably, the compounds of the present invention areco-administered with piperacillin intravenously or amoxicillinintravenously or orally.

[0243] A compound's structural formula includes any tautomers, anystereoisomers (except where stereochemistry is clearly noted) and anycrystalline forms.

[0244] IC₅₀ Determination for the Penem Inhibitor

[0245] β-Lactamase inhibitory activity of the penem inhibitors wasdetermined spectrophotometrically as described by Bush et al., [Bush,K., Macalintal, C., Rasmussen, B. A., Lee, V. and Yang, Y. AntimicrobialAgents and Chemotherapy 1993, 37, 851]. Homogeneously purified class Aβ-lactamases TEM-1 from E. coli and 1 ml-1 from Enterobacter cloacae,class B enzyme CcrA from Bacteroides fragilis and class C enzyme AmpCfrom Enterobacter cloaca were employed in the assay. The enzymeconcentrations for TEM-1, 1 ml-1, CcrA and AmpC were 4.3, 7.1, 1.2 and2.1 nM, respectively. A wide range of inhibitor concentrations wereprepared in 50 mM PO₄, pH 7.0 to include the possible IC₅₀ values. Thesubstrate used to initiate the enzyme reaction was nitrocefin at 50μg/ml in the same buffer as the inhibitor. Initially the enzyme andinhibitor (20 μl each) were preincubated for 10 minutes at 25° C. priorto the addition of 160 μl volume of nitrocefin. Initial rates ofhydrolysis were monitored for 5 minutes at 495 nm using a MolecularDevices Spectra Max 250 with kinetic protocol of SoftMax Program.Readings from the Spectra Max 250 were exported and transferred toMicrosoft Excel. The percent of inhibition of each inhibitorconcentration was calculated based on the control enzyme activity. Theinhibitor concentration that caused a 50% reduction in the enzymaticactivity (IC₅₀) was determined graphically. TABLE 1 IC50 (nM) Class AClass B Class C Compound TEM-1 Imi Ccr AmpC Example 1 4.2 2.1 260 12Example 2 4.4 22 120 5.8 Example 3 5.4 28 320 6.2 Example 7 0.4 7.8 664.8 Example 8 1.2 50 14 1.5 Example 9 2.2 90 62 3.2 Example 10 10 65 1403.0 Example 11 1.0 18 61 1.2 Example 12 1.4 56 110 1.5 Example 13 2.9 16160 3.1 Example 14 2.5 68 26 3.8 Example 15 1.2 8.6 14 3.8 Example 163.1 25 12 4.2 Example 17 12 24 28 26 Example 18 2.8 50 120 9.2 Example19 4.8 2700 170 4.6 Example 20 1.4 9.6 18 3.1 Example 21 9.8 40 280 18Example 22 6.1 42 110 11 Example 23 4.6 40 140 7.8 Example 24 1.1 56 41.5 Example 25 1.1 123 162 2.7 Example 26 0.73 54 89 2.3 Example 27 25.5 73 2 Example 28 ND ND ND ND Example 29 ND ND ND ND Example 30 2.92300 7.8 2.5 Example 31 1.4 56 110 1.5 Example 32 ND ND ND ND Example 331.1 59 41 0.85 Example 34 4.2 34 99 6.5 Example 35 4.2 230 30 6.1Example 36 6.3 413 140 4.5

[0246] Antimicrobial susceptibility testing. The in vitro activities ofthe antibiotics were determined by the microbroth dilution method asrecommended by the National Committee for Clinical Laboratory Standards(NCCLS). (NCCLS. 2000. Methods for Dilution Antimicrobial SusceptibilityTests for Bacteria That Grow Aerobically; Approved Standards: M7-A5,vol. 19. National Committe for Clinical Laboratory Standards, Villanova,Pa.). Mueller-Hinton II broth (MHBII)(BBL Cockeysville, Md.), was usedfor the testing procedure. Microtiter plates containing 50 μl per wellof two-fold serial dilutions of piperacillin combined with a constantamount (4 ug/ml) of a B-lactamase inhibitor were inoculated with 50 μlof inoculum to yield the appropriate density (10⁵ CFU/ml) in 100 l finalvolume. The plates were incubated for 18-22 hours at 35° C. in ambientair. The minimal inhibitory concentration (MIC) for all isolates wasdefined as the lowest concentration of antimicrobial agent thatcompletely inhibits the growth of the organism as detected by theunaided eye. The MIC data obtained by the above said procedure areenlisted in Table 2. TABLE 2 Minimal Inhibitory Concentration (μg/ml)Data: Inc: 35° C. for 18 hours P. aeru S. Marces E. Coli E. Coli E.ColiE. Cloacae ginos cens E. Coli GC2847 GC2920 GC2894 GC1477 GC1764 GC1781E. Coli S. aureus Example 1 GC2844 (TEM-1) (IRT-2) (Ampc) (Ampc) (Ampc)Sme-1 + (Ampc) GC22033 GC2216 1 2 2 2 16 32 32 0.5 1 0.12 2 2 16 2 2 >648 1 1 0.25 3 2 2 1 2 64 16 1 2 0.5 4 2 8 2 2 64 32 2 2 0.50 7 2 2 4 2 161 1 1 <0.06 8 2 2 2 2 8 0.25 2 2 <0.06 9 1 2 1 2 16 4 1 2 <0.06 10 1 321 16 >64 4 1 1 <0.06 11 2 4 2 2 32 2 1 1 <0.06 12 2 4 2 2 32 1 1 1 <0.0613 0.5 1 2 0.5 16 1 0.5 2 <0.06 14 1 32 0.50 64 >64 64 16 2 1 15 2 16 28 32 8 2 2 <0.06 16 2 16 1 4 32 16 2 1 0.12 17 2 8 2 4 32 4 1 2 0.25 182 16 2 32 >64 64 2 2 0.50 19 2 8 2 8 >64 64 4 2 0.5 20 2 32 2 32 >64 642 2 <0.06 21 2 32 2 32 >64 64 2 1 0.25 22 2 >64 2 64 >64 64 4 2 0.5 23 264 2 32 >64 64 4 2 0.5 24 2 4 2 4 64 2 1 2 ND 25 2 4 2 2 32 0.5 2 2 ND26 2 8 2 16 32 8 2 4 ND 27 2 4 2 16 32 16 2 2 ND 28 2 4 2 4 16 2 2 2 ND29 2 8 2 8 32 8 2 2 ND 30 2 8 1 2 16 8 8 2 0.06 31 2 4 2 2 32 1 0.5 10.5 32 2 2 2 2 16 2 1 2 ND 33 2 4 4 2 16 0.5 1 4 0.06 34 4 32 4 32 >6432 2 2 ND 35 2 4 2 2 64 1 8 2 0.25 36 2 4 2 2 16 1 1 4 0.08

In Vivo Antibacterial Protection

[0247] Materials:

[0248] Animals:

[0249] Female mice strain CD-1, approximately 18-22 grams, were receivedfrom Charles River Laboratories and quarantined 7 days prior to use. Inaddition, mice may be rendered neutropenic using cytoxan.

[0250] Infections:

[0251] Clinical isolates that have been adapted to cause infection inmice, are used in the experiment, including infections with strains ofE. coli, K. pneumoniae, M. morganii, E. cloacae, S. marcescens, C.freundii, staphylococci, streptococci, P. aeruginosa and N. gonorrhoeae.

[0252] Preparation:

[0253] Animals are housed five to a cage with free access to food andwater, in accordance with NIH guidelines.

[0254] Experimental Protocol:

[0255] Mice are challenged by injecting 0.5 ml intraperitoneally or 0.05ml intranasally of a predetermined bacterial inoculum suspended inbroth, saline or hog gastric mucin (supplemented with dried bovinehemoglobin for N. gonorrhoeae). The bacterial inoculum is equivalent to10-100 LD₅₀s of the specific infecting strain and will result in deathof the non-treated control animals within 7 days: “Bacterial Virulencein Mice”. Antibacterial doses (dose concentration prepared by two foldserial dilutions of the antibiotic) are dissolved or suspended in 0.2%aqueous agar or methocel, phosphate buffered saline or an adjuvant areadministered orally, subcutaneously or intravenously in the followingmanner:

[0256] a) Orally or subcutaneously: Dose volume of 0.5 ml administered ½hr after infection. A second dose may be administered 3 hr. afterinfection for treatment of infections with more virulent organisms.

[0257] b) Intravenously: Dose volume of 0.2 ml, administered ½hr. afterinfection. For the treatment of infections with more virulent organisms,more doses, up to 48 hr may be administered. (Intravenous dosing willnot exceed 3 doses/24 hr period.)

[0258] c) Oral pretreatment: Under special circumstances, the pH of thestomach needs to be adjusted in order to increase the gastric stabilityof the antibiotic. For this purpose, 0.5 ml of phosphate buffered saline(pH 7.8, 0.06M) (or specific approved adjuvant) is administered orally ½hr after infection, followed 5 minutes later by 0.5 ml of antibiotic(also orally) contained in phosphate buffered saline (pH 7.8, 0.06M).

[0259] Animal Species

[0260] A detailed explanation as to the number of animals needed for thedetermination of in vivo efficacy follows:

[0261] A) Novel antibiotics are tested at 5 different dose levels with 5mice per dose level at each of three routes of administration (oral,subcutaneous and intravenous). Initially the three routes ofadministration should be investigated so as to determine if the drug isorally absorbed and/or which is the most effective route. This wouldrequire 25 mice/route with 3 routes/antibiotic or 75 mice per novelcompound tested. One to two novel antibiotics will be tested perexperiment (75-150 mice)

[0262] B) The effectiveness of the new compound must be compared to thatof a standard, or antibiotic of known effectiveness. Known or previouslytested antibiotics are tested at 5 dose levels with 5 mice per doselevel by a single route of administration, for a total of 25mice/antibiotic. Usually 3-6 antibiotics will be tested per experiment.(75-150 mice).

[0263] C) Untreated controls—In each of the above tests, untreatedanimals are infected with 3 different concentrations of bacterialinoculum with 10 mice per concentration (30 mice total in each and everytest). These untreated controls are used to determine and maintain theinfection level between 10-100 LD50s as required for test to testcomparison and validity.

[0264] Determination of Protective Effects of Antibacterial Agents:

[0265] The protective effects of the antibacterial agent(s) are measuredby the survival of the infected untreated as compared to the treatedanimals. For this determination, animals are observed for 7 days aftertreatment. A census of survivors is taken twice daily and at that timedead as well as moribund animals are removed. The 7 day survival ratiofrom three separate tests are pooled for estimation of median effectivedose (ED50) by computerized program for probit analysis (Cleeland, R.and E. Squires. 1991. Evaluation of New Antimicrobials in Vitro and inExperimental Animal Infections. In Antibiotics in Laboratory Medicine”,3rd. ed., edited by Victor Lorian. Willams and Wilkins Baltimore, Md.pp. 752-783). The test is performed three times on separate days toprovide a statistically valid number of animals and to minimizevariation in test results on a day to day and test to test basis. TABLE3 Ratio of Piperacillin vs. Example ED₅₀ mg/kg Inhibitor 1 32-64 2:12 >64 2:1 3 16-32 4:1 4 32-64 4:1 7 22.8 4:1 8 18.9 4:1 9 31.3 4:1 10 1113.9 4:1 12 20.0 4:1 13 18.0 14 15 16 17 37.9 4:1 18 19 59.2 4:1 20 2122 128 4:1 23 128 4:1 24 64 25 30 26 30 27 28 28 31 29 46 30 ND 31 20 3246 33 >64 34 32 35 19 36 90

Process of Invention

[0266] Compounds of the general formula I can be prepared by a novel,mild and a facile way, by condensing an appropriately substitutedaldehyde 4 with a 6-bromo-penem derivative of structure 1. (Scheme 1) inthe presence of anhydrous MgBr₂ or MgBr₂: etherate and a base such astriethylamine or DBU or DMAP, preferably at −20° C. to −40° C. Theintermediate aldol product 5 can be functionalized with acid chloridesor anhydrides to an acetate, triflate or a tosylate 6. Compound 6 can besmoothly converted to the desired product by a reductive eliminationprocess using a metal such as activated zinc and phosphate buffer at 20°C. to 35° C. at a pH of 6.5 to 8.0. If the protecting group on thecarboxylate oxygen is a para-nitrobenzyl substitiuent then the reductiveelimination and deprotection can be achieved by a single step. However,if the protecting group is other than a para-nitrobenzyl substituent, atwo step procedure can be followed depending up on the nature of theprotecting group. The product can be isolated as a free acid or as analkali metal salt. The above mentioned two step procedure can be carriedout in one step by carrying out the entire process without isolating theintermediate 6. This is a very general, relatively simple and efficientprocedure in terms of yield and economic feasibility. This procedure canbe adopted to large scale synthesis and is amenable to a variety ofaldehydes. Alternatively, compound 6 can be hydrogenated at 40 psipressure in the presence of Pd/C (10%) in THF and 6.5 phosphate bufferto yield the final product.

[0267] The above mentioned aldol condensation reaction is very versatileand it can be applied to any bromopenem derivative, where the carboxygroup is protected other than 4-nitrobenzyl moiety. Example of otherprotecting group include benzyl, para-methoxy benzyl derivative,benzyhydrol, trityl, alkyl and allyl derivatives.

[0268] However, when the protecting group is other than 4-nitrobenzylgroup, a separate deprotection step need to be carried out after thereductive elimination procerdure.

[0269] The chemistry involved in the deprotection step is well known topeople who are skilled in that art.

[0270] The required aldehydes 4 for the above mentioned transformationscan be prepared from their respective alcohol derivatives by MnO₂oxidation or by Swern oxidation. In some cases the required aldehydefunctionality can be introduced directly in the heterocyclic moiety by aVilsmier Haack reaction using DMF/POCl₃. The aldehydes required for thepresent investigation may be prepared as depicted in Schemes 2 to 5. TheN-(tert-butoxycarbonyl)-(ie) t-Boc protected-4-piperidone is treatedwith DMF/POCl₃ to yield 4-chloro-3-formyl derivative. (Scheme 2). Thisreaction can be conducted on tetrahydro-4H-pyran-4-one and thecorresponding tetrahydro-4H-thiopyran-4-one derivative to give thecorresponding oxygen and the sulfur derivatives. This reaction can alsobe conducted on five to eight membered cyclic ketones derivatives. Thechloro formyl intermediate can be reacted with 2-mercapto ethyl acetateto give the thieno derivative. The ester can be converted to alcohol,which can be converted to the starting aldehyde functionality. Scheme 3illustrates the preparation of the imidazolo-tetrahydro pyridinederivative and imidazolo pyrazine derivative. 2-aminopyridine or2-aminopyrazine can be reacted with ethyl bromopyruvate in boilingethanol to give the cyclized derivative (Scheme 3). Reduction of onering can be achieved.

[0271] by hydrogenating it over Pd/C under 40 psi pressure in a parapparatus. Subsequently the ester group can be reduced to alcohol andconverted to the aldehyde. In the case of X═N the intermediate aminoester can be derivatized using an appropriate R₁Q (where Q is a leavinggroup or a condensing group). In the case of Scheme 3, where R₁=H can besynthesized by the procedure outlined in Scheme 4.

[0272] Additional aldehydes may be synthesized as outlined in Schemes5-7.

[0273] Aldehydes required for examples 24-32 and 34, 35 were prepared bythe route indicated schemes 8 to 18.

EXPERIMENTALS Example 1 5 Preparation of(5R,6Z)-6-[(5-benzyl-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)methylene]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid

[0274] Step1: Ethyl5-benzoyl-4,5,6,7-tetrahydrothieno[3,2-c]pyridine-2-carboxylate:

[0275] To a stirred dry DMF (7.3 g, 100 mmol), POCl₃ (12.25 g, 80 mmol)was slowly added between 0° C. to 50° C. After the addition thesolidified mass was dissolved in CH₂Cl₂ (20 ml) and stirred at roomtemperature for 2 hrs. Again the temperature was cooled to 0° C. and1-benzoyl-4-piperidone in CH₂Cl₂ was added slowly. After the additionthe reaction mixture was stirred at room temperature for 2 hrs andpoured over crushed ice and sodium acetate. It was stirred for 30minutes at room temperature.

[0276] Extracted with CH₂Cl₂; washed well with water; dired overanhydrous MgSO₄ and concentrated. The crude product was dissolved inCH₂Cl₂ and ethylmercaptoacetae (9.6 g, 80 mmol)/Et₃N (10.1 g, 100 mmol)was added slowly at room temperature. The reaction mixture was refluxedfor 2 hrs and quenched with water. CH₂Cl₂ layer was washed well withwater; dried over anhydrous MgSO₄; filtered and concentrated. Theproduct was purified by SiO₂ column chromatography by eluting it with50% ethylacetae; hexane. Yellow oil; Yield: 6.4 gms (25%); M+H 316.

[0277] Step: 2(5-benzyl-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)methanol:

[0278] To stirred suspension of LAH (2.0 gms) a solution of ethyl5-benzoyl-4,5,6,7-tetrahydrothieno[3,2-c]pyridine-2-carboxylate (6.0 g,19 mmol) in THF was added slowly at 0° C. After addition reactionmixture was stirred for 30 minutes and quenched with saturated NH₄Cl. Itwas diluted with CHCl₃ and filtered. The fitrate was washed withsaturated brine solution and dried over anhydrous MgSO₄. It was filteredand taken to next step with out purifications. Yield: 4.5 g 91%. Yellowliquid.

[0279] Step 3: 2-Formyl(5-benzyl-4,5,6,7-tetrahydrothieno[3,2-c]pyridine:

[0280] To a stirred solution of(5-benzyl-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)methanol (4.0 g,15.4 mmol) in CH₂Cl₂ (300 ml) active MnO₂ (20 g, excess) was added andstirred at room temperature for 18 hrs. At the end, the reaction mixturewas filtered through celite and washed with CHCl₃. Reaction mixture waswashed well with water; dried and concentrated. The product was found tobe pure and taken to next step without purifications. Yield: 3.0 g(76%); (M+H: 257).

[0281] Step 4:4-Nitrobenzy-6-[(acetyloxy)(5-benzyl-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate:

[0282] 2-Formyl (5-benzyl-4,5,6,7-tetrahydrothieno[3,2-c]pyridine (565mg, 2.2 mmol) and the dry THF solution (20 mL) of (5R,6S)-6-bromo-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid 4-nitro-benzyl ester (772 mg, 2.0 mmol) were added successively tothe dry acetonitrile (15 mL) solution of anhydrous MgBr₂: O(Et)₂ (390mg, 1.5 mmol)under an argon atmosphere at room temperature. Aftercooling to −20° C., Et₃N (2.0 mL) was added in one portion. The reactionvessel was covered with foil to exclude light. The reaction mixture wasstirred for 2 h at −20° C. and treated with acetic anhydride (1.04 mL)in one portion. The reaction mixture was warmed to 0° C. and stirred for15 h at 0° C. The mixture was diluted with ethyl acetate and washed with5% citric acid aqueous solution, saturated sodium hydrogen carbonate,and brine. The organic layer was dried (MgSO₄) and filtered through apad of Celite. The pad was washed with ethyl acetate. The filtrate wasconcentrated under reduced pressure. The residue was applied to silicagel column chromatography, then the column was eluted with ethylacetate:hexane (1:1). Collected fractions were concentrated underreduced pressure and the mixture of diastereo isomers were taken to nextstep. Pale yellow amorphous solid; Yield: 550 mg, 40%; M+H 687.

[0283] Step-5:(5R,6Z)-6-[(5-benzyl-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)methylene]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid:

[0284]4-Nitrobenzy-6-[(acetyloxy)(5-benzyl-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate(450mg, 0.65 mmol) was dissolved in THF (20 mL) and acetonitrile (10 mL).Freshly activated Zn dust (5.2 g) was added rapidly with 0.5 M phosphatebuffer (pH 6.5, 28 mL). The reaction vessel was covered with foil toexclude light. The reaction mixture was vigorously stirred for 2 hoursat room temperature. The reaction mixture was filtered, cooled to 3° C.,and 0.1 M NaOH was added to adjust pH to 8.5. The filtrate was washedwith ethyl acetate and the aqueous layer was separated. The aqueouslayer was concentrated under high vacuum at 35° C. to give yellowprecipitate. The product was purified by HP21 resin reverse phase columnchromatography. Initially the column was eluted with deionized water (2lits) and latter with 10% CAN: Water. The fractions containing theproduct were collected and concentrated at reduced pressure at roomtemperature. The yellow solid was washed with acetone and filtered.Dried. Yield: 50 mg, 18%; as yellow crystals; mp. 198° C.; (M+H) 411.

[0285]¹H NMR (DMSO-d₆)δ d 2.7 (m, 2H), 2.8 (bm, 2H), 3.4 (m, 2H), 3.8(s, 2H), 6.3 (s, 1H), 6.5 (s, 1H), 7.1(s, 1H), 7.28(s, 1H), 7.4 (s, 5H).

Example 2 Preparation of(5R),(6Z)-6-(7-Methyl-5,6,7,8-tetrahydroimidazo[2-a]pyrazin-2-ylmethylene)-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicAcid, Sodium Salt

[0286] Step 1: Imidazo[1,2-a]pyrazine-2-carboxylic Acid Ethyl Ester:

[0287] Ethyl bromopyruvate (62.9 g) was added to the DME (258 mL)solution of 2-aminopyrazine (24.8 g) at room temperature and stirred for2.5 h. The reaction mixture was cooled to 0° C. and stirred for 30 minto afford a pale brown precipitate. The precipitate was filtered andwashed with Et₂O to give pale brown crystals. The suspension of theprecipitate (66.1 g) in EtOH (1.29 L) was heated at reflux temperatureto turn to clear solution. After refluxing for 2 h, the reaction mixturewas concentrated under reduced pressure, then mixed with CHCl₃ andsaturated NaHCO₃aq. The mixture was filtered through a pad of Celite andthe separated organic layer was dried (MgSO₄) and filtered. The filtratewas concentrated under reduced pressure. The residue was applied tosilica gel column chromatography, then the column was eluted withCHCl₃-MeOH ({fraction (99/1)}˜{fraction (97/3)}), and collectedfractions were concentrated under reduced pressure followed byrecrystallization from CHCl₃-Et₂O. The titled compound was obtained aspale pink crystals. Yield: 10.9 g, 22%).

[0288]¹H NMR(CDCl₃)δd 1.46(t, 3H, J=7.2 Hz), 4.49(q, 2H, J=7.2 Hz),7.96(d, 1H, J=4.7 Hz), 8.08(dd, 1H, J=1.2, 4.7 Hz), 8.26(s, 1H), 9.21(d, 1H, J=1.2 Hz).

[0289] Step 2: 5,6,7,8-Tetrahydroimidazo[1,2-a]pyrazine-2-carboxylicAcid Ethyl Ester, Hydrochloride:

[0290] 0.46 M HCl-EtOH (169 mL) and 10% Pd-C (50% wet) (1.37 g) wereadded to the EtOH (546 mL) solution ofimidazo[1,2-a]pyrazine-2-carboxylic acid ethyl ester (13.7 g). Themixture was hydrogenated under H₂ at 40 psi at room temperature for 15h. The reaction mixture was filtered and Pd-C was washed with EtOH. Thefiltrate was concentrated under reduced pressure. The residue wasapplied to silica gel column chromatography, then the column was elutedwith CHCl₃-MeOH ({fraction (9/1)}˜{fraction (2/1)}). The titled compoundwas obtained as brown crystals Yield: 10.4 g, 63%.

[0291]¹H NMR(CDCl₃)δ d 1.38(t, 3H, J=7.1 Hz), 3.90(t, 2H, J=5.7 Hz),4.40(q, 2H, J=7.1 Hz), 4.59(t, 2H, J=5.7 Hz), 4.80(s, 2H), 8.20(s, 1H).

[0292] Step 3:7-Methyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-2-carboxylic AcidEthyl Ester:

[0293] Et₃N (3.44 mL), 37% HCHO aq. (2.02 mL) and NaBH₃CN (1.78 g) wereadded successively to the MeOH (75 mL) solution of5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-2-carboxylic acid ethyl ester,hydrochloride (5.2 g) at room temperature and stirred for 3.5 h under anitrogen atmosphere. The mixture was diluted with CH₂Cl₂ and washed with50% K₂CO₃ aq. The organic layer was dried (K₂CO₃) and filtered. Thefiltrate was concentrated under reduced pressure. The residue wasapplied to silica gel column chromatography, then the column was elutedwith CHCl₃-acetone ({fraction (1/1)}˜½). The titled compound wasobtained as orange oil. Yield: 2.68 g, 57%).

[0294]¹H NMR(CDCl₃)δ d 1.37(t, 3H, J=7.1 Hz), 2.50(s, 3H), 2.85(t, 2H,J=5.5 Hz), 3.69(s, 2H), 4.06(t, 2H, J=5.5 Hz), 4.36(t, 2H, J=7.1 Hz),7.52(s, 1H).

[0295] Step 4:7-Methyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-2-carbaldehyde:

[0296] 1.01 M solution of DIBAL in toluene (13.6 mL) was added to thedry CH₂Cl₂ (86 mL) solution of7-methyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-2-carboxylic acidethyl ester (1.8 g) under a nitrogen atmosphere at −78° C. and stirredfor 2 h. The mixture was quenched with 1 M HCl. The reaction mixture wasfiltered through a pad of Celite. The filtrate was washed with 50% K₂CO₃aq. and the aqueous layer was extracted with CH₂Cl₂ three times. Thecombined organic layer was dried (K₂CO₃) and filtered. The filtrate wasconcentrated under reduced pressure. The residue was applied to silicagel column chromatography, then the column was eluted with CHCl₃-MeOH({fraction (19/1)}˜{fraction (9/1)}). The titled compound 5 was obtainedas colorless crystals. Yield: 591 mg, 42%).

[0297]¹H NMR(CDCl₃)δ d 2.51(s, 3H), 2.87(t, 2H, J=5.5 Hz), 3.70(s, 2H),4.10(t, 2H, J=5.5 Hz), 7.53(s, 1H), 9.82(d, 1H, J=1.4 Hz).

[0298] Step 5: (5R,6RS)-6-[(RS)-Acetoxy(7-methyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazin-2-yl)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicAcid 4-nitrobenzyl Ester (Diastereo Mixture):

[0299] 7-Methyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-2-carbaldehyde(1.19 g) was added to the dry acetonitrile (97 mL) solution of anhydrousMgBr₂ (4.05 g) under a nitrogen atmosphere at room temperature. The dryTHF solution (97 mL) of (5R,6S)-6-bromo-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid 4-nitro-benzyl ester (3.32 g) was added to the mixture, cooled to−20° C., and Et₃N (3.0 mL) was added in one portion. The reaction vesselwas covered with foil to exclude light. The reaction mixture was stirredfor 4.5 h at −20° C. and treated with acetic anhydride (1.36 mL) in oneportion. The reaction mixture was warmed to 0° C. and stirred for 17 hat 0° C. The mixture was diluted with ethyl acetate and washed with 5%citric acid aqueous solution, saturated sodium hydrogen carbonate, andbrine. The organic layer was dried (MgSO₄) and filtered. The filtratewas concentrated under reduced pressure. The residue was applied tosilica gel column chromatography, then the column was eluted withCHCl₃-acetone ({fraction (9/1)}˜{fraction (2/1)}). The titled compoundwas obtained as two diastereo mixture. Red oil, Yield: 1.13 g.

[0300]¹H NMR(CDCl₃)δ d 1.20(s, 0.81×3H), 2.24(s, 0.19×3H), 2.48(s, 3H),2.80˜2.84(m, 2H), 3.57˜3.67(m, 2H), 3.97˜4.02(m, 2H), 5.27(d, 1H, J=13.6Hz), 5.42(d, 0.19×1H, J=13.6 Hz), 5.45(d, 0.81×1H, J=13.6 Hz), 6.07(s,0.19×1H), 6.30(s. 0.81×2H), 6.79(s, 0.19×1H), 6.80(s, 0.19×1H), 7.02(s,0.81×1H), 7.44(s, 0.19×1H), 7.47(s, 0.81×1H), 7.60(d, 0.19×2H, J=8.2Hz), 7.62(d, 0.81×2H, J=8.6 Hz), 8.22˜8.26(m, 2H).

[0301] Step 6:(5R),(6Z)-6-(7-Methyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazin-2-ylmethylene)-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicAcid, Sodium Salt:

[0302] (5R,6RS)-6-[(RS)-Acetoxy(7-methyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazin-2-yl)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid 4-nitrobenzyl ester (1.11 g) was dissolved in THF (32 mL) andacetonitrile (32 mL). Freshly activated Zn dust (4.46 g) was addedrapidly with 0.5 M phosphate buffer (pH 6.5, 48 mL). The reaction vesselwas covered with foil to exclude light. The reaction mixture wasvigorously stirred for 2 h at room temperature. The reaction mixture wasfiltered through a pad of Celite, cooled to 3° C., and 1 M NaOH wasadded to adjust pH to 7.5. The filtrate was washed with ethyl acetateand the aqueous layer was separated. The aqueous layer was concentratedunder high vacuum at 35° C. The concentrate was applied to Diaion HP-21(20 mL, Mitsubishi Kasei Co. Ltd.) resin column chromatography. Afteradsorbing, the column was eluted with H₂O-MeCN({fraction(1/0)}˜{fraction (95/5)}). The combined fractions were concentratedunder high vacuum at 35° C. and lyophilized to give the title compoundas a yellow amorphous solid. Yield: 417 mg, 65%: mp 200° C. (dec); ¹HNMR(D₂O)δ d 2.32(s, 3H), 2.79˜2.81(m, 2H), 3.54(s, 2H), 3.95(t, 2H,J=5.6 Hz), 6.39(s, 1H), 6.85(s, 1H), 6.87(s, 1H), 7.26(s, 1H).

Example 3 Preparation of (5R),(6Z)-7-Oxo-6-(5,6,7,8-tetrahydroimidazo[1,2-a]pyrazin-2-ylmethylene)-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt

[0303] 2-Ketopiperazine

[0304] 2-Ketopiperazine may be prepared according to procedures in U.S.Pat. No. 5,629,322.

[0305] Step 1: 4-p-Nitrobenzyloxycarbonyl-2-ketopiperazine

[0306] The 48.7% solution of p-nitrobenzyloxycarbonyl chloride in1,4-Dioxane (10.7 mL) was added to the dichloromethane (110 mL) solutionof 2-Ketopiperazine (2.21 g) and diisopropylethylamine (4.6 mL) at 0° C.and stirred for 0.5 h at 0° C. Water (300 mL) was added to the reactionmixture, and extracted with dichloromethane (3×100 mL). The organiclayer was dried (MgSO₄) and filtered. The filtrate was concentratedunder reduce pressure. The residue was applied to silica gel columnchromatography, eluted with CHCl₃-methanol (30:1), and the titlecompound was obtained as white solid (7.1 g, quant.).

[0307]¹H NMR (d, CDCl₃)δ 3.42-3.45 (m, 2H), 3.74 (t, 2H, J=5.4 Hz), 4.19(s, 2H), 5.26 (s, 2H), 6.39 (brs, 1H), 7.52 (d, 2H, J=8.6 Hz), 8.24 (d,2H, J=8.6 Hz).

[0308] Step 2: 5-Methoxy-4-p-nitrobenzyloxycarbonyl-1,2,3,6-tetrahydropyrazine:

[0309] Trimethyloxonium tetrafluoroborate (97%, 3.7 g) was added to thedry dichloromethane (120 mL) solution of4-p-nitrobenzyloxycarbonyl-2-ketopiperazine (6.7 g) at room temperatureand stirred for 17 hours. The reaction mixture was treated withsaturated sodium hydrogen carbonate aqueous solution, and the organiclayer was separated. The aqueous layer was extracted with ethyl acetate(3×100 mL), then the combined organic layer was washed with saturatedsodium hydrogen carbonate aqueous solution and brine. The organic layerwas dried (MgSO₄) and filtered. The filtrate was concentrated underreduce pressure and the title compound was obtained as a pale brownsolid. Yield; 5.7 g, 80.6.

[0310]¹H NMR (d, CDCl₃)δ 3.48 (m, 2H), 3.57 (m, 2H), 3.70 (s, 3H), 3.97(s, 2H), 5.26 (s, 2H), 7.52 (d, 2H, J=8.7 Hz), 8.23 (d, 2H, J=8.7 Hz).

[0311] Step 3: 2-Imino-4-p-nitrobenzyloxycarbonyl piperazine:

[0312] The mixture of5-methoxy-4-p-nitrobenzyloxycarbonyl-1,2,3,6-tetrahydropyrazine (5.7 g)and ammonium chloride (1.6 g) in dry ethanol (100 mL) was heated toreflux for 4 hours. The reaction mixture was then concentrated underreduced pressure. Dichloromethane (100 mL) was added to the residue andextracted with water (3×50 mL) then the combined aqueous layer waswashed with dichloromethane. The aqueous layer was neutralized with 10%potassium carbonate aqueous solution and then extracted withdichloromethane (8×50 mL). The combined organic layer was dried (MgSO₄)and filtered. The filtrate was concentrated under reduced pressure andthe title compound was obtained as a white solid. Yield: 4.9 g, 91.2%.

[0313]¹H NMR (d, CDCl₃)δ 3.49 (brs, 4H), 3.98 (brs, 2H), 5.26 (s, 2H),7,52 (d, 2H, J=8.6 Hz), 8.23 (d, 2H, J=8.6 Hz).

[0314] Step 4:7-p-Nitrobenzyloxycarbonyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-2-carbaldehyde(9) and 1-p-nitrobenzyloxycarbonyl-5,6,7,8tetrahydroimidazo[1,2-a]pyrazine-3-carbaldehyde:

[0315] The mixture of 2-bromo-3-hydroxypropenal (2.8 g),p-toluenesulfonic acid monohydrate (33 mg) and 2-propanol (3.5 mL) incyclohexane (28 mL) was azeotroped until the vaper temperature rose to80° C. The reaction mixture was concentrated under reduce pressure. Theresidue was dissolved in dry acetonitrile (30 mL). The dry acetonitrile(310 mL) solution of 2-imino-4-p-nitrobenzyloxycarbonyl piperazine (4.7g) was added at room temperature. The reaction mixture was stirred atroom temperature for 3 h, and then the reaction solution was removed invacuo. The residue was dissolved in ethyl acetate (170 mL) andtriethylamin (2.4 mL) was added, then the reaction mixture was heated toreflux for 1.5 h. The reaction mixture was cooled to room temperature,and then water (170 mL) was added to the reaction mixture and separated.The aqueous layer was extracted with dichloromethane (2×100 mL). Thecombined organic layer was dried (MgSO₄) and filtered. The filtrate wasconcentrated under reduce pressure. The residue was applied to silicagel column chromatography, eluted with CHCl₃-methanol (50:1), and thetitle compound was obtained as a brown solid, (Yield: 2.9 g, 51.6%) andits regio isomer (orange amorphous solid, Yield; 0.8 g, 14.9%) wereobtained.

[0316]¹H NMR (d, CDCl₃) 3.99 (t, 2H, J=5.4 Hz), 4.14 (t, 2H, J=5.4 Hz),4.85 (s, 2H), 5.29 (s, 2H), 7.54 (d, 2H, J=8.6 Hz), 7.57 (s, 1H), 8.24(d, 2H, J=8.6 Hz), 9.85 (s, 1H).

[0317] Regio isomer ¹H NMR (d, CDCl₃)δ 3.95 (t, 2H, J=5.4 Hz), 4.44 (t,2H, J=5.4 Hz), 4.87 (s, 2H), 5.29 (s, 2H), 7.54 (d, 2H, J=8.7 Hz), 7.78(s, 1H), 8.24 (d, 2H, J=8.7 Hz), 9.71 (s, 1H).

[0318] Step 5:(5R)-6-[Acetoxy-(7-p-nitrobenzyloxycarbonyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazin-2-yl)-methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid p-nitrobenzyl Ester:

[0319] The dry acetonitrile (25 mL) solution of7-p-nitrobenzyloxycarbonyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-2-carbaldehyde(1.6 g) was added to the dry acetonitrile (55 mL) solution of MgBr₂ (2.2g) under an nitrogen atmosphere at room temperature then the mixture wasstirred for 10 min. The dry THF (80 mL) solution of (5R,6S)-6-bromo-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid 4-nitro-benzyl ester (1.8 g) was added, the mixture was cooled to−20° C. then triethylamine (1.6 mL) was added in one portion. Thereaction vessel was covered with foil to exclude light. The reactionmixture was stirred for 3 h at −20° C. and treated with4,4-dimethylamino pyridine (58.3 mg) and acetic anhydride (0.89 mL) inone portion. The reaction mixture was warmed to 0° C. and stirred for 15h at 0° C. 10% Citric acid aqueous solution (320 mL) was added to thereaction mixture and the aqueous layer was extracted with ethyl acetate(3×160 mL). The organic layer was washed with water, saturated sodiumhydrogen carbonate and brine, dried (MgSO₄) and filtered. The filtratewas concentrated under reduced pressure. The residue was applied tosilica gel column chromatography, eluted with CH₂Cl₂-acetone (20:1), andthe title compound was obtained as two diastereo mixture (81: 19, brownfoamy amorphous solid. Yield: 2.1 g, 59.9%.

[0320]¹H NMR (d, CDCl₃)δ 2.01 (s, 2.43H), 2.24 (s, 0.57H), 3.93-,3.96(m, 2H), 4.02-4.05 (m, 2H), 4.74-4.76 (m, 2H), 5.28 (d, 1H, J=13.5 Hz),5.28 (s, 2H), 5.45 (d, 1H, J=13.5 Hz), 6.07 (s, 0.19H), 6.29 (s, 0.81H),6.31 (s, 0.81H), 6.80 (s, 0.19H), 6.83 (s, 0.19H), 7.08 (s, 0.81H), 7.43(s, 0.19H), 7.46 (s, 0.81H), 7.54 (d, 2H, J=8.6 Hz), 7.61 (d, 2H, J=8.8Hz), 8.24 (d, 4H, J=8.3 Hz).

[0321] Step 6: (5R),(6Z)-7-Oxo-6-(5,6,7,8-tetrahydroimidazo[1,2-a]pyrazin-2-ylmethylene)-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicAcid, Sodium Salt:

[0322](5R)-6-[Acetoxy-(7-p-nitrobenzyloxycarbonyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazin-2-yl)-methyl]-6-bromo-7-oxo-4-thia-1azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid p-nitrobenzyl ester (2.0g) was dissolved in THF (63 mL). Freshly activated Zn dust (7.9 g) wasadded rapidly with 0.5 mol/L phosphate buffer (pH 6.5, 63 mL). Thereaction vessel was covered with foil to exclude light. The reactionmixture was vigorously stirred for 2 h at room temperature. The reactionsolution was filterd through a pad of Celite and the pad was washed withwater (150 mL) and n-butanol (150 mL). The aqueous layer was separatedand then the organic layer was extracted with water (2×50 mL). Thecombined aqueous layer was concentrated to 61 g and applied to DiaionHP-21 resin (80 mL, Mitsubishi Kasei Co. Ltd.) column chromatography.After adsorbing, the column was eluted with water and then 5%acetonitrile aqueous solution. The combined fractions were concentratedunder high vacuum at 35° C. and lyophilized to give the title compoundas a yellow amorphous solid. Yield: 172 mg, 20.1%: mp 150° C. (dec); ¹HNMR (d, D₂O)δ3.02 (t, 2H, J=5.6 Hz), 3.82 (s, 2H), 3.89 (d, 2H, J=5.6Hz), 6.38 (s, 1H), 6.84 (s, 1H), 6.87 (s, 1H), 7.24 (s, 1H); IR (KBr)

Example 4 Preparation of(5R,6Z)-6-{[5-(4-methoxybenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl]methylene}-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid

[0323] Step 1: 5-tert-butyl 2-ethyl6,7-dihydrothieno[3,2-c]pyridine-2,5(4H)-dicarboxylate:

[0324] 5-tert-butyl 2-ethyl6,7-dihydrothieno[3,2-c]pyridine-2,5(4H)-dicarboxylate was preparedaccording to the procedure as outlined in Example 1, (Step 1). Startingfrom tert-butyl-1-piperidinecarboxylate (9.9 g, 50 mmol), POCl₃ (6.3 g,40 mmol) and DMF (3.8 g, 50 mmol). The chloroformyl intermediate wasreacted with ethyl mercaptoacetate (6.0 g, 50 mmol) and Et₃N. Theproduct was purified by SiO₂ column chromatography by eluting it with3:1 hexane; ethylacetae. Yield: 8.7 g, 56%; White liquid. (M+H) 312.

[0325] Step 2: tert-butyl2-(hydroxymethyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-carboxylate:

[0326] tert-butyl2-(hydroxymethyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-carboxylate wasprepared according to the procedure outlined in Example 1, (Step 2).Starting from 5-tert-butyl 2-ethyl6,7-dihydrothieno[3,2-c]pyridine-2,5(4H)-dicarboxylate (1.0 g, 3.21mmol) and LiAlH₄ (500 mg, excess), 807 mg (92% yield) of the alcoholderivative was isolated as white liquid. (M+H) 270.

[0327] Step 3: tert-butyl2-(formyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-carboxylate:

[0328] tert-butyl2-(formyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-carboxylate wasprepared according to the procedure outlined in Example 1, (Step 3).Starting from tert-butyl2-(hydroxymethyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-carboxylate(1.0 g 3.7 mmol) in methylene chloride (100 ml) and active MnO₂ (5 g,excess), 800 g (81% Yield) of the aldehyde derivative was isolated asbrown solid. (M+H) 268.

[0329] Step 4: 2-(formyl)-6,7-dihydrothieno[3,2-c]-5(4H)-pyridine:

[0330] 2-(formyl)-6,7-dihydrothieno[3,2-c]-5(4H)-pyridine was preparedstarting from tert-butyl2-(formyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-carboxylate (1.0 g 3.7mmol) was dissolved in CH₂Cl₂ (20 ml), MeOH (90% 20 ml) and 1N. HCl indioxane (10 ml). The reaction mixture was stirred at room temperaturefor 48 hrs. At the end reaction mixture was concentrated to dryness andtaken to next step without purification. Yield: 750 mg (HCl salt,Quantitative); M+H 168.

[0331] Step 5: 2-Formyl[5-(4-methoxybenzyl)4,5,6,7-tetrahydrothieno][3,2-c]pyridine:

[0332] To a stirred solution of2-(formyl)-6,7-dihydrothieno[3,2-c]-5(4H)-pyridine (1.4 g, 5.2 mmol) inDMF (20 ml), 4-methoxybenzyl chloride (0.94 g, 6.2 mmol) andN,N-diisopropylethylamine (10 ml, excess) was added at room temperature.The reaction mixture was stirred for 24 hrs and quenched with water. Thereaction mixture was extracted with chloroform; washed well with waterand dried over anhydrous MgSO₄. It was filtered and concentrated. Theproduct was purified by SiO₂ column chromatography by eluting it withethylacetate. Pale yellow oil. Yield: 470 mg, 35%; M+H 288.

[0333] Step 6:4-Nitrobenzy-6-[(acetyloxy)[5(4-methoxybenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate:

[0334] 2-Formyl[5-(4-methoxybenzyl)-4,5,6,7-tetrahydrothieno][3,2-c]pyridine (574 mg,2.0 mmol) and the dry THF solution (20 mL) of (5R,6S)-6-bromo-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid 4-nitro-benzyl ester (772 mg, 2.0 mmol) were added successively tothe dry acetonitrile (15 mL) solution of anhydrous MgBr₂: O(Et)₂ (390mg, 1.5 mmol)under an argon atmosphere at room temperature. Aftercooling to −20° C., Et₃N (2.0 mL) was added in one portion. The reactionvessel was covered with foil to exclude light. The reaction mixture wasstirred for 2 h at −20° C. and treated with acetic anhydride (1.04 mL)in one portion. The reaction mixture was warmed to 0° C. and stirred for15 h at 0° C. The mixture was diluted with ethyl acetate and washed with5% citric acid aqueous solution, saturated sodium hydrogen carbonate,and brine. The organic layer was dried (MgSO₄) and filtered through apad of Celite. The pad was washed with ethyl acetate. The filtrate wasconcentrated under reduced pressure. The residue was applied to silicagel column chromatography, then the column was eluted with ethylacetate:hexane (1:1). Collected fractions were concentrated underreduced pressure and the mixture of diastereo isomers were taken to nextstep. Pale yellow amorphous solid; Yield: 550 mg, 40%; M+H 714 and 716.

[0335] Step-7:(5R,6Z)-6-{[5-(4-methoxybenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)]methylene}-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid:

[0336]4-Nitrobenzy-6-[(acetyloxy)[5(4-methoxybenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate(300 mg, 0.42 mmol) was dissolved in THF (20 mL) and acetonitrile (10mL). Freshly activated Zn dust (5.2 g) was added rapidly with 0.5 Mphosphate buffer (pH 6.5, 28 mL). The reaction vessel was covered withfoil to exclude light. The reaction mixture was vigorously stirred for 2h at room temperature. The reaction mixture was filtered, cooled to 3°C., and 0.1 M NaOH was added to adjust pH to 8.5. The filtrate waswashed with ethyl acetate and the aqueous layer was separated. Theaqueous layer was concentrated under high vacuum at 35° C. to giveyellow precipitate. The product was purified by HP21 resin reverse phasecolumn chromatography. Initially the column was eluted with deionizedwater (2 lits) and latter with 10% CAN: Water. The fractions containingthe product were collected and concentrated at reduced pressure at roomtemperature. The yellow solid was washed with acetone and filtered.Dried. Yield: 50 mg, 18%; as yellow crystals; mp. 127° C.; (M+H) 441.

[0337]¹H NMR (DMSO-d₆)δ d 2.7 (m, 2H), 2.8 (bm, 2H), 3.4 (m, 2H), 3.74(s, 3H) 3.8 (s, 2H), 6.6 (s, 1H), 6.88 (dd, 2H), 7.14(s, 1H), 7.24(dd,2H), 7.4 (s, 1H), 7.59 (s, 1H).

Example 5 Preparation of (5R),(6Z)-6-(5,6-dihydro-8H-imidazo[2,1-c][1,4]thiazin-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicAcid, Sodium Salt

[0338] Step 1: 5-Methylthio-3,6-dihydro-2H-[1,4]thiazine Hydroiodide

[0339] 5-Methylthio-3,6-dihydro-2H-[1,4]thiazine hydroiodide wasprepared by the method as outlined in U.S. Pat. No. 5,629,322.

[0340] Step 2: 3-Iminothiomorpholin Hydrochloride

[0341] 5-Methylthio-3,6-dihydro-2H-[1,4]thiazine hydroiodide (7.1 g) wasdissolved with 10% K₂CO₃ aqueous solution (150 mL) and the aqueous layerwas extracted with CH₂Cl₂ (5×70 mL). The combined organic layer wasdried (MgSO₄), filtered and concentrated under reduce pressure. Ammoniumchloride (1.7 g) was added to the obtained residue in dry ethanol (128mL) and heated to reflux for 1 h. The reaction mixture was cooled toroom temperature. The reaction solution was removed in vacuo and theIminothiomorpholin hydrochloride was obtained as brown solid (4.3 g,quant.).

[0342]¹H NMR (d, DMSO-d⁶)δ3.15 (t, 2H, J=5.9 Hz), 3.74 (t, 2H, J=5.9Hz), 3.83 (s, 2H), 8.97 (brs, 1H), 9.38 (brs, 1H), 9.99 (brs, 1H).

[0343] Step 3: 5,6-Dihydro-8H-imidazo[2,1-c][1,4]thiazine-2-carbardehydeand 5,6-Dihydro-8H-imidazo[2,1-c][1,4]thiazine-3-carbardehyde

[0344] The mixture of 2-bromo-3-hydroxypropenal (7, 4.3 g),p-toluenesulfonic acid monohydrate (52 mg) and 2-propanol (5.3 mL) incyclohexane (43 mL) was azeotroped until the vaper temperature rose to80° C. The reaction mixture was concentrated under reduce pressure. Theresidue was dissolved in dry ethanol (28 mL). The mixture of the dryethanol (143 mL) solution of 3-iminothiomorpholin hydrochloride (4.3 g)and 28% methanol solution of sodium methylate (5.0 mL) were added atroom temperature. The reaction mixture was stirred at room temperaturefor 1 h, and then the reaction solution was removed in vacuo. Theresidue was dissolved in chloroform (128 mL) and triethylamine (3.6 mL)was added, then the reaction mixture was heated to reflux for 2.5 h. Thereaction mixture was cooled to room temperature and then concentratedunder reduce pressure. The residue was dissolved with dichloromethane(300 mL) and washed with 50% K₂CO₃ aqueous solution (2×100 mL). Theorganic layer was dried (MgSO₄) and filtered. The filtrate wasconcentrated under reduce pressure. The residue was applied to silicagel column chromatography, eluted with CHCl₃-acetone (10:1), and5,6-Dihydro-8H-imidazo[2,1-c][1,4]thiazine-2-carbardehyde (brown solid,445 mg, 10.3%) and5,6-Dihydro-8H-imidazo[2,1-c][1,4]thiazine-3-carbardehyde (brown solid,872 mg, 20.2%) were obtained.

[0345] 5,6-Dihydro-8H-imidazo[2,1-c][1,4]thiazine-2-carbardehyde: ¹H NMR(d, CDCl₃)δ 3.07 (t, 2H, J=5.7 Hz), 3.95 (s, 2H), 4.33 (t, 2H, J=5.7Hz), 7.55 (s, 1H), 9.83 (s, 1H).

[0346] 5,6-Dihydro-8H-imidazo[2,1-c][1,4]thiazine-3-carbardehyde: ¹H NMR(d, CDCl₃) δ3.05 (t, 2H, J=5.7 Hz), 3.98 (s, 2H), 4.61 (t, 2H, J=5.7Hz), 7.73 (s, 1H), 9.69 (s. 1H).

[0347] Step 4: (5R),(6Z)-6-(5,6-dihydro-8H-imidazo[2,1-c][1,4]thiazin-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicAcid, Sodium Salt:

[0348] The dry acetonitrile (20 mL) solution of5,6-dihydro-8H-imidazo[2,1-c][1,4]thiazine-2-carbardehyde (392 mg) wasadded to the dry acetinitrile (20 mL) solution of MgBr₂ (1.1 g) under anitrogen atmosphere at room temperature then the mixture was stirred for10 min. The dry THF (40 mL) solution of (5R,6S)-6-bromo-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid 4-nitro-benzyl ester (1.0 g) was added and the mixture was cooledto −20° C. then triethylamine (0.8 mL) was added in one portion. Thereaction vessel was covered with foil to exclude light. The reactionmixture was stirred for 3.5 h at −20° C. and treated with4-dimethylamino pyridine (30 mg) and acetic anhydride (0.44 mL) in oneportion. The reaction mixture was warmed to 0° C. and stirred for 14 hat 0° C. 10% Citric acid aqueous solution (240 mL) was added to thereaction mixture and the aqueous layer was extracted with ethyl acetate(3×100 mL). The combined organic layer was washed with water, saturatedsodium hydrogen carbonate and brine, dried (MgSO₄) and filtered. Thefiltrate was concentrated under reduced pressure. The residue wasroughly purified by silica gel column chromatography, eluted withCH₂Cl₂-acetone (50:1), and crude(5R)-6-[acetoxy-(5,6-dihydro-8H-imidazo[2,1-c][1,4]thiazin-2-yl)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid p-nitrobenzyl ester was obtained as solid.

[0349] The solid obtained above was purified by SiO₂ columnchromatography by eluting it with 505 ethylacetae:hexane. The paleyellow solid obtained was dissolved in THF (17 mL). Freshly activated Zndust (2.2 g) was added rapidly with 0.5 mol/L phosphate buffer (pH 6.5,17 mL). The reaction vessel was covered with foil to exclude light. Thereaction mixture was vigorously stirred for 2 h at room temperature. Thereaction solution was filterd through a pad of Celite and the pad waswashed with water (40 mL) and n-butanol (30 mL). The aqueous layer wasseparated and then the organic layer was extracted with 0.5 mol/Lphosphate buffer (pH 6.5, 2×10 mL). The combined aqueous layer wasconcentrated to 23 g, 1 mol/L NaOH was added to adjust pH to 7.25 andapplied to Diaion HP-21 resin (30 mL, Mitsubishi Kasei Co. Ltd.) columnchromatography. After adsorbing, the column was eluted with water andthen 10% acetonitrile aqueous solution. The combined active fractionswere concentrated under high vacuum at 35° C. and lyophilized to give(5R),(6Z)-6-(5,6-dihydro-8H-imidazo[2,1-c][1,4]thiazin-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt as a yellow amorphous solid (168 mg, 20.9%).

[0350] mp 135° C. (dec); ¹H NMR (d, D₂O)δ3.00 (t, 2H, J=5.7 Hz), 3.80(AB, 2H, J=16.7, 18.1 Hz), 4.19 (t, 2H, J=5.7 Hz), 6.44 (d, 1H, J=0.8Hz), 6.89 (s, 1H), 6.93 (s, 1H), 7.29 (s, 1H); M+H=322.

Example 6 Preparation of (5R),(6Z)-6-(6,7-Dihydro-5H-pyrrolo[1,2-a]imidazol-2-ylmethylene)-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicAcid, Sodium Salt

[0351] Step 1: 6,7-Dihydro-5H-pyrrolo[1,2-a]imidazole-2-carbaldehyde

[0352] 28% Sodium methoxide (5.26 g) was added to the EtOH (250 mL)solution of 4,5-dihydro-3H-pyrrol-2-ylamine hydrochloride (3.27 g) atroom temperature. After stirring for 5 min at room temperature,2-bromo-3-propoxy-propenal (5.79 g) was added to the mixture at roomtemperature, then the reaction mixture was stirred for 1 h at roomtemperature. The reaction mixture was taken to dryness in vacuo. Theresidue was dissolved in CHCl₃ (300 mL) and triethylamine (3.8 mL) wasadded. The mixture was heated to reflux for 3 hours. The reactionmixture was cooled to room temperature, washed with 50% K2CO3, driedover anhydrous K2CO3, filtered, and evaporated under reduced pressure.The residue was applied with silicagel column chromatography, elutedwith CHCl3-acetone (2:1), and6,7-Dihydro-5H-pyrrolo[1,2-a]imidazole-2-carbaldehyde (41%, 1.51 g) wasobtained as a pale yellow solid.

[0353]¹H NMR (d, CDCl₃):δ 2.62-2.7 (m, 2H), 2.90-2.94 (m, 2H), 4.07 (t,2H, J=7.2 Hz), 7.59 (s, 1H), 9.80 (s, 1H).

[0354] Step 2: (5R),(6Z)-6-(6,7-Dihydro-5H-pyrrolo[1,2-a]imidazol-2-ylmethylene)-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt

[0355] 6,7-Dihydro-5H-pyrrolo[1,2-a]imidazole-2-carbaldehyde (1.36 g)was added to the dry acetonitrile (155 mL) solution of anhydrous MgBr₂(5.64 g) under an argon atmosphere at room temperature. The dry THFsolution (155 mL) of (5R,6S)-6-bromo-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid 4-nitro-benzyl ester (3.86 g) was added to the mixture, cooled to−20° C., and Et₃N (4.18 mL) was added in one portion. The reactionvessel was covered with foil to exclude light. The reaction mixture wasstirred for 3 h at −20° C. and treated with acetic anhydride (1.89 mL)and DMAP (370 mg) in one portion. The reaction mixture was warmed to 0°C. and stirred for 14.5 h at 0° C. The mixture was diluted with ethylacetate and washed with 1 M citric acid aqueous solution, saturatedsodium hydrogen carbonate, and brine. The organic layer was dried(MgSO₄) and filtered. The pad was washed with ethyl acetate. Thefiltrate was concentrated under reduced pressure. The residue wasdissolved in THF (166 mL) and acetonitrile (77 mL). Freshly activated Zndust (23.2 g) was added rapidly with 0.5 M phosphate buffer (pH 6.5, 243mL). The reaction vessel was covered with foil to exclude light. Thereaction mixture was vigorously stirred for 2 h at room temperature. Thereaction mixture was filtered, cooled to 3° C., and 1 M NaOH was addedto adjust pH to 8. The filtrate was washed with ethyl acetate and theaqueous layer was separated. 1 M NaOH was added to the aqueous layeragain to adjust pH to 8. The resultant mixture was concentrated underhigh vacuum at 35° C. The concentrate was applied to Diaion HP-21 (20mL, Mitsubishi Kasei Co. Ltd.) resin column chromatography. Afteradsorbing, the column was eluted with H₂O-MeCN({fraction(1/0)}˜{fraction (9/1)}) to give the purified active fractions of (5R),(6Z)-6-(6,7-Dihydro-5H-pyrrolo[1,2-a]imidazol-2-ylmethylene)-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt. The combined fractions were concentrated under highvacuum at 35° C. and lyophilized to give the titled as a yellowamorphous solid (681 mg, 24%, pH 7.8).

[0356] mp 190° C. (dec); ¹H NMR(d, D₂O): δ: 2.48-2.56 (m, 2H), 2.74-2.79(m, 2H), 3.94-3.99 (m, 2H), 6.47 (d, 1H, J=0.7 Hz), 6.94 (s, 1H), 6.95(s, 1H), 7.36 (s, 1H); (M+H) 291.

Example 7 Preparation of (5R),(6Z)-6-(5,6-Dihydro-8H-imidazo[2,1-c]1,4]oxazin-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic Acid, Sodium Salt

[0357] Step 1: Morpholin-3-one

[0358] Morpholin-3-one was prepared in the method of U.S. Pat. No.5,349,045.

[0359] Step 2: Morpholin-3-thione

[0360] A mixture of morpholin-3-one (4.7 g) and Lawesson's reagent (10.3g) in dry THF (94 mL) was heated to reflux for 1.5 h. The reactionmixture was cooled to room temperature and the reaction solvent wasremoved in vacuo. The residue was applied to silica gel columnchromatography and eluted with CHCl₃-methanol (50:1) to obtain a yellowsolid. Recrystallization of the crude product from hexane-ethyl acetategave the title (4.0 g, 72.2%) as yellow powder.

[0361]¹H NMR (CDCl₃) δ 3.45 (t, 2H, J=5.1 Hz), 3.91 (t, 2H, J=5.1 Hz),4.55 (s, 2H).

[0362] Step 3: 5-Methylthio-3,6-dihydro-2H-[1,4]oxazine

[0363] A mixture of morpholin-3-thione (4.7 g) and methyl iodide (13 mL)in dry CH₂Cl₂ (140 mL) was stirred at room temperature for 15 h. Thereaction mixture was filtered and the solid was washed with CH₂Cl₂. Theobtained solid was dissolved with 50% K₂CO₃ aqueous solution (150 mL)and the aqueous layer was extracted with CH₂Cl₂ (8×100 mL). The combinedCH₂Cl₂ layer was dried (MgSO₄) and filtered. The filtrate wasconcentrated under reduce pressure and the title was obtained as paleyellow oil (3.6 g, 67.8%).

[0364]¹H NMR (CDCl₃) δ 2.32 (s, 3H), 3.71-3.74 (m, 4H), 4.14-4.15 (m,2H).

[0365] Step 4: 3-Iminomorpholin Hydrochloride

[0366] A mixture of 5-methylthio-3,6-dihydro-2H-[1,4]oxazine (3.6 g) andammonium chloride (1.5 g) in dry ethanol (136 mL) was heated to refluxfor 1 h. The reaction mixture was cooled to room temperature. Thereaction solvent was removed in vacuo and the title was obtained as apale brown solid (3.6 g, 97.7%).

[0367]¹H NMR (DMSO-d⁶) δ 3.34 (m, 2H), 3.86 (t, 2H, J=5.2 Hz), 4.47 (s,2H).

[0368] Step 5: 5,6-Dihydro-8H-imidazo[2,1-c][1,4]oxazine-2-carbaldehyde(9) and 5,6-dihydro-8H-imidazo[2,1-c][1,4]oxazine-3-carbaldehyde

[0369] The mixture of 2-bromo-3-hydroxypropenal (4.1 g),p-toluenesulfonic acid monohydrate (52 mg) and 2-propanol (5.2 mL) incyclohexane (42 mL) was azeotroped until the vapor temperature rose to80° C. The reaction mixture was concentrated under reduce pressure. Theresidue was dissolved in dry ethanol (50 mL). A mixture of the dryethanol (200 mL) solution of 3-iminomorpholin hydrochloride (3.4 g) and28% methanol solution of sodium methylate (4.8 g) was added at roomtemperature. The reaction mixture was stirred at room temperature for 2h, and then the reaction solvent was removed in vacuo. The residue wasdissolved in chloroform (125 mL) and triethylamine (3.5 mL) was added,then the reaction mixture was heated to reflux for 2 h. The reactionmixture was cooled to room temperature and then concentrated underreduce pressure. The residue was dissolved in dichloromethane (300 mL)and washed with 50% K₂CO₃ aqueous solution (2×100 mL). The organic layerwas dried (MgSO₄) and filtered. The filtrate was concentrated underreduce pressure. The residue was applied to silica gel columnchromatography and eluted with CHCl₃-acetone (4:1) to obtain the title(pale orange solid, 1.4 g, 36.3%) and the other regio isomer. (paleorange solid, 609 mg, 16.1%).

[0370] Desired product: ¹H NMR (CDCl₃) δ 4.08-4.15 (m, 4H), 4.88 (s,2H), 7.58 (s, 1H), 9.85 (s, 1H).

[0371] The unwanted regio isomer: ¹H NMR (CDCl₃) δ 4.06 (t, 2H, J=5.2Hz), 4.40 (t, 2H, J=5.2 Hz), 4.90 (s, 2H), 7.75 (s, 1H), 9.72 (s, 1H).

[0372] Step 6: 5R), (6Z)-6-(S,6-Dihydro-8H-imidazo[2,1-c][1,4]oxazin-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt

[0373] The dry acetonitrile (66 mL) solution of5,6-dihydro-8H-imidazo[2,1-c][1,4]oxazine-2-carbaldehyde (1.2 g) wasadded to the dry acetonitrile (66 mL) solution of MgBr₂ (3.6 g) under anitrogen atmosphere at room temperature then the mixture was stirred for10 min. The dry THF (132 mL) solution of p-nitrobenzyl (5R,6S)-6-bromopenem-3-carboxylate (3.4 g) was added and the mixture wascooled to −20° C. then triethylamine (2.8 mL) was added in one portion.The reaction vessel was covered with foil to exclude light. The reactionmixture was stirred for 4 h at −20° C. and treated with 4-dimethylaminopyridine (100 mg) and acetic anhydride (1.5 mL) in one portion. Thereaction mixture was warmed to 0° C. and stirred for 18 h at 0° C. 10%Citric acid aqueous solution (1 L) was added to the reaction mixture andthe aqueous layer was extracted with ethyl acetate (3×500 mL). Thecombined organic layer was washed with water, saturated sodium hydrogencarbonate and brine, dried (MgSO₄) and filtered. The filtrate wasconcentrated under reduced pressure and crude(5R)-6-[acetoxy-(5,6-dihydro-8H-imidazo[2,1-c][1,4]oxazin-2-yl)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid p-nitrobenzyl ester was obtained as brown amorphous solid.

[0374] Freshly activated Zn dust (14 g) was added rapidly with 0.5 mol/Lphosphate buffer (pH 6.5, 72 mL) to the THF (72 mL) solution of(5R)-6-[acetoxy-(5,6-dihydro-8H-imidazo[2,1-c][1,4]oxazin-2-yl)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid p-nitrobenzyl ester. The reaction vessel was covered with foil toexclude light. The reaction mixture was vigorously stirred for 2.5 h atroom temperature. The reaction solution was filtered through a pad ofCelite and the pad was washed with water (170 mL) and n-butanol (170mL). The aqueous layer was separated and then the organic layer wasextracted with 0.5 mol/L phosphate buffer (pH 6.5, 2×50 mL). Thecombined aqueous layer was concentrated to 90 g, 1 mol/L NaOH was addedto adjust pH to 7.5 and applied to Diaion HP-21 resin (120 mL,Mitsubishi Kasei Co. Ltd.) column chromatography. After adsorbing, thecolumn was eluted with water and then 5% acetonitrile aqueous solution.The combined active fractions was concentrated under high vacuum at 35°C. and lyophilized to give the title as a yellow amorphous solid (756mg, 29.1%).

[0375] Mp 130° C. (dec); ¹H NMR (DMSO-d₆) δ 3.98-4.01 (m, 2H), 4.04-4.07(m, 2H), 4.74 (AB, 2H, J=15.3, 22.9 Hz), 6.40 (d, 1H, J=0.8 Hz), 6.55(s, 1H), 6.95 (d, 1H, J=0.6 Hz), 7.54 (s, 1H); IR (KBr) 3412, 1741,1672, 1592, 1549 cm⁻¹; λ^(max)(H₂O) 304 nm.

Example 8 Preparation of(5R),(6Z)-6-(5,6-Dihydro-4H-pyrrolo[1,2-b]pyrazol-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicAcid, Sodium Salt

[0376] Step 1: 5,6-Dihydro-4H-pyrrolor[2-b]pyrazole-2-carboxylic AcidEthyl Ester

[0377] The titled compound was prepared in the same way of Ranganathanand co-workers (Indian J. Chem. 1991, 30 B, 169-175).

[0378] Step 2: (5,6-Dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl)methanol

[0379] MeOH (2.73 mL) was added to the THF (180 mL) solution of LiBH₄(1.63 g) under a nitrogen atmosphere at room temperature, and then5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-2-carboxylic acid ethyl ester(8.11 g) was added to the suspension and stirred for 2 h at 40° C. Themixture was quenched with 1 mol/L HCl at pH 1 and stirred for 1 h atroom temperature. Solid K₂CO₃ was added to the solution to adjust pH to8 and the mixture was extracted with AcOEt. The organic layer was dried(MgSO₄) and filtered. The filtrate was concentrated under reducedpressure to afford the title compound as brown crystals (4.87 g, 78%).

[0380]¹H NMR (CDCl₃) δ 2.44 (t, 1H, J=5.8 Hz), 2.54-2.62 (m, 2H), 2.87(t, 2H, J=7.4 Hz), 4.10 (t, 2H, J=7.2 Hz), 4.63 (d, 2H, J=5.8 Hz), 5.96(s, 1H).

[0381] Step 3: 5,6-Dihydro-4H-pyrrolo[2-b]pyrazole-2-carbaldehyde

[0382] MnO₂ (activated) (24.4 g) was added to the CHCl₃ (350 mL)solution of (5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl)methanol (4.87 g)and refluxed for 1 h under a nitrogen atmosphere. The reaction mixturewas filtered through a pad of Celite. The filtrate was reduced underreduced pressure. The residue was applied to silica gel columnchromatography, then the column was eluted with n-hexane-AcOEt({fraction (1/1)}-½). The title compound was obtained as yellow oil(4.35 g, 91%).

[0383]¹H NMR (CDCl₃) δ 2.63-2.71 (m, 2H), 2.95 (t, 2H, J=7.4 Hz), 4.22(t, 2H, J=7.4 Hz), 6.52 (s, 1H), 9.89 (s, 1H).

[0384] Step 4: (5R),(6Z)-6-(5,6-Dihydro-4H-pyrrolo[1,2-b]pyrazol-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicAcid, Sodium Salt

[0385] 5,6-Dihydro-4H-pyrrolo[1,2-b]pyrazole-2-carbaldehyde (1.36 g) wasadded to the dry acetonitrile (148 mL) solution of anhydrous MgBr₂ (5.52g) under a nitrogen atmosphere at room temperature. The dry THF solution(148 mL) of (5R,6S)-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid4-nitrobenzyl ester (cont. 97%) (3.97 g) was added to the mixture,cooled to −20° C., and Et₃N (4.18 mL) was added in one portion. Thereaction vessel was covered with foil to exclude light. The reactionmixture was stirred for 4 h at −20° C. and treated with acetic anhydride(1.89 mL) and DMAP (123 mg) in one portion. The reaction mixture waswarmed to 0° C. and stirred for 14 h at 0° C. The mixture was dilutedwith ethyl acetate and washed with 5% citric acid aqueous solution,saturated sodium hydrogen carbonate, water and brine. The organic layerwas dried (MgSO₄) and filtered. The filtrate was concentrated underreduced pressure.

[0386] The residue was dissolved in THF (106 mL) and acetonitrile (49mL). Freshly activated Zn dust (22.5 g) was added rapidly with 0.5 Mphosphate buffer (pH 6.5, 155 mL). The reaction vessel was covered withfoil to exclude light. The reaction mixture was vigorously stirred for1.5 h at room temperature. The reaction mixture was filtered through apad of Celite. The filtrate was washed with ethyl acetate and theaqueous layer was separated. The aqueous layer was cooled to 3° C. and 1M NaOH was added to adjust pH to 8.0. The mixture was concentrated underhigh vacuum at 35° C. The concentrate was applied to Diaion HP-21 (79mL, Mitsubishi Kasei Co. Ltd.) resin column chromatography. Afteradsorbing, the column was eluted with H₂O-MeCN ({fraction(1/0)}-{fraction (9/1)}). The combined fractions were concentrated underhigh vacuum at 35° C. and lyophilized to give the title compound as ayellow amorphous solid (848 mg, 29%, pH 7.1).

[0387] Mp 190° C. (dec); ¹H NMR (D₂O) δ 2.49 (m, 2H), 2.78 (t, 2H, J=7.4Hz), 4.02 (t, 2H, J=7.4 Hz), 6.01 (s, 1H), 6.29 (s, 1H), 6.90 (s, 2H).

Example 9 Preparation of(5R)(6Z)-7-Oxo-6-(4,5,6,7-tetrahydropyrazolo[1.5-a]pyridin-2-ylmethylene)-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicAcid, Sodium Salt

[0388] Step 1: Tetrahydropyridino[1,2-c][1,2,3]oxadiazolone

[0389] Conc. HCl (1.96 mL) and NaNO₂ (2.2 g) were added to the H₂O (21mL) solution of DL-pipecolic acid (3.04 g) under a nitrogen atmosphereat 0° C. and stirred for 1 h. The solution was extracted with CH₂Cl₂ andorganic layer was washed with brine. The mixture was dried over Na₂SO₄and concentrated under reduced pressure to afford crude(2RS)-1-nitrosopiperidine-2-carboxylic acid as pale yellow crystals.

[0390] Trifluoroacetic anhydride (1.93 g) was added to the THF (92 mL)solution of crude (2RS)-1-nitrosopiperidine-2-carboxylic acid under anitrogen atmosphere at 0° C. and stirred for 5 h at 0° C. and for 2 h atroom temperature. The solution was concentrated under a reducedpressure. The residue was applied to silica gel column chromatography,then the column was eluted with n-hexane-AcOEt ({fraction(1/1)}-{fraction (0/1)}). The titled compound was obtained as colorlesscrystals (1.10 g, 33%).

[0391]¹H NMR (CDCl₃) δ 1.93-1.99 (m, 2H), 2.08-2.15 (m, 2H), 2.65 (t,2H, J=6.5 Hz), 4.26 (t, 2H, J=6.1 Hz).

[0392] Step 2: 4,5,6,7-Tetrahydropyrazolo[1,5-a]pyridine-2-carboxylicacid ethylester:

[0393] Ethyl propiolate (804 mg) was added to the o-xylene (15 mL)solution of tetrahydropyridino[1,2-c][1,2,3]oxadiazolone (1.04 g) undera nitrogen atmosphere and refluxed for 16 h. The solution wasconcentrated under a reduced pressure. The residue was applied to silicagel column chromatography, then the column was eluted withn-hexane-AcOEt ({fraction (2/1)}-{fraction (1/1)}). The titled compoundwas obtained as yellow oil (871 mg, 65%), and4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine-3-carboxylic acid ethyl esterwas obtained as yellow oil (345 mg, 26%).

[0394]¹H NMR (CDCl₃) δ 1.39 (t, 3H, J=7.1 Hz), 1.84-1.91 (m, 2H),2.02-2.09 (m, 2H), 2.82 (t, 2H, J=6.4 Hz), 4.22 (t, 2H, J=6.2 Hz), 4.39(q, 2H, J=7.1 Hz), 6.53 (s, 1H).

[0395] Step 3: (4.5,6,7-Tetrahydropyrazolo[1,5-a]pyridin-2-yl)methanolMeOH (0.29 mL) was added to the THF (19 mL) solution of LiBH₄ (cont.90%) (174 mg) under a nitrogen atmosphere at room temperature, then4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine-2-carboxylic acid ethyl ester(862 mg) was added to the suspension and stirred for 1 h at roomtemperature and 1.5 h at 40° C. The mixture was quenched with 1 mol/LHCl at pH 1 and stirred for 1 h at room temperature. Solid K₂CO₃ wasadded to the solution to adjust pH to 8 and the mixture was extractedwith AcOEt. The organic layer was dried (MgSO₄) and filtered. Thefiltrate was concentrated under reduced pressure to afford titledcompound as pale yellow oil (691 mg, 95%).

[0396]¹H NMR (CDCl₃) δ 1.80-1.87 (m, 2H), 1.98-2.05 (m, 2H), 2.77 (t,2H, J=6.4 Hz), 2.81-2.84 (br, 1H), 4.09 (t, 2H, J=6.1 Hz), 4.62 (d, 2H,J=5.3 Hz), 5.96 (s, 1H).

[0397] Step 4: 4,5,6,7-Tetrahydropyrazolo[1,5-a]pyridine-2-carbaldehyde

[0398] MnO₂ (activated) (3.36 g) was added to the CHCl₃ (44 mL) solutionof (4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-2-yl)methanol (673 mg) andrefluxed for 1 h under a nitrogen atmosphere. The reaction mixture wasfiltered through a pad of Celite. The filtrate was reduced under reducedpressure. The residue was applied to silica gel column chromatography,then the column was eluted with n-hexane-AcOEt ({fraction (2/1)}-½). Thetitled compound was obtained as pale yellow oil (510 mg, 77%).

[0399]¹H NMR (CDCl₃) δ 1.90 (m, 2H), 2.10 (m, 2H), 2.84 (t, 2H, J=6.4Hz), 4.23 (t, 2H, J=6.2 Hz), 6.52 (s, 1H), 9.92 (s, 1H).

[0400] Step 5:(5R)(6Z)-7-Oxo-6-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-2-ylmethylene)-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt

[0401] 4,5,6,7-Tetrahydropyrazolo[1,5-a]pyridine-2-carbaldehyde (483 mg)was added to the dry acetonitrile (48 mL) solution of anhydrous MgBr₂(1.81 g) under a nitrogen atmosphere at room temperature. The dry THFsolution (48 mL) of (5R,6S)-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid4-nitrobenzyl ester (cont. 97%) (1.28 g) was added to the mixture,cooled to −20° C., and Et₃N (1.35 mL) was added in one portion. Thereaction vessel was covered with foil to exclude light. The reactionmixture was stirred for 2 h at −20° C. and treated with acetic anhydride(0.61 mL) and DMAP (40 mg) in one portion. The reaction mixture waswarmed to 0° C. and stirred for 16 h at 0° C. The mixture was dilutedwith ethyl acetate and washed with 5% citric acid aqueous solution,saturated sodium hydrogen carbonate, water and brine. The organic layerwas dried (MgSO₄) and filtered. The filtrate was concentrated underreduced pressure.

[0402] The residue was dissolved in THF (35 mL) and acetonitrile (16mL). Freshly activated Zn dust (7.43 g) was added rapidly with 0.5 Mphosphate buffer (pH 6.5, 51 mL). The reaction vessel was covered withfoil to exclude light. The reaction mixture was vigorously stirred for1.5 h at room temperature. The reaction mixture was filtered through apad of Celite. The filtrate was washed with ethyl acetate and theaqueous layer was separated. The aqueous layer was cooled to 3° C. and 1M NaOH was added to adjust pH to 8.0. The mixture was concentrated underhigh vacuum at 35° C. The concentrate was applied to Diaion HP-21 (105mL, Mitsubishi Kasei Co. Ltd.) resin column chromatography. Afteradsorbing, the column was eluted with H₂O-MeCN ({fraction(1/0)}-{fraction (85/15)}). The combined fractions were concentratedunder high vacuum at 35° C. and lyophilized to give the title compoundas a yellow amorphous solid (427 mg, 41%, pH 7.7).

[0403] Mp 190° C. (dec); ¹H NMR (D₂O) δ 1.67-1.71 (m, 2H), 1.85-1.89 (m,2H), 2.64 (t, 2H, J=6.3 Hz), 3.97 (t, 2H, J=6.1 Hz), 5.97 (s, 1H), 6.25(s, 1H), 6.85 (s, 1H), 6.88 (s, 1H).

Example 10 Preparation of(5R),(6Z)-6-(7-Methyl-6-oxo-5,6,7,8-tetrahydro-imidazo[1,2-a]pyrazin-2-ylmethylene)-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicAcid Sodium Salt

[0404] Step 1: 5-Methoxy-1-methyl-3,6-dihydro-1H-pyrazin-2-one

[0405] The titled compound was prepared in the same way of S. Rajappaand B. G. Advani (Tetrahedron. 1973, 29, 1299-1302).

[0406] Step 2: 5-Amino-1-methyl-3,6-dihydro-1H-pyrazin-2-one

[0407] A mixture of 5-methoxy-1-methyl-3,6-dihydro-1H-pyrazin-2-one (2.3g) and ammonium chloride (936 mg) in dry ethanol (32 mL) was stirred atroom temperature for 1 h and then refluxed for 2 h. The reaction mixturewas cooled to room temperature and evaporated under reduced pressure.The residue was triturated with chloroform at room temperature for 30min. The precipitate was filtered off and dried in vacuo. The5-amino-1-methyl-3,6-dihydro-1H-pyrazin-2-one hydrochloride was obtainedas a pale brown powder (1.7 g, 66%).

[0408] A solution of 5-amino-1-methyl-3,6-dihydro-1H-pyrazin-2-onehydrochloride (662 mg) in methanol (10 mL) was added 10% potassiumcarbonate aqueous solution at 0□ and then stirred for 40 min at 0□. Themixture was concentrated under reduced pressure. The residue wastriturated with chloroform (18 mL) and methanol (2 mL) at roomtemperature for 30 min. The precipitate was filtered off and dried invacuo. The compound was obtained as a pale brown powder (515 mg,quantitative).

[0409]¹H NMR (DMSO-d⁶) δ 2.88 (s, 3H), 3.94 (s, 2H), 4.42 (s, 2H).

[0410] Step 3:7-Methyl-6-oxo-5,6,7,8-tetrahydro-imidazo[1,2-a]pyrazine-2-carbaldehydeand7-Methyl-6-oxo-5,6,7,8-tetrahydro-imidazo[1,2-a]pyrazine-3-carbaldehyde

[0411] The solution of 2-bromo-3-isopropoxy-propenal (1.3 g) in dryacetonitrile (60 mL) was added to the solution of5-amino-1-methyl-3,6-dihydro-1H-pyrazin-2-one (782 mg) in dryacetonitrile (60 mL) at room temperature. The reaction mixture wasstirred at room temperature for 20 h, added triethylamine (0.95 mL) andthen refluxed for 2 h. The reaction mixture was cooled to roomtemperature and then evaporated under reduce pressure. The residue wasdissolved in chloroform (10 mL) and washed with 50% K₂CO₃ aqueoussolution (10 mL). The aqueous layer was extracted with chloroform. Theorganic layer was dried (MgSO₄) and filtered. The filtrate wasevaporated under reduce pressure. The residue was applied to silica gelcolumn chromatography and eluted with CHCl₃-MeOH (95:5) to obtain thetitle compound7-Methyl-6-oxo-5,6,7,8-tetrahydro-imidazo[1,2-a]pyrazine-2-carbaldehydeas a pale yellow solid (541 mg, 49.1%) and its regio isomer7-Methyl-6-oxo-5,6,7,8-tetrahydro-imidazo[1,2-a]pyrazine-3-carbaldehydeas a pale yellow solid (128 mg, 11.6%).7-Methyl-6-oxo-5,6,7,8-tetrahydro-imidazo[1,2-a]pyrazine-2-carbaldehyde:¹H NMR (CDCl₃) δ 3.17 (s, 3H), 4.68 (s, 2H), 4.78 (s, 2H), 7.66 (s, 1H),9.83 (s, 1H).

[0412]7-Methyl-6-oxo-5,6,7,8-tetrahydro-imidazo[1,2-a]pyrazine-3-carbaldehyde:¹H NMR (CDCl₃) δ 3.16 (s, 3H), 4.70 (s, 2H), 5.03 (s, 2H), 7.82 (s, 1H),9.73 (s, 1H).

[0413] Step 4: (5R,6RS)-6-[Acetoxy-(7-methyl-6-oxo-5,6,7,8-tetrahydro-imidazo[1,2-a]pyrazin-2-yl)-methyl]-6-bromo-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid 4-nitro-benzyl ester

[0414] 7-Methyl-6-oxo-5, 6, 7,8-tetrahydro-imidazo[1,2-a]pyrazine-2-carbaldehyde (319 mg) was added tothe dry acetonitrile (32 mL) solution of anhydrous MgBr₂ (786 mg) undera nitrogen atmosphere at room temperature. The dry THF solution (32 mL)of (5R,6S)-6-bromo-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid 4-nitro-benzyl ester (687 mg) was added to the mixture, cooled to−20° C., and triethylamine (0.60 mL) was added in one portion. Thereaction vessel was covered with foil to exclude light. The reactionmixture was stirred for 3 h at −20° C. and treated with4-dimethylaminopyridine (44 mg) and acetic anhydride (0.35 mL) in oneportion. The reaction mixture was warmed to 0° C. and stirred for 20 hat 0° C. The mixture was diluted with ethyl acetate and H₂O. Afterseparating organic layer, the aqueous layer was extracted with ethylacetate. The organic layers were combined and washed with 5% citric acidaqueous solution and brine. The organic layer was dried (MgSO₄) andfiltered. The filtrate was concentrated under reduced pressure. Theresidue was applied to silica gel column chromatography, then elutedwith, chloroform. The title compound was obtained as diastereo mixture(yellow amorphous solid; 410 mg, 38%).

[0415]¹H NMR (6, CDCl₃) 2.03 (s, 0.7×3H), 2.09 (s, 0.3×3H), 3.15 (s,3H), 4.59-4.62 (m, 2H), 4.66 (s, 0.3×2H), 4.67 (s, 0.7×2H), 5.28 (d, 1H,J=13.5 Hz), 5.43 (d, 0.3×1H, J=13.5 Hz), 5.45 (d, 0.7×1H, J=13.5 Hz),6.07 (s, 0.3×1H), 6.28 (s, 0.7×1H), 6.32 (s, 0.7×1H), 6.83 (s, 0.3×1H),6.86 (s, 0.3×1H), 7.10 (s, 0.7×1H), 7.44 (s, 0.3×1H), 7.47 (s, 0.7×1H),7.60 (d, 0.7×2H, J=8.6 Hz), 7.61 (d, 0.3×2H, J=8.6 Hz), 8.24 (d, 2H,J=8.6 Hz),

[0416] Step 5:(5R),(6Z)-6-(7-Methyl-6-oxo-5,6,7,8-tetrahydro-imidazo[2-a]pyrazin-2-ylmethylene)-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicAcid Sodium Salt and(5R),(6E)-6-(7-Methyl-6-oxo-5,6,7,8-tetrahydro-imidazo[1,2-a]pyrazin-2-ylmethylene)-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicAcid Sodium Salt

[0417] (5R,6RS)-6-[Acetoxy-(7-methyl-6-oxo-5,6,7,8-tetrahydro-imidazo[1,2-a]pyrazin-2-yl)-methyl]-6-bromo-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid 4-nitro-benzyl ester (481 mg) was dissolved in THF (6.7 mL) andacetonitrile (3.1 mL). Freshly activated Zn dust (1.92 g) and 0.5 Mphosphate buffer (pH 6.5, 9.9 mL) were added to the mixture. Thereaction vessel was covered with foil to exclude light. The reactionmixture was vigorously stirred for 2 h at room temperature. The reactionsolution was mixed with ethyl acetate and filtered through a pad ofCelite. The pad was washed with water and the aqueous layer wasseparated. The aqueous layer was cooled to 3° C. and 1 M NaOH was addedto adjust pH to 8.0. The mixture was concentrated under high vacuum at35° C. and lyophilized. The residue was separated by the preparativeHPLC (Inertsil ODS-2, GL Science Inc., 10×250 mm, 0.05 mol/L phosphatebuffer (pH 7.1): CH₃CN=93: 7, 4.0 mL/min.). The separated fractions of(5R),(6Z)-6-(7-Methyl-6-oxo-5,6,7,8-tetrahydro-imidazo[1,2-a]pyrazin-2-ylmethylene)-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid sodium salt and(5R),(6E)-6-(7-Methyl-6-oxo-5,6,7,8-tetrahydro-imidazo[1,2-a]pyrazin-2-ylmethylene)-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid sodium salt were cooled to 3° C. and 1 M NaOH was added to adjustpH to 8.0 respectively. Each solution was concentrated under high vacuumat 35° C. Each concentrate was applied to Diaion HP-21 (60 mL,Mitsubishi Kasei Co. Ltd.) resin column chromatography. After adsorbing,the column was eluted with water and then with 5% acetonitrile-water.The combined fractions were concentrated under high vacuum at 35° C. andlyophilized to give the title compound(5R),(6Z)-6-(7-Methyl-6-oxo-5,6,7,8-tetrahydro-imidazo[1,2-a]pyrazin-2-ylmethylene)-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid sodium salt as a yellow amorphous solid (125 mg, 44.4%, Mp 115-117°C. (dec)) and compound(5R),(6E)-6-(7-Methyl-6-oxo-5,6,7,8-tetrahydro-imidazo[1,2-a]pyrazin-2-ylmethylene)-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid sodium salt as yellow amorphous solid (19 mg, 6.7%) respectively.

[0418] Compound (5R), (6Z)-6-(7-Methyl-6-oxo-5,6,7,8-tetrahydro-imidazo[1,2-a]pyrazin-2-ylmethylene)-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid sodium salt ¹H NMR (6, D₂O) 2.99 (s, 3H), 4.54 (s, 2H), 4.66 (s,2H), 6.38 (s, 1H), 6.85 (s, 1H), 6.90 (s 1H), 7.30 (s, 1H).

[0419] Compound (5R),(6E)-6-(7-Methyl-6-oxo-5,6,7,8-tetrahydro-imidazo[1,2-a]pyrazin-2-ylmethylene)-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid sodium salt ¹H NMR (6, D₂O) 2.94 (s, 3H), 4.45 (s, 2H), 4.56 (s,2H), 6.22 (s, 1H), 6.48 (s, 1H), 6.94 (s, 1H), 7.69 (s 1H).

Example 11 Preparation of(5R)(6Z)-6-(6,7-Dihydro-4H-pyrazolo[5,1-c][1,4]thiazin-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicAcid, Sodium Salt

[0420] Step 1: (3R)-Thiomorpholine-3-carboxylic Acid

[0421] The titled compound was prepared in the same way of Shiraiwa andco-workers (Biosci. Biotechnol. Biochem. 1998, 62, 2382-2387).

[0422] Step 2: 3-Oxo-3a,4,6,7-tetrahydro-3H-2-oxa-5-thia-1-aza-7a-azonioindenide

[0423] NaNO₂ (3.14 g) was added to the 1 mol/L HCl (33.7 mL) solution of(3R)-thiomorpholine-3-carboxylic acid (4.96 g) under a nitrogenatmosphere at 0° C. and stirred for 0.5 h. The solution was extractedwith CHCl₃ (5 times) and the organic layer was washed with brine. Themixture was dried over MgSO₄ and concentrated under reduced pressure toafford crude (3R)-4-nitrosothiomorpholine-3-carboxylic acid as paleyellow crystals.

[0424] Trifluoroacetic anhydride (7.07 g) was added to the THF (169 mL)solution of crude (3R)-4-nitrosothiomorpholine-3-carboxylic acid under anitrogen atmosphere at 0° C. and stirred for 3 h at 0° C. and for 17 hat room temperature. The solution was concentrated under a reducedpressure. The residue was applied to silica gel column chromatography,then the column was eluted with n-hexane-AcOEt ({fraction(1/1)}-{fraction (0/1)}). The titled compound was obtained as pale browncrystals (3.41 g, 64%).

[0425]¹H NMR (CDCl₃) δ 3.15 (t, 2H, J=5.5 Hz), 3.71 (s, 2H), 4.54 (t,2H, J=5.5.

[0426] Hz).

[0427] Step 3: 6,7-Dihydro-4H-pyrazolo[5.1-c][1.4]thiazine-2-carboxylicAcid Ethyl Ester

[0428] Ethyl propiolate (2.33 g) was added to the o-xylene (72 mL)solution of3-oxo-3a,4,6,7-tetrahydro-3H-2-oxa-5-thia-1-aza-7a-azonioindenide (3.41g) under a nitrogen atmosphere and refluxed for 15 h. The solution wasconcentrated under a reduced pressure. The residue was applied to silicagel column chromatography, then the column was eluted withn-hexane-AcOEt ({fraction (2/1)}-{fraction (1/1)}). The titled compoundwas obtained as yellow oil (3.13 g, 68%), and the other unwanted regioisomer 6,7-dihydro-4H-pyrazolo[5,1-c][1,4]thiazine-3-carboxylic acidethyl ester was obtained as yellow oil (556 mg, 12%).

[0429]¹H NMR (CDCl₃) δ 1.31 (t, 3H, J=7.1 Hz), 3.04 (t, 2H J=5.7 Hz),3.81 (s, 2H), 4.32 (q, 2H, J=7.1 Hz), 4.40 (t, 2H, J=5.7 Hz), 6.54 (s,1H).

[0430] Step 4: (6,7-Dihydro-4H-pyrazolo[5,1-c][1,4]thiazin-2-yl)methanolLiBH₄ (cont. 90%) (536 mg) and MeOH (0.9 mL) was added to the THF (59mL) solution of 6,7-dihydro-4H-pyrazolo[5,1-c][1,4]thiazine-2-carboxylicacid ethyl ester (3.13 g) under a nitrogen atmosphere at roomtemperature and stirred for 3 h at 40° C. The mixture was quenched with1 mol/L HCl at pH 1 and stirred for 1 h at room temperature. Solid K₂CO₃was added to the solution to adjust pH to 8 and the mixture wasextracted with AcOEt. The organic layer was dried (K₂CO₃) and filtered.The filtrate was concentrated under reduced pressure to afford titledcompound as pale yellow oil (2.51 g, quant.).

[0431]¹H NMR (CDCl₃) δ 2.58 (br, 1H), 3.07 (t, 2H, J=5.7 Hz), 3.84 (s,2H), 4.33 (t, 2H, J=5.7 Hz), 4.63 (d, 2H, J=3.9 Hz), 6.05 (s, 1H).

[0432] Step 5:6,7-Dihydro-4H-pyrazolo[5,1-c][1,4]thiazine-2-carbaldehyde

[0433] MnO₂ (activated) (11.46 g) was added to the CHCl₃ (135 mL)solution of (6,7-dihydro-4H-pyrazolo[5,1-c][1,4]thiazin-2-yl)methanol(2.31 g) and refluxed for 1 h under a nitrogen atmosphere. The reactionmixture was filtered through a pad of Celite. The filtrate wasconcentrated under a reduced pressure. The residue was applied to silicagel column chromatography, then the column was eluted with n-hexane-AcOEt ({fraction (1/1)}). The titled compound was obtained as paleyellow crystals (1.78 g, 78%).

[0434]¹H NMR (CDCl₃) δ 3.15 (t, 2H, J=5.8 Hz), 3.90 (s, 2H), 4.48 (t,2H, J=5.8 Hz), 6.58 (s, 1H), 9.92 (s, 1H).

[0435] Step 6:(5R)(6Z)-6-(6,7-Dihydro-4H-pyrazolo[5,1-c][1,4]thiazin-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt

[0436] 6,7-Dihydro-4H-pyrazolo[5,1-c][1,4]thiazine-2-carbaldehyde (841mg) was added to the dry acetonitrile (39 mL) solution of anhydrousMgBr₂ (1.88 g) under a nitrogen atmosphere at room temperature. The dryTHF solution (39 mL) of (5R,6S)-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid4-nitrobenzyl ester (cont. 99.7%) (1.93 g) was added to the mixture,cooled to −20° C., and Et₃N (2.79 mL) was added in one portion. Thereaction vessel was covered with foil to exclude light. The reactionmixture was stirred for 3 h at −20° C. and treated with acetic anhydride(0.94 mL) and DMAP (61 mg) in one portion. The reaction mixture waswarmed to 0° C. and stirred for 17 h at 0° C. The mixture was dilutedwith ethyl acetate and washed with 5% citric acid aqueous solution,saturated sodium hydrogen carbonate, water and brine. The organic layerwas dried (MgSO₄) and filtered. The filtrate was concentrated underreduced pressure.

[0437] The residue was dissolved in THF (83 mL) and acetonitrile (39mL). Freshly activated Zn dust (7.72 g) was added rapidly with 0.5 Mphosphate buffer (pH 6.5, 122 mL). The reaction vessel was covered withfoil to exclude light. The reaction mixture was vigorously stirred for1.5 h at room temperature. The reaction mixture was filtered through apad of Celite. The filtrate was washed with ethyl acetate and theaqueous layer was separated. The aqueous layer was cooled to 3. ° C. and1 M NaOH was added to adjust pH to 8.0. The mixture was concentratedunder high vacuum at 35° C. The concentrate was applied to Diaion HP-21(150 mL, Mitsubishi Kasei Co. Ltd.) resin column chromatography. Afteradsorbing, the column was eluted with H₂O-MeCN ({fraction(1/0)}-{fraction (85/15)}). The combined fractions were concentratedunder high vacuum at 35° C. and lyophilized to give the title compoundas a yellow amorphous solid (371 mg, 22%, pH 8.0).

[0438] Mp 190° C. (dec); ¹H NMR (D₂O) δ 3.03 (t, 2H, J=5.7 Hz), 3.75 (s,2H), 4.22 (t, 2H, J=5.7 Hz), 6.07 (s, 1H), 6.27 (s, 1H), 6.86 (s, 1H),6.89 (s, 1H).

Example 12 Preparation of(5R)(6Z)-7-Oxo-6-(4H-5-thia-1,6a-diazapentalen-2-ylmethylene)-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt

[0439] Step 1: 3-Oxo-3a, 4-dihydro-3H,6H-2-oxa-5-thia-1-aza-6a-azonio-3a-pentalenide

[0440] Conc. HCl (15 mL) and NaNO₂ (16.6 g) were added to the H₂O (166mL) solution of L-thioproline (24.3 g) under a nitrogen atmosphere at 0°C. and stirred for 2 h. The solution was extracted with CH₂Cl₂, organiclayer was dried over MgSO₄ and concentrated under reduced pressure toafford the crude N-nitroso derivative as a yellow solid.

[0441] Trifluoroacetic anhydride (5.0 mL) was added to the THF (350 mL)solution of crude N-nitrosothioproline under a nitrogen atmosphere at 0°C. and stirred for 5 h at 0° C. The solution was concentrated underreduced pressure. The residue was applied to silica gel columnchromatography, then the column was eluted with n-hexane -AcOEt (1:1).The titled compound was obtained as a pale brown solid (4.0 g, 15.1%).

[0442]¹H NMR (CDCl₃): δ4.04 (t, 2H, J=1.7 Hz), 5.40 (t, 2H, J=1.7 Hz).

[0443] Step 2: 4H-5-Thia-1,6a-diazapentalen-2-Carboxylic Acid Ethylester

[0444] Ethyl propiolate (3.1 mL) was added to the o-xylene (130 mL)solution of 3-oxo-3a, 4-dihydro-3H,6H-2-oxa-5-thia-1-aza-6a-azonio-3a-pentalenide (4.0 g) under a nitrogenatmosphere and refluxed for 19 h. The solution was cooled to roomtemperature and concentrated under reduced pressure. The residue wasapplied to silica gel column chromatography, then the column was elutedwith n-hexane-AcOEt (4:1). The titled compound was obtained as a yellowsolid (2.7 g, 49.3%), and 4H-5-thia-1,6a-diazapentalen-3-carboxylic acidethylester was obtained as pale yellow crystals (1.2 g, 21.7%).

[0445]¹H NMR (CDCl₃) δ 1.40 (t, 3H, J=7.1 Hz), 4.11 (d, 2H, J=2.1 Hz),4.40 (q, 2H, J=7.1 Hz), 5.24 (t, 2H, J=1.6 Hz), 6.61 (s, 1H).

[0446] Step 3: (4H-5-Thia-1,6a-diazapentalen-2-yl)methanol LiBH₄ (cont.90%) (459 mg) was added to the ether (126 mL) solution of4H-5-thia-1,6a-diazapentalen-2-carboxylic acid ethylester (2.5 g) andMeOH (0.77 mL) under a nitrogen atmosphere at room temperature, thenrefluxed for 1.5 h. The mixture was quenched with 1 mol/L HCl (25 mL)and stirred for 1 h at room temperature. The mixture was neutralized bysaturated sodium hydrogen carbonate solution and separated. The aqueouslayer was extracted with dichloromethane (10×25 mL). The organic layerwas dried (MgSO₄) and filtered. The filtrate was concentrated underreduced pressure. The residue was applied to silica gel columnchromatography, then the column was eluted with AcOEt. The titledcompound was obtained as a pale yellow solid (1.7 g, 87.9%).

[0447]¹H NMR (CDCl₃) δ 2.95 (t, 1H, J=5.6 Hz), 4.07 (s, 2H), 4.62 (d,2H, J=5.1 Hz), 5.13 (t, 1H, J=1.6 Hz), 6.04 (s, 1H).

[0448] Step 4: 4H-5-Thia-1,6a-diazapentalen-2-carbaldehyde

[0449] The dry dichloromethane (8 mL) solution of dimethylsulfoxide (2.2mL) was added dropwise to the dry dichloromethane (110 mL) solution ofoxalyl chloride (2.0 mL) at −78° C. The reaction mixture was stirred for15 min at the same temperature. The dry dichloromethane (40 mL) solutionof (4H-5-thia-1,6a-diazapentalen-2-yl)methanol, (1.7 g) was addeddropwise to the reaction mixture at −78° C., and stirring was continuedfor an additional 15 min. The reaction mixture was allowed to warm to−45° C. and stirred for 1 h. Triethylamine (11.3 mL) was added dropwiseand the reaction mixture was allowed to warm to 0° C. After 20 min,saturated ammonium chloride solution (50 mL) and water (100 mL) wereadded and separated. The aqueous layer was extracted with AcOEt (3×150mL). The combined organic layers were washed with water (200 mL) andbrine (200 mL), dried (MgSO₄) and filtered. The filtrate wasconcentrated under reduced pressure. The residue was applied to silicagel column chromatography, then the column was eluted with hexane-AcOEt(1:1). The titled compound was obtained as a yellow solid (1.7 g,quant.).

[0450]¹H NMR (CDCl₃) δ 4.13 (s, 2H), 5.26 (d, 2H, J=1.4 Hz), 6.59 (s,1H), 9.90 (s, 1H).

[0451] Step 5;(5R)(6Z)-7-Oxo-6-(4H-5-thia-1,6a-diazapentalen-2-ylmethylene)-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt

[0452] The dry acetonitrile (92 mL) solution of4H-5-thia-1,6a-diazapentalen-2-carbaldehyde (1.7 g) was added to the dryacetinitrile (92 mL) solution of MgBr₂ (5.0 g) under a nitrogenatmosphere at room temperature then the mixture was stirred for 10 min.The dry THF (184 mL) solution of p-nitrobenzyl (5R,6S)-6-bromopenem-3-carboxylate (4.3 g) was added and the mixture wascooled to −20° C. then triethylamine (7.4 mL) was added in one portion.The reaction vessel was covered with foil to exclude light. The reactionmixture was stirred for 3 h at −20° C. and treated with 4-dimethylaminopyridine (138 mg) and acetic anhydride (2.1 mL) in one portion. Thereaction mixture was warmed to 0° C. and stirred for 15 h at 0° C. The 1mol/L Citric acid aqueous solution (1000 mL) was added to the reactionmixture and the aqueous layer was extracted with ethyl acetate (3×400mL). The combined organic layers were washed with water, saturatedsodium hydrogen carbonate and brine, dried (MgSO₄) and filtered. Thefiltrate was concentrated under reduced pressure and crude(5R)-6-[acetoxy-(4H-5-thia-1,6a-diazapentalen-2-yl)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid p-nitrobenzyl ester was obtained as a brown amorphous solid.

[0453] Freshly activated Zn dust (19.3 g) was added rapidly with 0.5mol/L phosphate buffer (pH 6.5, 100 mL) to the THF (100 mL) solution ofcrude(5R)-6-[acetoxy-(4H-5-thia-1,6a-diazapentalen-2-yl)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid p-nitrobenzyl ester. The reactionvessel was covered with foil to exclude light. The reaction mixture wasvigorously stirred for 2.5 h at room temperature. The reaction solutionwas filtered through a pad of Celite and the pad was washed with water(200 mL) and n-butanol (200 mL). The aqueous layer was separated andthen the organic layer was extracted with 0.5 mol/L phosphate buffer (pH6.5, 2×50 mL). The combined aqueous layers were concentrated to 90 g, 1mol/L NaOH was added to adjust pH to 8.0 and applied to Diaion HP-21resin (180 mL, Mitsubishi Kasei Co. Ltd.) column chromatography. Afteradsorbing, the column was eluted with water and then 15% acetonitrileaqueous solution. The combined active fractions were concentrated underhigh vacuum at 35° C. and lyophilized to give the title compound as ayellow amorphous solid (634 mg, 17.4%, pH 7.25).

[0454] Mp 150° C. (dec); ¹H NMR (D₂O) δ4.00 (s, 2H), 5.09 (s, 2H), 6.14(s, 1H), 6.36 (s, 1H), 6.91 (s, 1H), 6.92 (s, 1H); IR (KBr) 3381, 1752,1683, 1600, 1558 cm⁻¹; λ^(max) (H₂O) 292, 196 nm.

Example 13 Preparation of(5R)(6Z)-6-(7H-Imidazo[1,2-c]thiazol-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt

[0455] Step 1: Thiazolidin-4-one

[0456] The titled compound was prepared in the same way of Marvin M. andAllen R. Harkness. (Tetrahedron Letters. 1994, 35, 6971-6974).

[0457] Step 2: Thiazolidine-4-thione

[0458] Lawesson's reagents (33.5 g) added to the solution ofthiazolidin-4-one (14.2 g) in dry THF (690 mL) and the reaction mixturewas refluxed for 2 h. The mixture was cooled to room temperature andevaporated under reduced pressure. The residue was triturated withCHCl₃:MeOH=7:3 solution (65 mL) at room temperature for 30 min. Theprecipitate was filtered off, washed with CHCl₃:n-hexane=7:3 solution(15 mL) and dried in vacuo. The thiazolidine-4-thione was obtained as apale yellow powder (10.7 g, 65%).

[0459]¹H NMR (CDCl₃) δ 4.08 (s, 2H), 4.70 (s, 2H).

[0460] Step 3: 4-Methylthio-2,5-dihydro-thiazole

[0461] Methyl iodide (28.4 g) was added to the boiling solution ofthiazolidine-4-thione (9.5 g) in chloroform (400 mL), and the reactionmixture was refluxed for 1.5 h. To the reaction mixture, an additionalmethyl iodide (56.8 g) was added in 5 portions at 30-60 min intervals.After refluxing for additional 1 h, the reaction mixture was cooled toroom temperature. Then 10% potassium carbonate aqueous solution (200 mL)was added and stirred for 15 min at room temperature. After separatingorganic layer, the aqueous layer was extracted with CHCl₃ (100 mL×3).Organic layers were combined, dried (MgSO₄) and filtered. The filtratewas concentrated under reduced pressure and dried in vacuo. Afterdrying, the title compound was obtained as brown oil (11.0 g, quant.).

[0462]¹H NMR (CDCl₃) δ 2.51 (s, 3H), 3.91 (t, 2H, J=3.5 Hz), 5.21 (t,2H, J=3.5 Hz).

[0463] Step 4: Thiazolidin-4-ylideneamine

[0464] A mixture of 4-methylthio-2,5-dihydrothiazole (10.7 g) andammonium chloride (6.4 g) in dry ethanol (400 mL) was refluxed for 27.5h. The reaction mixture was cooled to room temperature and evaporatedunder reduced pressure. The residue was dissolved in chloroform (300 mL)and 10% potassium carbonate aqueous solution (200 mL), then stirred for20 min at room temperature. After separating organic layer, the aqueouslayer was extracted with chloroform (100 mL×5). Organic layers werecombined, dried (MgSO₄) and filtered. The filtrate was concentratedunder reduced pressure and dried in vacuo to obtain crudethiazolidin-4-ylideneamine (5.5 g) as a brown solid that included byproduct, which is an ethoxy derivative and4-methylthio-2,5-dihydrothiazole, which is the starting material. Theratio of these three compounds was determined to be 61:34:5 respectivelyby ¹H-NMR.

[0465]¹H NMR (CDCl₃) δ 3.75 (t, 2H, J=2.8 Hz), 4.97 (t, 2H, J=2.9 Hz).

[0466] Step 5: 7H-Imidazo[1,2-c]thiazole-2-carbaldehyde

[0467] The solution of 2-bromo-3-isopropoxypropenal (6.9 g) in dryacetonitrile (326 mL) was added to the solution of crudethiazolidin-4-ylideneamine (3.3 g) in dry acetonitrile (326 mL) at roomtemperature. The reaction mixture was stirred at room temperature for19.5 h, added triethylamine (4.9 mL) and then refluxed for 2 h. Thereaction mixture was cooled to room temperature and then evaporatedunder reduce pressure. The residue was dissolved in dichloromethane (300mL) and washed with 50% potassium carbonate aqueous solution (20 g).After filtration and separation, the aqueous layer was extracted withdichloromethane (50 mL×4). The organic layers were combined, dried(MgSO₄) and filtered. The filtrate was evaporated under reducedpressure. The residue was applied to silica gel column chromatographyand eluted with CHCl₃-MeOH (100:3) to obtain crude7H-Imidazo[1,2-c]thiazole-2-carbaldehyde as a brown solid. The crudeproduct was re-crystallized twice from CHCl₃-n-hexane (1St: 30:5,2^(nd): 30:60) at 0° C. to give the required aldehyde as pale browncrystals (Yield: 1.84 g, 15%).

[0468]¹H NMR (CDCl₃) δ 4.09 (t, 2H, J=1.3 Hz), 5.08 (t, 2H, J=1.2 Hz),7.63 (s, 1H), 9.81 (s, 1H).

[0469] Step 6:(5R)(6Z)-6-(7H-Imidazo[1,2-c]thiazol-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo

[0470] [3.2.0]hept-2-ene-2-carboxylic Acid, Sodium Salt

[0471] 7H-Imidazo[1,2-c]thiazole-2-carbaldehyde (841 mg) was added tothe dry acetonitrile (116 mL) solution of anhydrous MgBr₂ (2.93 g) undera nitrogen atmosphere at room temperature. The dry THF solution (116 mL)of (5R,6S)-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid4-nitrobenzyl ester (cont. 99.7%) (2.51 g) was added to the mixture,cooled to −20° C., and Et₃N (2.20 mL) was added in one portion. Thereaction vessel was covered with foil to exclude light. The reactionmixture was stirred for 4 h at −20° C. and treated with acetic anhydride(1.26 mL) and DMAP (160 mg) in one portion. The reaction mixture waswarmed to 0° C. and stirred for 15 h at 0° C. The mixture was dilutedwith ethyl acetate and washed with 5% citric acid aqueous solution,saturated sodium hydrogen carbonate, water and brine. The organic layerwas dried (MgSO₄) and filtered. The filtrate was concentrated underreduced pressure.

[0472] The residue was dissolved in THF (53 mL) and acetonitrile (25mL). Freshly activated Zn dust (15.1 g) and 0.5 M phosphate buffer (pH6.5, 78 mL) were added to the mixture. The reaction vessel was coveredwith foil to exclude light. The reaction mixture was vigorously stirredfor 1.5 h at room temperature. The reaction mixture was filtered througha pad of Celite. The filtrate was washed with ethyl acetate and theaqueous layer was separated. The aqueous layer was cooled to 3° C. and 1M NaOH was added to adjust pH to 8.0. The mixture was concentrated underhigh vacuum at 35° C. The concentrate was applied to Diaion HP-21 (321mL, Mitsubishi Kasei Co. Ltd.) resin column chromatography. Afteradsorbing, the column was eluted with H₂O-MeCN ({fraction(1/0)}-{fraction (9/1)}). The combined fractions were concentrated underhigh vacuum at 35° C. and lyophilized to give the title compound as ayellow amorphous solid (1.1 g, 51%, pH 7.5).

[0473] Mp 145° C. (dec); ¹H NMR (D₂O) δ 3.85 (s, 2H), 4.88 (s, 2H), 6.32(s, 1H), 6.78 (s, 1H), 6.85 (s, 1H), 7.27 (s, 1H).

Example 14 Preparation of(5R,6Z)-7-oxo-6-[(4-oxo-6,7-dihydro-4H-pyrazolo[5,1-c],1,4]oxazin-2-yl)methylene]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicAcid.

[0474] Step 1: Diethyl1-(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)-1H-pyrazole-3,5-dicarboxylate

[0475] To a solution of diethyl 3,5-pyrazoledicarboxylate (2.17 g, 10mmol) in acetonitrile (10 ml), under nitrogen, was added potassiumcarbonate (2.07 g, 15 mmol), and 2-bromoethoxy-t-butyidimethylsilane(2.90 g, 12 mmol). The mixture was stirred at reflux for 18 hr. It wasthen cooled to room temperature, diluted with ethyl acetate (20 ml), andfiltered through Magnesol. The filter pad was eluted wtih 2×10 ml ofethyl acetate, and the combined filtrate was evaporated. The residue wasdissolved in hexanes and passed through a column of silica gel (70 g).After eluting with hexanes (100 ml), the column was eluted with ethylacetate. The ethyl acetate eluent was evaporated to give 3.71 g of acolorless oil; MS m/e 371 (MH⁺).

[0476] Step 2:1-(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)-1H-pyrazole-3,5-dimethanol

[0477] To a solution of diethyl1-(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)-1H-pyrazole-3,5-dicarboxylate(0.74 g, 2 mmol) in methylene chloride (8 ml), under nitrogen, was added12 ml of a 1.0 M solution of diisobutylaluminum hydride in methylenechloride at 0° C. After stirring at 0° C. for 0.5 hr, the mixture waaswarmed to room temperature for 0.5 hr. It was then quenched with 15 mlof saturated ammonium chloride solution and extracted with ethylacetate. The organic extract was washed with brine, dried over anhydroussodium sulfate, and evaporated to give 0.44 g of a white solid; mp82-83° C.; MS m/e 287 (MH⁺).

[0478] Step3:1-(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)-1H-pyrazole-3,5-dicarbaldehyde

[0479] To a stirred solution of1-(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)-1H-pyrazole-3,5-dimethanol(1.18 g, 4 mmol) in methylene chloride (20 ml), was added4-methylmorpholine-N-oxide (2.89 g, 24 mmol) and molecular sieve 4A (4g). The reaction mixture was stirred at room temperature for 10 min. andthen treated with tetrapropylammonium peruthenate (0.15 g, 0.4 mmol).Stirring was continued for 2 hr. The methylene chloride solution wasconcentrated and diluted with ether (40 ml). The mixture was filteredthrough a pad of silica gel (40 g) and the filter pad was eluted with2×20 ml ether. The combined eluent was washed with 1 N HCl and brine,dried over anhydrous sodium sulfate, and evaporated to give 0.79 g of awhite solid; mp 63-64° C.; MS m/e 283 (MH⁺).

[0480] Step 4:4-oxo-6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazine-2-carbaldehyde

[0481] To a solution of1-(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)-1H-pyrazole-3,5-dicarbaldehyde(1.02 g, 6.07 mmol) in THF (30 ml) was added 6.68 ml of a 1.0 M solutionof tetrabutylammonium fluoride in THF at 0° C. After stirring for 1 hr,the mixture was treated with 10 ml of saturated ammonium chloridesolution and extracted with ethyl acetate. The organic solution waswashed with brine, dried over anhydrous sodium sulfate, filtered throughMagnesol and evaporated. The crude gum was washed with hexanes, dried invacuo, and then dissolved in methylene chloride (20 ml). To thissolution was added 4-methylmorpholine-N-oxide (2.89 g, 24 mmol) andmolecular sieve 4A (6 g). The mixture was stirred at room temperaturefor 10 min. and then treated with tetrapropylammonium peruthenate (0.11g, 0.3 mmol). Stirring was continued for 2 hr. The methylene chloridesolution was concentrated and diluted with ethyl acetate (40 ml). Themixture was filtered through a pad of silica gel (40 g) and the filterpad was eluted with 2×20 ml ethyl acetate. The combined eluent waswashed with 1N HCl and brine, dried over anhydrous sodium sulfate, andevaporated to give 0.30 g of a white solid; mp 135-136° C.; MS m/e 167(MH⁺).

[0482] Step 5: 4-nitrobenzyl(5R)-6-[(acetyloxy)(4-oxo-6.7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-2-yl)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate

[0483] To a solution of MgBr₂ (0.46 g, 2.52 mmol) in acetonitrile (13ml) under nitrogen was added4-oxo-6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazine-2-carbaldehyde (0.14 g,0.84 mmol) at room temperature with stirring. A solution of(5R,6S)-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid 4-nitrobenzyl ester (0.32 g, 0.84 mmole) in THF (13 ml) was thenadded, and the mixture was cooled to −20° C. Triethylamine (0.35 ml,2.52 mmol) was introduced, and the mixture was stirred at −20° C. in thedark for 4 hr. It was then treated with acetic anhydride (0.2 ml, 2.0mmol), and 4-N,N-dimethylaminopyridine (12 mg, 0.1 mmol), and kept at 0°C. for 18 hr. The mixture was concentrated and the residue was dissolvedin ethyl acetate. The ethyl acetate solution was washed with 5% citricacid, saturated sodium bicarbonate solution, and brine, dried overanhydrous sodium sulfate, and evaporated. The crude material waschromatographed with silica gel (EtOAc-CH2Cl2/1:5) to give 0.27 g of anoff-white solid; mp 107-110° C.; MS m/e 595 (MH⁺).

[0484] Step 6:(5R,6Z)-7-oxo-6-[(4-oxo-6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-2-yl)methylene]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicAcid

[0485] To a solution of 4-nitrobenzyl(5R)-6-[(acetyloxy)(4-oxo-6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-2-yl)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate(0.22 g, 0.37 mmol) in THF (15 ml), under nitrogen, was added 15 ml of aphosphate buffer solution (0.5M, pH 6.5), and 80 mg of 10% Pd/C. Themixture was hydrogenated at 40-50 psi for 3 hr, and then filteredthrough Celite. The filter pad was washed with THF, and the filtrate wasextracted with ethyl acetate. The organic extract was dried overanhydrous magnesium sulfate and evaporated. The residue was washed withether to give 0.07 g of a yellow solid; MS m/e 320 (MH⁺); ¹H NMR(DMSO-d₆) δ 4.55-4.57 (m, 2H), 4.76-4.80 (m, 2H), 6.50 (s, 1H), 6.63 (s,1H), 7.58 (s, 1H), 7.76 (s, 1H).

Example 15 Preparation of6-(6,7-Dihydro-4H-thieno[3,2-c]pyran-2-ylmethylene)-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid

[0486] Step 1: Preparation of6,7-Dihydro-4H-thieno[3,2-c]pyran-2-carbaldehyde POCI3 (3.83 ml, 50mmol) was added dropwise to ice cooled DMF (3.85 ml, 50 mmol) within 3minutes. DCM (20 ml) was added and the bath was removed when thereaction media appeared to be pasty. The reaction was kept at 23° C. for2 hrs. Then it was cooled to 0° C. again. 4H-pyran-4-one (5 gram, 50mmol) in 10 ml DCM was then added dropwise within 3 minutes. Thereaction was kept at 0° C. for 2 hrs. Pour the mixture onto ice andsodium acetate solution and extract with DCM (2×200). The combinedorganic layers were dried over magnesium sulfate. Filter off the dryingagent and concentrate gave 5.0 gram of product. The compound wasdissolved in DCM (200 ml) and was added 6.0 gram of ethyl2-6,7-Dihydro-4H-thieno[3,2-c]thiopyran-2-carbaldehyde-acetate and 10 mlTEA. The mixture was refluxed for 18 hrs. Then it was washed with waterand dried over magnesium sulfate. It was then filtered, concentrated andflash chromatographed with 20 ethyl acetate in hexane. The collectedmaterial was dissolved in 100 ml THF and LAH (150 ml, 0.5M in THF) wasinjected and left at 23° C. for 10 minutes. Then it was refluxed for 18hrs. Quenched at 23° C. by adding water and eventually 1N HCl to clearup the mixture. Extract with ethyl acetate (2×200 ml) and combinedorganic layers dried over magnesium sulfate. Filter and concentrate gave2.3 gram product. The crude material was dissolved in DCM (300 ml) andmanganese dioxide (15 gram was added). The reaction was carried on at23° C. for 0.5 hr. Then 2×15 gram of oxidant was added each half an hourlater. The material was then filtered through a pad of celiteconcentrated. Flash column chromatography gave 1.206 gram (14% yield)oil product.

[0487] H-NMR:δ 9.84(s, 1H), 7.41(s, 1H), 4.74 (s, 2H), 4.00 (t, 2H,J=5.6 Hz), 2.96 (t, 2H, J=5.6 Hz); MS: 169.1 (M+H)

[0488] Step 2: Preparation of6-(6,7-Dihydro-4H-thieno[3,2-c]pyran-2-ylmethylene)-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicAcid

[0489] 6,7-Dihydro-4H-thieno[3,2-c]pyran-2-carbaldehyde (336 mg, 2 mmol)was dissolved in 20 ml acetonitrile and magnesium bromide (516 mg, 2mmol) was then added under N2 atmosphere. The mixture was stirred at 23°C. for half an hour.6-Bromo-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid4-nitro-benzyl ester (770 mg, 2 mmol) in 20 ml THF was then injected allat once and the mixture was immediately cooled to −20° C./Triethylamine(1 ml) was then injected and the mixture stirred at −20° C. for threehrs. Then acetic anhydride (0.4 ml) was injected and the mixture wasstirred at 0° C. for 18 hrs. The reaction media was then diluted with400 ml ethyl acetate and washed with 100 ml 5% citric acid, 100 mlsaturated sodium bicarbonate, and 100 ml brine. The organic layer wasthen dried over magnesium sulfate, filtered and concentrated. Flashcolumn chromatography using 20% ethyl acetate in hexane gave 491 mg(41%) product. This product was then dissolved in 15 ml THF and 15 mlaqueous phosphate buffer (pH=6.5). The mixture was then subjected to 45psi hydrogen for one hour with 0.5 gram 10% palladium on carbon. Then itwas filtered through a pad of celite and concentrated in vacuo to removemost of the THF. The solution was then cooled to zero degree andbasified to pH=8 with 1 N sodium hydroxide. Then it was purified viareverse phase HPLC using 2 liter of water followed by 5% acetonitrile inwater. Water was then removed through concentrate in vacuo and 100 mg(38%) of product was collected; MP: >250° C.;

[0490] H-NMR: δ 7.36 (s, 1H), 7.15(s, 1H), 6.55(s, 1H), 6.44(s, 1H),4.61 (s, 2H), 3.88(m, 2H), 2.86 (m, 2H), 2.27 (m, 2H), 1.43 (t, 3H)

[0491] MS: 320.3(M−H)

Example 16 Preparation of6-(6,7-Dihydro-4H-thieno[3,2-c]thiopyran-2-ylmethylene)-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicAcid

[0492] Step 1: Preparation of6,7-Dihydro-4H-thieno[3,2-c]thiopyran-2-carbaldehyde

[0493] POCl3 (4.02 ml, 43 mmol) was added dropwise to ice cooled DMF(3.34 ml, 43 mmol) within 3 minutes. DCM (20 ml) was added and the bathwas removed when the reaction media appeared to be pasty. The reactionwas kept at 23° C. for 2 hrs. Then it was cooled to 0° C. again.Tetrahydro-thiopyran-4-one (5 gram, 43 mmol) in 10 ml DCM was then addeddropwise within 3 minutes. The reaction was kept at 0° C. for 2 hrs.Dilute with DCM (250 ml) and then wash with ice cold 200 ml saturatedsodium acetate aqueous solution. The organic layer was dried over sodiumsulfate. Filter off the drying agent, concentrate and flash columnchromatography using 10% ethyl acetate in hexane gave 1.3 gram (8 mmol)of product. The compound was dissolved in DCM (100 ml) and was added 1.2ml (11 mmol) of ethyl 2-mercapto-acetate and 1 ml TEA. The mixture wasrefluxed for 18 hrs. Then it was washed with water and dried overmagnesium sulfate. Filter, concentrate and flash chromatograph with 20ethyl acetate in hexane produced 1.1 gram (11% yield) of product

[0494] H-NMR:δ 6.68(s, 1H), 4.73 (s, 2H), 3.68(s, 2H), 3.04 (t, 2H,J=7.6 Hz), 2.91 (t, 2H, J=7.6 Hz).; MS (EI): 185.99 (M+)

[0495] The 1.1 gram (4.8 mmol)6,7-Dihydro-4H-thieno[3,2-c]thiopyran-2-carboxylic acid ethyl ester wasdissolved in 100 ml THF and LAH (40 ml, 0.5M in DMG) was injected andthe reaction was left at 23° C. for 10 minutes. Then it was refluxed for18 hrs. Quenched at 23° C. with water (10 ml). The organic layerdecanted and the remaining was washed with 20 ml DCM. The combinedorganic layers dried over sodium sulfate. Filter, concentrate and flashcolumn chromatograph with 10-20% ethyl acetate produced 940 mg crudeproduct. This crude material was dissolved in DCM (40 ml) and manganesedioxide (2 gram was added). The reaction was carried on at 23° C. forhalf an hour. The material was then filtered through a pad of celiteconcentrated. Flash column chromatography gave 320 mg (36%) product.

[0496] H-NMR:δ 9.82(s, 1H), 7.46 (s, 1H), 3.56 (s, 2H), 3.15 (t, 2H,J=7.2 Hz), 2.95 (t, 2H, J=7.2 Hz).; MS (EI): 228.02 (M+)

[0497] Step 2: Preparation of6-(6,7-Dihydro-4H-thieno[3,2-c]thiopyran-2-ylmethylene)-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicAcid

[0498] 6,7-Dihydro-4H-thieno[3,2-c]thiopyran-2-carbaldehyde (320 mg,1.72 mmol) was dissolved in 17 ml acetonitrile and magnesium bromideetherate (450 mg, 1.74 mmol) was then added under N2 atmosphere. Themixture was stirred at 23° C. for half an hour.6-Bromo-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid4-nitro-benzyl ester (660 mg, 1.72 mmol) in 17 ml THF was then injectedall at once and the mixture was immediately cooled to −20°C./Triethylamine (1 ml) was then injected and the mixture stirred at−20° C. for three hrs. Then acetic anhydride (0.4 ml) was injected andthe mixture was stirred at 0° C. for 18 hrs. The reaction media was thendiluted with 400 ml ethyl acetate and washed with 100 ml 5% citric acid,100 ml saturated sodium bicarbonate, and 100 ml brine. The organic layerwas then dried over magnesium sulfate, filtered and concentrated. Flashcolumn chromatography using 20% ethyl acetate in hexane gave 461 mg(44%) product. This product was then dissolved in 20 ml THF and 20 mlaqueous phosphate buffer (pH=6.5). The mixture was then subjected to 40psi hydrogen for one hour and half with 0.5 gram 10% palladium oncarbon. Then it was filtered through a pad of celite and concentrated invacuo to remove most of the THF. The solution was then cooled to zerodegree and basified to pH=8 with 1 N sodium hydroxide. Then it waspurified via reverse phase HPLC using 2 liter of water followed by 5%acetonitrile in water. Water was then removed through concentrate invacuo and 21 mg (8.6%) of product was collected.

[0499] MP: >250° C.

[0500] H-NMR: 7.34 (s, 1H), 7.18(s, 1H), 6.59(s, 1H), 6.44(s, 1H), 3.71(s, 2H), 2.93(s, 2H), 2.50 (s, 2H).; MS: 338.0(M+H)

Example 17 Preparation of6-(5-Methyl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-2-ylmethylene)-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicAcid

[0501] Step 1: Preparation of(5-Methyl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-2-yl)-methanol

[0502] 6,7-Dihydro-4H-thieno[3,2-c]pyridine-2,5-dicarboxylic aciddiethyl ester (46 gram, 163 mmol) was dissolved in 200 ml THF. Thesolution was injected LAH (1M, THF) 300 ml at 23° C. Then it was stirredat 23° C. for 18 hrs. The reaction was quenched with 10 ml water anddried directly over sodium sulfate. Filter and concentrate yielded 29.3gram (160 mmol, 98%) crude product.

[0503] H-NMR: 6.55(s, 1H), 4.70 (s, 2H), 3.41 (s, 2H), 2.86 (t, 2H,J=5.6 Hz), 2.73 (t, 2H, J=5.6 Hz), 2.38 (s, 3H); MS: 184.0(M+H)

[0504] Step 2: Preparation of5-Methyl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine-2-carbaldehyde

[0505] DMSO (1.7 ml, 24 mmol) in 5 ml CH₂Cl₂ was cooled to −50-60° C.Oxalyl chloride (1 ml, 11 mmol) in 20 ml DCM was then added within 5minutes at 50° C. The mixture was kept at −50° C. for 5 minutes and then1.67 gram (9 mmol) of(5-Methyl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-2-yl)-methanol in 20ml DCM was added at 50° C. and the mixture was stirred for another 15minutes at 50° C. Triethylamine (7 ml) was then added at −50° C. andafter 5 minutes the bath was removed and the mixture is naturally warmedup to 23° C. It was washed with 100 ml water and extracted with 100 mlethyl acetate. The combined organic layers were dried over magnesiumsulfate. Filter. Concentrate and flash column chromatograph using 0-15%methanol in ethyl acetate yielded 736 mg (45% yield) product.

[0506] H-NMR: 9.81(s, 1H), 7.42 (s, 1H), 3.56 (s, 2H), 3.00 (t, 2H,J=5.6 Hz), 2.91 (t, 2H, J=5.6 Hz), 2.51 (s, 3H); MS: 182.1(M+H)

[0507] Step 3: Preparation of6-(5-Methyl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-2-ylmethylene)-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid

[0508] 2-formyl-6,7-dihydro-4H-thieno[3,2-c]pyridine-5-carboxylic acidethyl ester (724 mg, 4 mmol) was dissolved in 40 ml acetonitrile andmagnesium bromide etherate (1.2 gram, 4.65 mmol) was then added under N2atmosphere. The mixture was stirred at 23° C. for half an hour.6-Bromo-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid4-nitro-benzyl ester (1.54 gram, 4 mmol) in 40 ml THF was then injectedall at once and the mixture was immediately cooled to −20° C.Triethylamine (2 ml) was then injected and the mixture stirred at −20°C. for 3 hrs. Then acetic anhydride (0.66 ml) was injected and themixture was stirred at 0° C. for 48 hrs. The reaction media was thendiluted with 500 ml ethyl acetate and washed with 50 ml 5% citric acid,50 ml saturated sodium bicarbonate, and 50 ml brine. Another 300 mlethyl acetate was used to wash each aqueous solution. The combinedorganic layers were then dried over sodium sulfate. Filter, concentrate,and flash column chromatograph using 20% ethyl acetate in hexane gave1.56 gram (64% yield) product. This product was then dissolved in 20 mlTHF and 20 ml aqueous phosphate buffer (pH=6.5). The mixture was thensubjected to 40 psi hydrogen for two hrs with 0.5 gram 10% palladium oncarbon. Then it was filtered through a pad of celite and concentrated invacuo to remove most of the THF. The solution was then cooled to zerodegree and basified to pH=8 with 1 N sodium hydroxide. Then it waspurified via reverse phase HPLC using 2 liter of water followed by 5%acetonitrile in water. Water was then removed through concentrate invacuo and 112 mg (13%) of product was collected.

[0509] MP: >250° C.

[0510] H-NMR: δ 7.48 (s, 1H), 7.37(s, 1H), 7.21 (s, 1H), 7.10(s, 1H),3.41 (s, 2H), 2.88 (s, 2H), 2.68(s, 2H), 2.37(s, 3H); MS: 335.0(M+H)

Example 18 Preparation of2-(2-Carboxy-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-en-6-ylidenemethyl)-6,7-dihydro-4H-thieno[3,2-c]pyridine-5-carboxylicAcid Ethyl Ester

[0511] 2-Formyl-6,7-dihydro-4H-thieno[3,2-c]pyridine-5-carboxylic acidethyl ester (480 mg, 2 mmol) was dissolved in 20 ml acetonitrile andmagnesium bromide etherate (516 mg, 2 mmol) was then added under N2atmosphere. The mixture was stirred at 23° C. for half an hour.6-Bromo-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid4-nitro-benzyl ester (770 mg, 2 mmol) in 20 ml THF was then injected allat once and the mixture was immediately cooled to −20° C. Triethylamine(1 ml) was then injected and the mixture stirred at −20° C. for 3 hrs.Then acetic anhydride (0.4 ml) was injected and the mixture was stirredat 0° C. for 48 hrs. The reaction media was then diluted with 200 mlethyl acetate and washed sequentially with 50 ml 5% citric acid, 50 mlsaturated sodium bicarbonate, and 50 ml brine. The organic layer wasthen dried over sodium sulfate. Filter, concentrate, and flash columnchromatograph using 20% ethyl acetate in hexane gave 690 mg (50%, yield)product. A fraction of this product (456 mg, 0.69 mmol) was thendissolved in 15 ml THF and 15 ml aqueous phosphate buffer (pH=6.5). Themixture was then subjected to 40 psi hydrogen for two hrs with 0.5 gram10% palladium on carbon. Then it was filtered through a pad of celiteand concentrated in vacuo to remove most of the THF. The solution wasthen cooled to zero degree and basified to pH=8 with 1 N sodiumhydroxide. Then it was purified via reverse phase HPLC using 2 liter ofwater followed by 5% acetonitrile in water. Water was then removedthrough concentrate in vacuo and 18 mg (5%) of product was collected.

[0512] MP: >250° C.

[0513] H-NMR: 7.35 (s, 1H), 7.24 (s, 1H), 6.61 (s, 1H), 6.45(s, 1H),4.48 (s, 2H), 4.08 (quartet, 2H, J=7.2 Hz), 3.68 (m, 2H), 2.87(m, 2H),1.20 (t, 3H, J=7.2 Hz); MS: 393.0(M+H)

Example 19 Preparation of7-Oxo-6-(6,7,8,9-tetrahydro-5H-imidazo[1,2-a]azepin-2-ylmethylene)-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid

[0514] Step 1: Preparation of6,7,8,9-Tetrahydro-5H-imidazo[1,2-a]azepine-2-carbaldehyde

[0515] Thiocaprolactam (6.45 gram, 50 mmol) was dissolved in 400 mlCH₂Cl₂ and methyl iodide (16 ml, 5eq) was next added. The mixture wasstirred under nitrogen for 18 hrs. Then it was treated with 100 mlpotassium carbonate (50%, aq.). The organic layer was then dried overmagnesium sulfate. After filtration and concentration 7.3 gram ofmaterial was obtained. This material was dissolved 300 ml ethanol and2.83 gram of ammonium chloride was added. The mixture was refluxed for 1hr. Then the solvent was removed in vacuo. Half of the material wasadded 200 ml ethanol and then followed by addition of 1.35 gram (25mmol) sodium methoxide and 4.8 gram (25 mmol)2-Bromo-3-isopropoxy-propenal and the mixture was stirred at 23° C. for2 hrs. Then the solvent was removed and 200 ml chloroform was addedalong with 10 ml triethyl amine. The mixture was refluxed for 2 hrs andthen cooled to 23° C. The reaction media was partitioned between 300 mlDCM and 2×150 potassium carbonate (50%). The organic layer was driedover magnesium sulfate. After filtration and concentration 2.1 gram ofoil product was obtained.

[0516] H-NMR: 9.62 (s, 1H), 7.60 (s, 1H), 6.61 (s, 1H), 6.45(s, 1H),4.58 (s, 2H), 2.96 (2m, H), 1.90(m, 2H), 1.72 (m, 2H); MS: 164.9(M+H)

[0517] Step 2: Preparation of7-Oxo-6-(6,7,8,9-tetrahydro-5H-imidazo[1,2-a]azepin-2-ylmethylene)-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicAcid

[0518] 6,7,8,9-Tetrahydro-5H-imidazo[1,2-a]azepine-2-carbaldehyde (1.312gram, 8 mmol) was dissolved in 80 ml acetonitrile and magnesium bromideetherate (2.94 gram, 8 mmol) was then added under N2 atmosphere. Themixture was stirred at 23° C. for half an hour.6-Bromo-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid4-nitro-benzyl ester (1.155 gram, 3 mmol) in 60 ml THF was then injectedall at once and the mixture was immediately cooled to −20° C.Triethylamine (4 ml) was then injected and the mixture stirred at −20°C. for 4 hrs. Then acetic anhydride (1 ml) was injected and the mixturewas stirred at 0° C. for 20 hrs. The reaction media was then dilutedwith 500 ml ethyl acetate and washed with 100 ml 5% citric acid, 100 mlsaturated sodium bicarbonate, and 100 ml brine. The organic layer wasthen dried over sodium sulfate. Filter, concentrate, and flash columnchromatograph using 20% ethyl acetate in hexane gave 800 mg product.This product was then dissolved in 20 ml THF and 20 ml aqueous phosphatebuffer (pH=6.5). The mixture was then subjected to 40 psi hydrogen for 1hr with 0.5 gram 10% palladium on carbon. Then it was filtered through apad of celite and concentrated in vacuo to remove most of the THF. Thesolution was then cooled to zero degree and basified to pH=8 with 1 Nsodium hydroxide. Then it was purified via reverse phase HPLC using 2liter of water followed by 5% acetonitrile in water. Water was thenremoved through concentrate in vacuo and 131 mg (31%) of product wascollected.

[0519] MP: >250° C.

[0520] H-NMR: δ 7.78 (s, 1H), 7.02 (s, 1H), 6.94 (s, 1H), 6.36 (s, 1H),3.92(m, 2H), 2.80 (m, 2H), 1.78 (m, 2H), 1.61(m, 2H), 1.54(m, 2H); MS:318.2(M+H).

Example 20 Preparation of(5R),(6Z)-6-(7-Benzyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazin-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicAcid, Sodium Salt

[0521] Step 1:7-Benzyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-2-carboxylic AcidEthyl Ester

[0522] Et₃N (6.27 mL), PhCHO (4.92 mL) were added successively to theEtOH (81 mL) solution of5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-2-carboxylic acid ethyl ester,hydrochloride (9.47 g) at room temperature and stirred for 3 h under anitrogen atmosphere. Then NaBH₃CN (2.97 g) was added to the reactionmixture and stirred for 19 h. The mixture was filtered through a pad ofCelite and diluted with CH₂Cl₂ and washed with 50% K₂CO₃ aq. The organiclayer was dried (K₂CO₃) and filtered. The filtrate was concentratedunder reduced pressure. The residue was applied to silica gel columnchromatography, then the column was eluted with CHCl₃-acetone ({fraction(1/0)}˜{fraction (9/1)}) and CHCl₃-MeOH ({fraction (19/1)}˜{fraction(9/1)}). The titled compound was obtained as pale yellow crystals (4.16g, 36%).

[0523]¹H NMR(CDCl₃) δ 1.36(t, 3H, J=7.1 Hz), 2.87(t, 2H, J=5.2 Hz),3.71(s, 2H), 3.75(s, 2H), 4.01(m, 2H), 4.34(q, 2H, J=7.1 Hz),7.25-7.34(m, 5H), 7.51(s, 1H).

[0524] Step 2:7-Benzyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-2-carbaldehyde 1.01 Msolution of DIBAL in toluene (1 mL+0.2 mL+0.3 mL) was added to the dryCH₂Cl₂ (5 mL) solution of7-benzyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-2-carboxylic acidethyl ester (283 mg) under a nitrogen atmosphere at −78° C. and stirredfor 1.5 h. The mixture was quenched with 1M HCl (5 mL). The reactionmixture was filtered through a pad of Celite. The filtrate was washedwith 50% K₂CO₃ aq. and the aqueous layer was extracted with CH₂Cl₂. Thecombined organic layer was dried (K₂CO₃) and filtered. The filtrate wasconcentrated under reduced pressure. The residue was applied to silicagel column chromatography, then the column was eluted with CHCl₃-acetone({fraction (9/1)}˜{fraction (4/1)}) and CHCl₃-MeOH (19/1). The titledcompound was obtained as colorless crystals (148 mg, 61%).

[0525]¹H NMR(CDCl₃) δ 2.90(t, 2H, J=5.5 Hz), 3.74(s, 2H), 3.76(s, 2H),4.06(t, 2H, J=5.5 Hz), 7.28˜7.35(m, 5H), 7.53(s, 1H), 9.80(s, 1H).

[0526] Step 3: (5R,6RS)-6-[(RS)-Acetoxy(7-benzyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazin-2-yl)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid 4-nitrobenzyl ester (diastereo mixture)

[0527] 7-Benzyl-5,6, 7,8-tetrahydroimidazo[1,2-a]pyrazine-2-carbaldehyde(139 mg) was added to the dry acetonitrile (8.7 mL) solution ofanhydrous MgBr₂ (325 mg) under a nitrogen atmosphere at roomtemperature. The dry THF solution (8.7 mL) of (5R,6S)-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid4-nitro-benzyl ester (223 mg) was added to the mixture, cooled to −20°C., and Et₃N (0.24 mL) was added in one portion. The reaction vessel wascovered with foil to exclude light. The reaction mixture was stirred for5 h at −20° C. and treated with acetic anhydride (0.11 mL) and DMAP (7mg) in one portion. The reaction mixture was warmed to 0° C. and stirredfor 15 h at 0° C. The mixture was diluted with ethyl acetate and washedwith 5% citric acid aqueous solution, saturated sodium hydrogencarbonate, water and brine. The organic layer was dried (MgSO₄) andfiltered. The filtrate was concentrated under reduced pressure. Theresidue was applied to silica gel column chromatography, then the columnwas eluted with n-hexane -AcOEt ({fraction (3/1)}˜{fraction (1/1)}). Thetitled compound was obtained as two diastereo mixture ({fraction(80/20)}, purple amorphous solid, 233 mg, 61%).

[0528]¹H NMR(CDCl₃) δ 1.99(s, 0.8×3H), 2.23(s, 0.2×3H), 2.83˜2.89(m,2H), 3.68(d, 2H, J=4.9 Hz), 3.71(s, 2H), 3.94˜4.13(m, 2H), 5.27(d, 1H,J=13.6 Hz), 5.41(d, 0.2×1H, J=13.6 Hz), 5.45(d, 0.8×1H, J=13.6 Hz),6.05(s, 0.2×1H), 6.28(s. 0.8×1H), 6.31(s, 0.8×1H), 6.790(s, 0.2×1H),6.793(s, 0.2×1H), 7.01(s, 0.8×1H), 7.27˜7.36(m, 5H), 7.42(s, 0.2×1H),7.46(s, 0.8×1H), 7.61(d, 2H, J=8.6 Hz), 8.22(d, 2H, J=8.6 Hz).

[0529] Step 4:(5R),(6Z)-6-(7-Benzyl-5,6,7,8-tetrahydroimidazo[1.2-a]pyrazin-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicAcid. Sodium Salt

[0530] (5R,6RS)-6-[(RS)-Acetoxy(7-benzyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazin-2-yl)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid 4-nitrobenzyl ester (1.27 g) was dissolved in THF (55 mL) andacetonitrile (25 mL). Freshly activated Zn dust (5.08 g) was addedrapidly with 0.5 M phosphate buffer (pH 6.5, 80 mL). The reaction vesselwas covered with foil to exclude light. The reaction mixture wasvigorously stirred for 2 h at room temperature. The reaction mixture wasfiltered through a pad of Celite. The filtrate was washed with ethylacetate and the aqueous layer was separated. The aqueous layer wascooled to 3° C. and 1 M NaOH was added to adjust pH to 8.0. The mixturewas concentrated under high vacuum at 35° C. The concentrate was appliedto Diaion HP-21 (79 mL, Mitsubishi Kasei Co. Ltd.) resin columnchromatography. After adsorbing, the column was eluted withH₂O-MeCN({fraction (1/0)}˜{fraction (4/1)}). The combined fractions wereconcentrated under high vacuum at 35° C. and lyophilized to give thetitle compound as a yellow amorphous solid (390 mg, 49%, pH 7.7).

[0531] Mp 180° C. (dec); ¹H NMR(D₂O) δ 2.84˜2.95(m, 2H), 3.61(d, 2H,J=7.2 Hz), 3.67(s, 2H), 3.96(t, 2H, J=5.7 Hz), 6.43(s, 1H), 6.89(s, 1H),6.93(s, 1H), 7.28 ˜7.37(m, 6H).

Example 21 Preparation of(5R,6Z)-7-oxo-6-{[5-(Pyridin-3-ylmethyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)]methylene}-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicAcid

[0532] Step 1: 2-Formyl[5-(Pyridin-3-ylmethyl)-4,5,6,7-tetrahydrothieno][3,2-c]pyridine:

[0533] To a stirred solution of2-(formyl)-6,7-dihydrothieno[3,2-c]-5(4H)-pyridine (1.05 g, 5.2 mmol) inDMF (20 ml), 3-picolyl chloride hydrochloride (0.852 g, 5.2 mmol) andN,N-diisopropylethylamine (10 ml, excess) was added at room temperature.The reaction mixture was stirred for 24 hrs and quenched with water. Thereaction mixture was extracted with chloroform; washed well with waterand dried over anhydrous MgSO₄. It was filtered and concentrated. Theproduct was purified by SiO₂ column chromatography by eluting it withethylacetate. Pale yellow semi-solid.

[0534] Yield: 800 mg, 59%; M+H 259.

[0535] Step 2:4-Nitrobenzy-6-[(acetyloxy)[5(pyridin-3-ylmethyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate:

[0536] 2-Formyl[5-(pyridin-3-ylmethyl)-4,5,6,7-tetrahydrothieno][3,2-c]pyridine (516mg, 2.0 mmol) and the dry THF solution (20 mL) of (5R,6S)-6-bromo-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid 4-nitro-benzyl ester (772 mg, 2.0 mmol) were added successively tothe dry acetonitrile (15 mL) solution of anhydrous MgBr₂: O(Et)₂ (390mg, 1.5 mmol)under an argon atmosphere at room temperature. Aftercooling to −20° C., Et₃N (2.0 mL) was added in one portion. The reactionvessel was covered with foil to exclude light. The reaction mixture wasstirred for 2 h at −20° C. and treated with acetic anhydride (1.04 mL)in one portion. The reaction mixture was warmed to 0° C. and stirred for15 h at 0° C. The mixture was diluted with ethyl acetate and washed with5% citric acid aqueous solution, saturated sodium hydrogen carbonate,and brine. The organic layer was dried (MgSO₄) and filtered through apad of Celite. The pad was washed with ethyl acetate. The filtrate wasconcentrated under reduced pressure. The residue was applied to silicagel column chromatography, then the column was eluted with ethylacetate:hexane (1:1). Collected fractions were concentrated underreduced pressure and the mixture of diastereo isomers were taken to nextstep. Pale yellow amorphous solid; Yield: 700 mg, 51%; M+H 685 and 687.

[0537] Step-3:(5R,6Z)-6-{[5-(pyridin-3-ylmethyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)]methylene}-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid:

[0538]4-Nitrobenzy-6-[(acetyloxy)[5(pyridin-3-ylmethyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate(686 mg, 1.0 mmol) was dissolved in THF (20 mL) and acetonitrile (10mL). Freshly activated Zn dust (5.2 g) was added rapidly with 0.5 Mphosphate buffer (pH 6.5, 28 mL). The reaction vessel was covered withfoil to exclude light. The reaction mixture was vigorously stirred for 2h at room temperature. The reaction mixture was filtered, cooled to 3°C., and 0.1 M NaOH was added to adjust pH to 8.5. The filtrate waswashed with ethyl acetate and the aqueous layer was separated. Theaqueous layer was concentrated under high vacuum at 35° C. to giveyellow precipitate. The product was purified by HP21 resin reverse phasecolumn chromatography. Initially the column was eluted with deionizedwater (2 lits) and latter with 10% CAN: Water. The fractions containingthe product were collected and concentrated at reduced pressure at roomtemperature. The yellow solid was washed with acetone and filtered.Dried. Yield: 50 mg, 12%; as yellow crystals; mp. 134-136° C.; (M+H)412.

[0539]¹H NMR (DMSO-d₆)δ d 2.8 (m, 2H), 2.92 (bm, 2H), 3.6 (m, 2H), 3.86(s, 2H), 6.3 (s, 1H), 6.41 (s, 1H), 7.17 (s, 1H), 7.29 (s, 1H), 7.35 (m,1H), 7.7 (m, 1H), 8.48 (d, 1H), 8.54 (s, 1H).

Example 22 Preparation of(5R,6Z)-7-oxo-6-{[5-(pyridin-3-ylcarbonyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)]methylene}7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicAcid

[0540] Step 1: 2-Formyl[5-(pyridin-3-ylcarbonyl)-4,5,6,7-tetrahydrothieno][3,2-]pyridine:

[0541] To a stirred solution of2-(formyl)-6,7-dihydrothieno[3,2-c]-5(4H)-pyridine (606 mg, 3.0 mmol) inDMF (20 ml), nicotinoyl chloride hydrochloride (531 mg, 3.0 mmol) andN,N-diisopropylethylamine (10 ml, excess) was added at room temperature.The reaction mixture was stirred for 24 hrs and quenched with water. Thereaction mixture was extracted with chloroform; washed well with waterand dried over anhydrous MgSO₄. It was filtered and concentrated. Theproduct was purified by SiO₂ column chromatography by eluting it withethylacetate. Pale yellow semi-solid.

[0542] Yield: 600 mg, 73%; M+H 273.

[0543] Step 2: 4-Nitrobenzy-6-[(acetyloxy)[5(pyridin-3-ylcarbonyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxlate:

[0544] 2-Formyl[5-(pyridin-3-ylcarbonyl)-4,5,6,7-tetrahydrothieno][3,2-c]pyridine (400mg, 1.4 mmol) and the dry THF solution (20 mL) of (5R,6S)-6-bromo-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid 4-nitro-benzyl ester (772 mg, 2.0 mmol) were added successively tothe dry acetonitrile (15 mL) solution of anhydrous MgBr₂: O(Et)₂ (619mg, 2.4 mmol)under an argon atmosphere at room temperature. Aftercooling to −20° C., Et₃N (2.0 mL) was added in one portion. The reactionvessel was covered with foil to exclude light. The reaction mixture wasstirred for 2 h at −20° C. and treated with acetic anhydride (1.04 mL)in one portion. The reaction mixture was warmed to 0° C. and stirred for15 h at 0° C. The mixture was diluted with ethyl acetate and washed with5% citric acid aqueous solution, saturated sodium hydrogen carbonate,and brine. The organic layer was dried (MgSO₄) and filtered through apad of Celite. The pad was washed with ethyl acetate. The filtrate wasconcentrated under reduced pressure. The residue was applied to silicagel column chromatography, then the column was eluted with ethylacetate:hexane (1:1). Collected fractions were concentrated underreduced pressure and the mixture of diastereo isomers were taken to nextstep. Pale yellow amorphous solid; Yield: 300 mg, 30%; M.pt. 71° C.; M+H701.

[0545] Step-3:(5R,6Z)-6-{[5-(pyridin-3-ylcarbonyl)-4.5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)]methylene}-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicAcid Sodium Salt:

[0546]4-Nitrobenzy-6-[(acetyloxy)[5(pyridin-3-ylcarbonyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate(800 mg, 1.14 mmol) was dissolved in THF (20 mL) and acetonitrile (10mL). Freshly activated Zn dust (5.2 g) was added rapidly with 0.5 Mphosphate buffer (pH 6.5, 28 mL). The reaction vessel was covered withfoil to exclude light. The reaction mixture was vigorously stirred for 2h at room temperature. The reaction mixture was filtered, cooled to 3°C., and 0.1 M NaOH was added to adjust pH to 8.5. The filtrate waswashed with ethyl acetate and the aqueous layer was separated. Theaqueous layer was concentrated under high vacuum at 35° C. to giveyellow precipitate. The product was purified by HP21 resin reverse phasecolumn chromatography. Initially the column was eluted with deionizedwater (2 lits) and latter with 10% CAN: Water. The fractions containingthe product were collected and concentrated at reduced pressure at roomtemperature. The yellow solid was washed with acetone and filtered.Dried. Yield: 50 mg, 12%; as yellow crystals; mp. 195° C.; (M+H) 426.

Example 23 Preparation of(5R,6Z)-7-oxo-6-{[5-(phenylacetyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)]methylene}-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid

[0547] Step 1: 2-Formyl[5-(phenylacetyl)-4,5,6,7-tetrahydrothieno][3,2-c]pyridine:

[0548] To a stirred solution of2-(formyl)-6,7-dihydrothieno[3,2-c]-5(4H)-pyridine (0.41 mg, 2 mmol) inDMF (20 ml), phenyl acetyl chloride (0.35 mg, 2.2 mmol) andN,N-diisopropylethylamine (10 ml, excess) was added at room temperature.The reaction mixture was stirred for 24 hrs and quenched with water. Thereaction mixture was extracted with chloroform; washed well with waterand dried over anhydrous MgSO₄. It was filtered and concentrated. Theproduct was purified by SiO₂ column chromatography by eluting it withethylacetate. White solid. Yield: 510 mg, 89%; M+H 286.

[0549] Step 2:4-Nitrobenzy-6-[(acetyloxy)[5(phenylacetyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate:

[0550] 2-Formyl[5-(phenylacetyl)-4,5,6,7-tetrahydrothieno][3,2-c]pyridine (340 mg, 1.2mmol) and the dry THF solution (20 mL) of (5R,6S)-6-bromo-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid 4-nitro-benzyl ester (390 mg, 1.0 mmol) were added successively tothe dry acetonitrile (15 mL) solution of anhydrous MgBr₂: O(Et)₂ (310mg, 1.2 mmol)under an argon atmosphere at room temperature. Aftercooling to −20° C., Et₃N (2.0 mL) was added in one portion. The reactionvessel was covered with foil to exclude light. The reaction mixture wasstirred for 2 h at −20° C. and treated with acetic anhydride (1.04 mL)in one portion. The reaction mixture was warmed to 0° C. and stirred for15 h at 0° C. The mixture was diluted with ethyl acetate and washed with5% citric acid aqueous solution, saturated sodium hydrogen carbonate,and brine. The organic layer was dried (MgSO₄) and filtered through apad of Celite. The pad was washed with ethyl acetate. The filtrate wasconcentrated under reduced pressure. The residue was applied to silicagel column chromatography, then the column was eluted with ethylacetate:hexane (1:1). Collected fractions were concentrated underreduced pressure and the mixture of diastereo isomers were taken to nextstep. Pale yellow amorphous solid; Yield: 360 mg, 50%; M+H 713.

[0551] Step-3:(5R,6Z)-6-{[5-(phenylacetyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)]methylene}-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicAcid:

[0552]4-Nitrobenzy-6-[(acetyloxy)[5(phenylacetyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate(300 mg, 0.4 mmol) was dissolved in THF (50 mL) and 0.5 M phosphatebuffer (pH 6.5, 28 mL). This was hydrogenated at 40 psi pressure, in thepresence of 10% Pd/C (80 mg) for 2 hrs. at the end, reaction mixture wasfiltered through a pad of celite and concentrated. The separated yellowsolid was dissolved in ethyl acetate and washed well with water. Theorganic layer was dried and concentrated. The separated yellow solid wastriturated with diethyl ether and filtered. The yellow solid was washedwell with diethyl ether and it was found to be 95% pure compound. Yield:160 mg, 91%; Yellow solid; mp. 166-169° C.; (M+H) 439.

Example 24 Preparation of(5R),(6Z)-6-(5,5-Dioxo-4,5,6,7-tetrahydro-5λ⁶-pyrazolo[5,1-c][1,4]thiazin-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicAcid, Sodium Salt

[0553] Step 1:5,5-Dioxo-4,5,6,7-tetrahydro-5λ⁶-pyrazolo[5,1-c][1,4]thiazine-2-carbaldehyde

[0554] m-Chloroperbenzoic acid (cont. 69%) (6.36 g) was added to theCH₂Cl₂ (111 mL) solution of6,7-dihydro-4H-pyrazolo[5,1-c][1,4]thiazine-2-carbaldehyde (1.86 g) at0° C. The reaction mixture was stirred for 0.5 h at the same temperatureand stirred for 18 h at room temperature. The reaction mixture wasconcentrated under reduced pressure. The residue was triturated with 10mL of THF and filtered to obtain crystals. The filtrate was concentratedunder reduced pressure. The residue was triturated with 5 mL of THF andfiltered to obtain crystals. The combined crystals were dried underreduced pressure to give the titled compound as colorless crystals (1.96g, 89%).

[0555]¹H NMR (CDCl₃) δ 3.60 (t, 2H, J=6.1 Hz), 4.47 (s, 2H), 4.87 (t,2H, J=6.1 Hz), 6.71 (s, 1H), 9.94 (s, 1H).

[0556] Step 2:(5R,6RS)-6-[(RS)-Acetoxy-(5,5-dioxo-4,5,6,7-tetrahydro-5λ⁶-pyrazolo[5,1-c][1,4]thiazin-2-yl)-methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid 4-nitrobenzyl ester5,5-Dioxo-4,5,6,7-tetrahydro-5λ⁶-pyrazolo[5,1-c][1,4]thiazine-2-carbaldehyde(1.95 g) was added to the dry acetonitrile (112 mL) solution ofanhydrous MgBr₂ (cont. 98%) (5.48 g) under a nitrogen atmosphere at roomtemperature. The dry THF solution (112 mL) of (5R,6S)-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid4-nitrobenzyl ester (cont. 96.5%) (3.88 g) was added to the mixture,cooled to −20° C., and Et₃N (cont. 99%) (3.79 mL) was added in oneportion. The reaction vessel was covered with foil to exclude light. Thereaction mixture was stirred for 3 h at −20° C. and treated with aceticanhydride (cont. 97%) (3.79 mL) and DMAP (cont. 99%) (120 mg) in oneportion. The reaction mixture was warmed to 0° C. and stirred for 16 hat 0° C. To the reaction mixture was added acetic anhydride (cont. 97%)(0.95 mL) and DMAP (cont. 99%) (120 mg) in one portion. The mixture wasdiluted with ethyl acetate and washed with 5% citric acid aqueoussolution, saturated sodium hydrogen carbonate and brine. The organiclayer was dried (MgSO₄), followed by concentration under reducedpressure. The residue was purified with a silica-gel columnchromatography (CHCl₃: acetone=19:1-4:1) to give the titled compound asa pale brown amorphous solid (diastereo-mixture (8:2), 1.35 g, 22%).

[0557]¹H NMR (CDCl₃) δ 2.07 (s, 3H×0.2), 2.25 (s, 3H×0.8), 3.45-3.60 (m,2H), 4.39 (d, 1H, J=17.0 Hz), 4.44 (d, 1H, J=17.0 Hz), 4.65-4.78 (m,2H), 5.28 (d, 1H, J=13.5 Hz), 5.43 (d, 1H×0.8, J=13.5 Hz), 5.44 (d,1H×0.2, J=13.5 Hz), 6.05 (s, 1H×0.8), 6.20 (s, 1H×0.8), 6.22 (s,1H×0.2H), 6.38 (s, 1H×0.2), 6.39 (s, 1H×0.2), 6.79 (s, 1H×0.8), 7.42 (s,1H×0.8), 7.44 (s, 1H×0.2), 7.60 (d, 2H, J=8.7 Hz), 8.24 (d, 2H, J=8.7Hz).

[0558] Step 3:(5R),(6Z)-6-(5,5-Dioxo-4,5,6,7-tetrahydro-5λ⁶-pyrazolo[5,1-c][1,4]thiazin-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicAcid, Sodium Salt

[0559] (5R,6RS)-6-[(RS)-Acetoxy-(5,5-dioxo-4,5,6,7-tetrahydro-5□⁶-pyrazolo[5,1-c][1,4]-thiazin-2-yl)-methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid 4-nitrobenzyl ester (1.33 g) was dissolved in THF (19 mL) andacetonitrile (9 mL). Freshly activated Zn dust (5.32 g) was addedrapidly with 0.5 M phosphate buffer (pH 6.5, 27 mL). The reaction vesselwas covered with foil to exclude light. The reaction mixture wasvigorously stirred for 1.5 h at room temperature. The insoluble materialwas filtered off and was washed with H₂O (27 mL). The filtrate was addedH₂O (27 mL) and washed with ethyl acetate (27 mL) and the aqueous layerwas cooled to 3° C. and 1 M HCl was added to adjust pH to 2.5. Themixture was stirred for 1 d at the same temperature and added H₂O (55mL), then stirred for 4 d at the same temperature. The mixture wasstirred for 10 h at room temperature. The resultant mixture was cooledto 3° C. and 1 M NaOH was added to adjust pH to 8. The mixture wasconcentrated under high vacuum at 35° C. The concentrate was treated toDiaion HP-21 (80 mL, Mitsubishi Kasei Co. Ltd.) resin columnchromatography. After adsorbing, the column was eluted with H₂O-MeCN({fraction (1/0)}-{fraction (9/1)}). The combined fractions wereconcentrated under high vacuum at 35° C. and lyophilized to give thetitle compound as a yellow amorphous solid (306 mg, 38%, pH 7.4).

[0560] Mp 180° C. (dec); ¹H NMR (D₂O) δ 3.83 (t, 2H, J=6.1 Hz), 4.68 (s,2H), 4.72 (t, 2H, J=6.1 Hz), 6.37 (s, 1H), 6.40 (s, 1H), 6.95 (s, 1H),6.98 (s, 1H).

Example 25 Preparation of(5R),(6Z)-7-Oxo-6-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylmethylene)-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicAcid, Sodium Salt

[0561] Piperazine-2-carboxylic Acid, Dihydrochloride:

[0562] The titled compound was prepared in the same way of M. T. Wu andco-workers (Bioorg. Med. Chem. Lett. 1993, 3, 2023-2028).

[0563] Step 1: Piperazine-1,3-dicarboxylic acid 1-(4-nitrobenzyl) Ester

[0564] CuCO₃.Cu(OH)₂.H₂O (15.8 g) was added to the H₂O (275 mL) solutionof piperazine-2-carboxylic acid, dihydrochloride (22.3 g), then themixture was refluxed and stirred for 10 min. The insoluble material wasfiltered off and was washed with hot H₂O (165 mL). The filtrate wascooled to room temperature, and NaHCO₃ (9.2 g) and 1,4-dioxane (220 mL)was added to the dark blue solution. The mixture was cooled to 0° C. andNaHCO₃ (18.5 g) and 50% solution of 4-nitrobenzyl chloroformate in1,4-dioxane (61.7 g) was added to the mixture for 0.5 h. After stirringfor additional 1.5 h at 0° C., the precipitate was filtered and washedwith cold H₂O (140 mL), EtOH (100 mL), acetone (200 mL) and Et₂O (100mL), then it was allowed to dry under reduced pressure to obtain thepale blue crystals. The crystals were added to the 1 mol/L HCl (330 mL)solution of EDTA-2Na (20.5 g) for 30 min, and stirred for 2 h at roomtemperature. The suspension was filtered and the filtered material wasdiluted with EtOH-H₂O (7:3, 550 mL) and refluxed for 10 min. Thereaction mixture was filtered to obtain the colorless crystals. Therecrystallization from the filtrate was carried out 3 times to obtainadditional crystals. The combined crystals were dried under reducedpressure to obtain the titled compound (26.25 g, 77%) as colorlesscrystals.

[0565]¹H NMR (D₂O) δ 2.54-2.61 (m, 1H), 2.89 (dt, 2H, J=12.7, 3.4 Hz),2.97 (br, 1H), 3.13 (br, 1H), 3.62-4.04 (m, 2H), 5.16 (s, 2H), 7.49 (d,2H, J=8.6 Hz), 8.14 (d, 2H, J=8.6 Hz).

[0566] Step 2: 5-(4-Nitrobenzyloxycarbonyl)-3-oxo-3a,4,6,7-tetrahydro-3H-2-oxa-1,5-diaza-7a-azoniainden-3a-ide

[0567] The H₂O (300 mL) solution of NaNO₂ (cont. 98.5%) (6.66 g) wasadded to the acetic acid (864 mL) solution ofpiperazine-1,3-dicarboxylic acid 1-(4-nitrobenzyl) ester (26.72 g) undera nitrogen atmosphere at 0° C. for 0.5 h and stirred for 1 h. Inaddition, the H₂O (132 mL) solution of NaNO₂ (cont. 98.5%) (2.41 g) wasadded to the solution at 0° C. for 0.5 h and stirred for 1 h. Thesolution was concentrated under reduced pressure and H₂O (500 mL) wasadded to the residue. The solution was extracted with AcOEt (5 times)and organic layer was washed with brine. The mixture was dried overMgSO₄, filtered and concentrated under reduced pressure to afford crude4-nitrosopiperazine-1,3-dicarboxylic acid 1-(4-nitrobenzyl) ester aspale brown amorphous (27.83 g (gross), 25.77 g (net), 88.2%).

[0568] The THF (10 mL) solution of trifluoroacetic anhydride (24.0 g)was added to the THF (371 mL) solution of crude4-nitrosopiperazine-1,3-dicarboxylic acid 1-(4-nitrobenzyl) ester undera nitrogen atmosphere at 0° C. for 15 min. The solution was stirred for1.5 h at 0° C. and for 1 h at room temperature. The THF (5 mL) solutionof trifluoroacetic anhydride (8.0 g) was added to the solution for 5 minand stirred for 20 h at room temperature. To the solution was addedtrifluoroacetic anhydride (8.0 g) for 5 min and the solution was stirredfor 4 h. The precipitate was filtered and washed with THF and Et₂O. Thefiltrate was concentrated under reduced pressure. The residue wastriturated with THF, filtered and washed with Et₂O. These materials werecombined and dried under reduced pressure to afford the titled compoundas colorless crystals (22.3 g, 91%).

[0569]¹H NMR (CDCl₃) δ 4.06 (t, 2H, J=5.4 Hz), 4.37 (t, 2H, J=5.4 Hz),4.63 (s, 2H), 5.30 (s, 2H), 7.54 (d, 2H, J=8.7 Hz), 8.25 (d, 2H, J=8.7Hz).

[0570] Step 3: 6,7-Dihydro-4H-pyrazolo[1,5-a]pyrazine-2,5-dicarboxylicacid 2-ethyl ester 5-(4-nitrobenzyl) ester

[0571] Ethyl propiolate (cont. 99%)(8.28 g) was added to the o-xylene(348 mL) solution of5-(4-nitrobenzyloxycarbonyl)-3-oxo-3a,4,6,7-tetrahydro-3H-2-oxa-1,5-diaza-7a-azoniainden-3a-ide(22.3 g) under a nitrogen atmosphere and refluxed for 16 h. The solutionwas concentrated under reduced pressure, followed by silica-gel columnchromatography 3 times (n-hexane/AcOEt={fraction (2/1)}-⅓). The titledcompound was obtained as pale yellow crystals (16.78 g, 64%). Besides,6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-3,5-dicarboxylic acid 3-ethylester 5-(4-nitrobenzyl) ester was obtained as pale yellow crystals (6.18g, 24%).

[0572]¹H NMR (CDCl₃) δ1.39 (t, 3H, J=7.1 Hz), 4.01 (t, 2H, J=5.5 Hz),4.31 (t, 2H, J=5.5 Hz), 4.40 (q, 2H, J=7.1 Hz), 4.79 (s, 2H), 5.29 (s,2H), 6.64 (s, 1H), 7.54 (d, 2H, J=8.6 Hz), 8.24 (d, 2H, J=8.6 Hz).

[0573] Step 4:2-Hydroxymethyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylic acid4-nitrobenzyl Ester

[0574] LiBH₄ (640 mg) and MeOH (1.2 mL) was added to the THF (267 mL)solution of 6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-2,5-dicarboxylic acid2-ethyl ester 5-(4-nitrobenzyl) ester (10 g) under a nitrogen atmosphereat room temperature and stirred for 3 h at 40° C. Additional LiBH₄ (523mg) and MeOH (1.0 mL) was added to the solution and stirred for 1 h at40° C. and 1 h at 50° C. The mixture was acidified with 3 mol/L HCl topH 2 and stirred for 1 h at room temperature, then solid K₂CO₃ was addedto the solution to adjust pH to 8. The insoluble material was filteredoff and the filtrate was extracted with AcOEt. The organic layer wasdried (K₂CO₃), and concentrated under reduced pressure. The residue waspurified with silica gel column chromatography (CHCl₃/MeOH={fraction(49/1)}-{fraction (19/1)}) to afford titled compound as pale yellowcrystals (8.44 g, 95%).

[0575]¹H NMR (CDCl₃) δ 1.69 (br, 1H), 3.98 (t, 2H, J=5.5 Hz), 4.19 (t,2H, J=5.5 Hz), 4.65 (s, 2H), 4.75 (s, 2H), 5.28 (s, 2H), 6.08 (s, 1H),7.53 (d, 2H, J=8.7 Hz), 8.24 (d, 2H, J=8.7 Hz). Step 5;2-Formyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylic acid4-nitrobenzyl Ester

[0576] MnO₂ (activated) (84.2 g) was added to the CHCl₃-MeOH (95:5, 253mL) solution of2-hydroxymethyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylic acid4-nitrobenzyl ester (8.42 g), and the mixture was refluxed for 1 h undera nitrogen atmosphere. The reaction mixture was filtered through a padof Celite. Silica-gel (20 g) was added to the filtrate and the solventwas removed under reduced pressure to give the silica-gel coating withcrude reactant. The above silica-gel was adsorbed to silica-gel columnchromatqgraphy and the column was eluted with CHCl₃-MeOH ({fraction(49/1)} to {fraction (19/1)}). The titled compound was obtained asyellow crystals (2.82 g, 34%).

[0577]¹H NMR (CDCl₃) □4.05 (t, 2H, J=5.5 Hz), 4.32 (t, 2H, J=5.5 Hz),4.81 (s, 2H), 5.29 (s, 2H), 6.62 (s, 1H), 7.54 (d, 2H, J=8.7 Hz), 8.24(d, 2H, J=8.7 Hz), 9.93 (s, 1H).

[0578] Step 6; 2-{(RS)-Acetoxy-[(5R,6RS)-6-bromo-2-(4-nitrobenzyloxycarbonyl)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-en-6-yl]-methyl}-6,7-dihydro-4H-Pyrazolo[1,5-a]pyrazine-5-carboxylicacid 4-nitrobenzyl Ester

[0579] 2-Formyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylic acid4-nitrobenzyl ester (2.71 g) was added to the dry acetonitrile (164 mL)solution of anhydrous MgBr₂ (cont. 98%) (6.17 g) under a nitrogenatmosphere at room temperature. The dry THF solution (164 mL) of (5R,6S)-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid4-nitrobenzyl ester (cont. 96.5%) (3.27 g) was added to the mixture,cooled to −20° C., and Et₃N (cont. 99%) (9.24 mL) was added in oneportion. The reaction vessel was covered with foil to exclude light. Thereaction mixture was stirred for 1.5 h at −20° C. and treated withacetic anhydride (cont. 97%) (3.19 mL) and DMAP (cont. 99%) (203 mg) inone portion. The reaction mixture was warmed to 0° C. and stirred for 1h at 0° C. Acetic anhydride (3.19 mL) was added to the solution andstirred for 15 h at 0° C. The mixture was diluted with ethyl acetate andwashed with 5% citric acid aqueous solution, saturated sodium hydrogencarbonate, water and brine. The organic layer was dried (MgSO₄),followed by concentration under reduced pressure. The residue waspurified with silica-gel column chromatography three times(n-hexane-AcOEt ({fraction (1/1)} to ⅔), CHCl₃-acetone ({fraction(29/1)} to {fraction (19/1)}) and CHCl₃-acetone ({fraction (29/1)})).The titled compound was obtained as yellow amorphous (diastereo-mixture(64:36), 3.30 g, 53%).

[0580]¹H NMR (CDCl₃) δ 2.06 (s, 3H×0.36), 2.26 (s, 3H×0.64), 3.95-4.04(m, 2H), 4.18 (s, 2H), 4.73 (d, 1H, J=18.2 Hz), 4.78 (d, 1H, J=18.2 Hz),5.28 (d, 1H, J=13.5 Hz), 5.28 (s, 2H), 5.43 (d, 1H×0.64, J=13.5 Hz),5.44 (d, 1H×0.36), 6.06 (s, 1H×0.64), 6.08 (s, 1H×0.64), 6.24 (s,1H×0.36), 6.27 (s, 1H×0.36), 6.41 (s, 1H×0.36), 6.79 (s, 1H×0.64), 7.42(s, 1H×0.64), 7.44 (s, 1H×0.36), 7.53 (d, 2H, J=8.6 Hz), 7.60 (d, 2H,J=8.8 Hz), 8.24 (d, 2H, J=8.8 Hz), 8.24 (d, 2H, J=8.6 Hz).

[0581] Step 7:(5R),(6Z)-7-Oxo-6-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylmethylene)-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt

[0582] To the THF (43 mL) and acetonitrile (20 mL) solution of2-{(RS)-acetoxy-[(5R,6RS)-6-bromo-2-(4-nitrobenzyloxycarbonyl)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-en-6-yl]-methyl}-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylicacid 4-nitrobenzyl ester was added Zn dust (12.36 g) rapidly with 0.5 Mphosphate buffer (pH 6.5, 63 mL). The reaction vessel was covered withfoil to exclude light. The reaction mixture was vigorously stirred for1.5 h at room temperature. The insoluble material was filtered off andwas washed with H₂O (63 mL). The filtrate was washed with ethyl acetate(63 mL) and the aqueous layer was cooled to 3° C. and 1 M HCl was addedto adjust pH to 2.5. The mixture was stirred for 4 h at the sametemperature and added H₂O (63 mL) and 1 M HCl to adjust pH to 2.5, thenstirred for 17 h at the same temperature. To the mixture was added 1 MNaOH to adjust pH to 8. The mixture was concentrated under high vacuumat 35° C. The concentrate was treated to Diaion HP-21 (124 mL,Mitsubishi Kasei Co. Ltd.) resin column chromatography. After adsorbing,the column was eluted with H₂O-MeCN ({fraction (1/0)}-{fraction(95/5)}). The combined fractions were concentrated under high vacuum at35° C. and lyophilized to give the title compound as a yellow amorphoussolid (288 mg, 22%, pH 8.8).

[0583] Mp 160° C. (dec); ¹H NMR (D₂O) δ 2.94(t, 2H, J=5.6 Hz), 3.67 (d,1H, J=17.2 Hz), 3.70 (d, 1H, J=17.2 Hz), 3.82 (t, 2H, J=5.6 Hz), 5.84(s, 1H), 6.03 (s, 1H), 6.65 (s, 1H), 6.67 (s, 1H).

Example 26 Preparation of(5R)(6Z)-6-(5,5-Dimethyl-4H-1,6a-diazapentalen-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt 5,5-Dimethyl-2-piperidone

[0584] 5-5-Dimethyl-2-piperadinone was prepared in the method ofNagasawa (J. Med. Chem., 20, 1176 (1977)).

[0585] Step 1: 3,3-Dichloro-5,5-dimethyl-2-piperidone

[0586] To a cold (0° C.) stirred solution of 5,5-dimethyl-2-piperidone(30.2 g, 0.24 mol) in 475 mL of CHCl₃, PCI₅ (57.1 g, 0.26 mol) was addedat such a rate that the temperature never exceeded 7° C. After theaddition was complete, stirring was continued for 10 min. Sulfurylchloride (96.6 g, 0.72 mol) was slowly added and the mixture was heatedunder reflux for 1 h. The solution was concentrated under reducedpressure. The residue was cooled in ice and diluted with 250 mL ofice-water. The product was then extracted with CHCl₃ (6×250 mL) and theorganic layer was dried (MgSO₄) and filtered. The filtrate wasconcentrated under reduced pressure. The residue was applied tosilica-gel column chromatography, and then the column was eluted withCHCl₃-MeOH (50:1). The titled compound was obtained as a white solid(41.3 g, 88.8%). (J. Med. Chem., 20, 1176 (1977))

[0587]¹H NMR (CDCl₃) δ 1.17 (s, 6H), 2.76 (s, 2H), 3.19 (d, 2H, J=3.0Hz), 6.82 (brs, 1H).

[0588] Step 2: 3-Chloro-5,5-dimethyl-2-piperidone

[0589] To 40.8 g (0.21 mol) of 3,3-dichloro-5,5-dimethyl-2-piperidonedissolved in 410 mL of AcOH was added 10% Pd/C (50% wet, 6.2 g) andNaOAc-3H₂O (62.4 g, 0.46 mol) and the mixture was hydrogenated at 300kPa for 20 min. The pressure of hydrogen was adjusted at 300 kPa every 5min. The catalyst was removed by filtration and the filtrateconcentrated under reduced pressure. CHCl₃ (400 mL) and water (300 mL)were added to the residue and the aqueous layer was neutralized with 4mol/L NaOH. The mixture was separated and the aqueous layer wasextracted with CHCl₃ (5×300 mL) and the organic layer was dried (MgSO₄)and filtered. The filtrate was concentrated under reduced pressure. Theresidue was applied to silica-gel column chromatography, and then thecolumn was eluted with hexane-AcOEt (1:1). The titled compound wasobtained as a white solid (20.4 g, 59.9%). (J. Med. Chem., 20, 1176(1977))

[0590]¹H NMR (CDCl₃) δ 1.10 (s, 3H), 1.12 (s, 3H), 2.02 (dd, 1H, J=10.8,13.6 Hz), 2.20 (ddd, 1H, J=2.2, 6.7,13.6 Hz), 2.97 (ddd, 1H, J=2.3, 3.9,12.1 Hz), 3.22 (d, 1H, J=12.1 Hz), 4.44 (dd, 1H, J=6.8, 10.7 Hz), 6.66(brs, 1H).

[0591] Step 3: 4,4-Dimethylpyrrolidine-2-carboxylic Acid

[0592] A suspension of 20.4 g (0.13 mol) of3-chloro-5,5-dimethyl-2-piperidone and 45.2 g (0.14 mol) of Ba(OH)₃-8H₂Oin 252 mL of water was heated in a Parr apparatus at 150° C. for 6 h.Then, 18.6 g (0.14 mol) of ammonium sulphate were added. The precipitatewas filtered off, and the solution was concentrated under reducedpressure to dryness. Crude 4,4-dimethylpyrrolidine-2-carboxylic acid wasobtained as a white solid (37.5 g). (J. Med. Chem., 20, 1176 (1977), EP0 447 704 A1, page 17)

[0593]¹H NMR (D₂O) δ 1.10 (s, 3H), 1.11 (s, 3H), 1.88 (dd, 1H, J=7.8,13.2 Hz), 2.21 (dd, 1H, J=9.2, 13.2 Hz), 3.12 (dd, 2H, J=11.5, 23.5 Hz),4.22 (dd, 1H, J=8.1, 8.9 Hz).

[0594] Step 4: 5,5-Dimethyl-3-oxo-3a, 4-dihydro-3H,6H-2-oxa-6-1-aza-6a-azonio-3a-pentalenide

[0595] To a suspension of 37.5 g of the crude4,4-dimethylpyrrolidine-2-carboxylic acid in 420 mL of AcOH was added asolution of 13.3 g (0.19 mol) of NaNO₂ in 210 mL of water over 15 min atroom temperature and stirred for 3 h. The solution was concentratedunder reduced pressure. Acetone (250 mL) was added to the residue andthe precipitate was filtered off, and the solution was concentratedunder reduced pressure to dryness and crude4,4-dimethyl-1-nitrosopyrrolidine-2-carboxylic acid was obtained asbrown oil.

[0596] To a solution of crude4,4-dimethyl-1-nitrosopyrrolidine-2-carboxylic acid in 252 mL of dry THFwas added trifluoroacetic anhydride (81.3 g, 0.39 mol) under a nitrogenatmosphere at 0° C. and stirred for 6 h at 0° C. The solution wasconcentrated under reduced pressure. The residue was applied tosilica-gel column chromatography, and then the column was eluted withn-hexane-AcOEt (2:1). The titled compound was obtained as a brown solid(12.0 g, 61.7%).

[0597]¹H NMR (CDCl₃) δ 1.38 (s, 6H), 2.71 (s, 2H), 4.12 (s, 2H).

[0598] Step 5:5,5-Dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-2-carboxylic Acidethylester

[0599] A solution of 5,5-dimethyl-3-oxo-3a, 4-dihydro-3H,6H-2-oxa-5-1-aza-6a-azonio-3a-pentalenide (10.8 g, 0.07 mol) and ethylpropiolate (10.8 mL, 0.11 mol) in o-xylene (350 mL) was refluxed under anitrogen atmosphere for 16 h. The solution was cooled to roomtemperature and concentrated under reduced pressure. The residue wasapplied to silica gel column chromatography, and then the column waseluted with n-hexane-AcOEt (3:1). The titled compound was obtained as apale brown solid (4.63 g, 31.7%), and5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-3-carboxylic acidethylester was obtained as a yellow solid (4.73 g, 32.4%).

[0600] 5,5-Dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-2-carboxylicacid ethylester: ¹H NMR (CDCl₃) δ 1,29 (s, 6H), 1.40 (t, 3H, J=7.1 Hz),2.71 (s, 2H), 3.93 (s, 2H), 4.39 (q, 2H, J=7.1 Hz), 6.54 (s, 1H).

[0601] 5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-3-carboxylicacid ethylester: ¹H NMR (CDCl₃) δ 1,32 (s, 6H), 1.33 (t, 3H, J=7.1 Hz),2.89 (s, 2H), 3.90 (s, 2H), 4.26 (q, 2H, J=7.1 Hz), 7.90 (s, 1H).

[0602] Step 6:5,5-Dimethyl-5,6-dihydro-4H-pyrrolo[1.2-b]pyrazole-2-carbaldehyde

[0603] To 4.63 g (22.2 mmol) of5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-2-carboxylic acidethylester in 222 mL of dry THF was added LiAlH₄ (0.85 g, 22.3 mmol)under a nitrogen atmosphere at 0° C., and then stirred for 1 h. Themixture was quenched with water (5.0 mL) and the precipitate wasfiltered through a pad of Celite and the pad was washed with water (50mL) and THF (150 mL). The filtrate was concentrated under reducedpressure, and then water (50 mL) was added. The aqueous layer wasextracted with CHCl₃ (5×100 mL). The organic layer was dried (MgSO₄) andfiltered. The filtrate was concentrated under reduced pressure and crude5,5-Dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-2-yl)methanol wasobtained as a yellow solid (3.19 μg).

[0604] To 3.19 g of the crude(5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl) methanol in 222mL of CHCl₃ was added activated MnO₂ (18.5 g) under a nitrogenatmosphere at room temperature, and then refluxed for 1 h. The mixturewas filtered through a pad of Celite and the filtrate was concentratedunder reduced pressure. The residue was applied to silica-gel columnchromatography, and then the column was eluted with hexane-AcOEt (3:1).The titled compound was obtained as a brown solid (2.48 g, 68.0% fromthe ester).

[0605]¹H NMR (CDCl₃) δ 1.32 (s, 6H), 2.73 (s, 2H), 3.95 (s, 2H), 6.52(s, 1H), 9.90 (s, 1H).

[0606] Step 7:(5R)(6Z)-6-(5,5-Dimethyl-4H-1,6a-diazapentalen-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicAcid, Sodium Salt

[0607] The dry acetonitrile (16 mL) solution of5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-2-carbaldehyde (2.48g, 15.1 mmol) was added to the dry acetinitrile (90 mL) solution ofMgBr₂ (3.07 g, 16.4 mmol) under a nitrogen atmosphere at roomtemperature, and then the mixture was stirred for 15 min. The dry THF(106 mL) solution of p-nitrobenzyl (5R, 6S)-6-bromopenem-3-carboxylate(5.30 g, 13.8 mmol) was added and the mixture was cooled to −20° C., andthen triethylamine (4.6 mL, 33.0 mmol) was added in one portion. Thereaction vessel was covered with foil to exclude light. The reactionmixture was stirred for 3 h at −20° C. and treated with 4-dimethylaminopyridine (172 mg, 1.4 mmol) and acetic anhydride (2.6 mL, 27.6 mmol) inone portion. The reaction mixture was warmed to 0° C. and stirred for 16h at 0° C. Ethyl acetate (420 mL) and 1 mol/L citric acid aqueoussolution (210 mL) was added to the reaction mixture and separated. Theorganic layer was washed with saturated sodium hydrogen carbonate andbrine, dried (MgSO₄) and filtered. The filtrate was concentrated underreduced pressure and crude(5R)-6-[acetoxy-(5,5-dimethyl-4H-1,6a-diazapentalen-2-yl)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid p-nitrobenzyl ester was obtained as brown amorphous.

[0608] Freshly activated Zn dust (32.0 g) was added rapidly with 0.5mol/L phosphate buffer (pH 6.5, 167 mL) to the THF (114 mL) andacetonitrile (53 mL) solution of crude(5R)-6-[acetoxy-(5,5-dimethyl-4H-1,6a-diazapentalen-2-yl)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid p-nitrobenzyl ester. The reaction vessel was covered with foil toexclude light. The reaction mixture was vigorously stirred for 1.5 h atroom temperature. The reaction solution was cooled at 0° C., and thenthe pH was adjusted to 8.0. Ethyl acetate (85 mL) was added to themixture and filtered through a pad of Celite. The pad was washed withwater (120 mL). The aqueous layer was separated and then the organiclayer was extracted with 0.5 mol/L phosphate buffer (pH 6.5, 2×50 mL).The combined aqueous layers were cooled at 0° C., and then the pH wasadjusted to 8.5. The mixture was concentrated to 325 g, and then appliedto Diaion HP-21 resin (240 mL, Mitsubishi Kasei Co. Ltd.) columnchromatography. After adsorbing, the column was eluted with water (480mL) and then acetonitrile aqueous solution (10%; 480 mL, 20%; 720 mL).The combined active fractions were concentrated under high vacuum at 35°C. and lyophilized to give the titled compound as a yellow amorphoussolid (2.00 g, 42.8%, pH 7.16).

[0609] Mp 150° C. (dec); ¹H NMR (D₂O) δ 1.19 (s, 6H), 2.67 (s, 2H), 3.85(s, 2H), 6.15 (s, 1H), 6.45 (s, 1H), 6.96 (s, 1H), 7.03 (s, 1H); IR(KBr) 3422, 1752, 1683, 1598, 1557 cm⁻¹; λ^(max) (H₂O) 296, 198 nm.

Example 27 Preparation of(5R),(6Z)-6-(5,6-Dihydro-4H-cyclopenta[b]furan-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicAcid, Sodium Salt

[0610] Step 1; 5,6-Dihydro-4H-cyclopenta[b]furan-2-carboxylic AcidMethyl Ester

[0611] The titled compound was prepared according to the procedure ofTim Johnson and co-workers (Synlett 2001, 5, 646-648).

[0612] Step 2: (5,6-Dihydro-4H-cyclopenta[b]furan-2-yl)methanol

[0613] 5,6-Dihydro-4H-cyclopenta[b]furan-2-carboxylic acid methyl ester(2.24 g) was added to the THF (59 mL) solution of LiAlH₄ (511 mg) undera nitrogen atmosphere at 0° C. and stirred for 1 h at 0° C. The mixturewas quenched with 10 mL of water and filtered. The filtrate wasconcentrated under reduced pressure and the obtained aqueous solutionwas extracted with CHCl₃. The organic layer was washed with brine anddried over MgSO₄ and filtered. The filtrate was concentrated to affordtitled compound as yellow oil (1.86 g, quant.).

[0614]¹H NMR (CDCl₃) δ 1.66 (t, 1H, J=5.9 Hz), 2.38-2.46 (m, 2H),2.50-2.55 (m, 2H), 2.65-2.70 (m, 2H), 4.54 (d, 2H, J=5.9 Hz), 6.15 (s,1H).

[0615] Step 3: 5,6-Dihydro-4H-cyclopenta[b]furan-2-carbaldehyde

[0616] Activated MnO₂ (9.3 g) was added to the CHCl₃ (135 mL) solutionof (5,6-dihydro-4H-cyclopenta[b]furan-2-yl)methanol (1.86 g) andrefluxed for 1 h under a nitrogen atmosphere. The reaction mixture wasfiltered through a pad of Celite. The filtrate was concentrated underreduced pressure. The residue was applied to silica gel columnchromatography, then the column was eluted with n-hexane-AcOEt({fraction (9/1)}-{fraction (7/1)}). The titled compound was obtained asyellow crystals (1.51 g, 77%).

[0617]¹H NMR (CDCl₃) δ 2.47-2.57 (m, 2H), 2.63 (t, 2H, J=6.8 Hz), 2.78(t, 2H, J=7.3 Hz), 7.06 (s, 1H), 9.44 (s, 1H).

[0618] Step 4: (5R,6RS)-6-[(RS)-Acetoxy(5,6-dihydro-4H-cyclopenta[b]furan-2-yl)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid 4-nitrobenzyl ester

[0619] The acetonitrile solution (50 mL) of5,6-dihydro-4H-cyclopenta[b]furan-2-carbaldehyde (1.33 g) was added tothe dry acetonitrile (101 mL) solution of anhydrous MgBr₂ (cont. 98%)(5.52 g) under a nitrogen atmosphere at room temperature. The dry THFsolution (151 mL) of (5R,6S)-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid4-nitrobenzyl ester (cont. 96.5%) (3.91 g) was added to the mixture,cooled to −20° C., and Et₃N (cont. 99%) (8.28 mL) was added in oneportion. The reaction vessel was covered with foil to exclude light. Thereaction mixture was stirred for 2 h at −20° C. and treated with aceticanhydride (cont. 97%) (4.13 mL) and DMAP (cont. 99%) (121 mg) in oneportion. The reaction mixture was warmed to 0° C. and stirred for 16 hat 0° C. The mixture was diluted with ethyl acetate and washed with 5%aqueous solution of citric acid, saturated sodium hydrogen carbonate andbrine. The organic layer was dried (MgSO₄) then filtered. The filtratewas concentrated under reduced pressure. The residue was purified with asilica-gel column chromatography (n-hexane:AcOEt=4:1-3:1) to give thetitled compound as a brown amorphous solid (3.34 g, 61%).

[0620]¹H NMR (CDCl₃) δ 2.21 (s, 3H), 2.40-2.48 (m, 2H), 2.53 (t, 2H,J=7.0 Hz), 2.69 (t, 2H, J=7.0 Hz), 5.28 (d, 1H, J=13.5 Hz), 5.43 (d, 1H,J=13.5 Hz), 6.00 (s, 1H), 6.37 (s, 1H), 6.71 (s, 1H), 7.41 (s, 1H), 7.60(d, 2H, J=8.1 Hz), 8.24 (d, 2H, J=8.1 Hz).

[0621] Step 5:(5R),(6Z)-6-(5,6-Dihydro-4H-cyclopenta[b]furan-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicAcid, Sodium Salt

[0622] (5R,6RS)-6-[(RS)-Acetoxy(5,6-dihydro-4H-cyclopenta[b]furan-2-yl)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid 4-nitrobenzyl ester (3.28 g) was dissolved in THF (46 mL) andacetonitrile (21 mL). Freshly activated Zn dust (13.12 g) was addedrapidly with 0.5 M phosphate buffer (pH 6.5, 67 mL). The reaction vesselwas covered with foil to exclude light. The reaction mixture wasvigorously stirred for 1.25 h at room temperature. The reaction mixturewas filtered through a pad of Celite. The filtrate was washed with ethylacetate and the aqueous layer was separated. The aqueous layer wascooled to 3° C. and 1 M NaOH was added to adjust pH to 8.0. The mixturewas concentrated under high vacuum at 35° C. The concentrate was appliedto Diaion HP-21 (181 mL, Mitsubishi Kasei Co. Ltd.) resin columnchromatography. After adsorbing, the column was eluted with H₂O-MeCN({fraction (1/0)}-{fraction (85/15)}). The combined fractions wereconcentrated under high vacuum at 35° C. and lyophilized to give thetitled crude product (288 mg). This was purified by Diaion HP-21 (100mL, Mitsubishi Kasei Co. Ltd.) resin column chromatography. Afteradsorbing, the column was eluted with H₂O-MeCN ({fraction(1/0)}-{fraction (85/15)}). The combined fractions were concentratedunder high vacuum at 35° C. and lyophilized to give the titled compoundas a yellow amorphous solid (185 mg, 10%, pH 7.2).

[0623] Mp 170° C. (dec); ¹H NMR (D₂O) δ 2.24-2.30 (m, 2H), 2.37 (t, 2H,J=6.5 Hz), 2.52-2.57 (t, 2H, J=7.1 Hz), 6.32 (s, 1H), 6.55 (s, 1H), 6.73(s, 1H), 6.86 (s, 1H).

Example 28 Preparation of(5R)(6Z)-6-(4,5-Dihydro-6-thia-1,7a-diazainden-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicAcid, Sodium Salt

[0624] Step 1: DL-Tetrahydro-1,3-thiazine-4-carboxylic AcidHydrochloride

[0625] DL-Tetrahydro-1,3-thiazine-4-carboxylic acid hydrochloride wasprepared according to the method of Lewis (J. Med. Chem., 21, 1070(1978)).

[0626] Step 2: 4,5-Dihydro-3aH,7H-2-oxa-3-oxo-6-thia-1-aza-7a-azonioinden

[0627] To a suspension of DL-tetrahydro-1,3-thiazine-4-carboxylic acidhydrochloride (48.6 g, 0.26 mol) in 666 mL of AcOH was added to thesolution of 27.4 g (0.40 mol) of NaNO₂ in 333 mL of water over 16 min atroom temperature and stirred for 3 h. The solution was concentratedunder reduced pressure. Acetone (300 mL) was added to the residue andthe precipitate was filtered off. The filtrate was concentrated underreduced pressure to dryness and crude3-nitroso[1,3]thiazinane-4-carboxylic acid was obtained as brownamorphous solid.

[0628] To a solution of crude 3-nitroso[1,3]thiazinane-4-carboxylic acidin 530 mL of dry THF was added trifluoroacetic anhydride (168.4 g, 0.80mol) over 60 min under a nitrogen atmosphere at 0° C. and stirred for 5h at 0° C. The solution was concentrated under reduced pressure. Theresidue was applied to silicagel column chromatography, and then thecolumn was eluted with n-hexane-AcOEt (1:2). The titled compound wasobtained as brown powder (28.0 g, 67.0%).

[0629]¹H NMR (CDCl₃) δ 3.00 (t, 2H, J=5.7 Hz), 3.07 (t, 2H, J=5.7 Hz),5.16 (s, 2H).

[0630] Step 3: 4,5-Dihydro-6-thia-1,7a-diazaindene-2-carboxylic AcidEthylester

[0631] A solution of4,5-dihydro-3aH,7H-2-oxa-3-oxo-6-thia-1-aza-7a-azonioinden (28.0 g, 0.18mol) and ethyl propiolate (27.0 mL, 0.27 mol) in o-xylene (590 mL) wasrefluxed under a nitrogen atmosphere for 16 h. The solution was cooledto room temperature and concentrated under reduced pressure. The residuewas applied to silicagel column chromatography, and then the column waseluted with n-hexane-AcOEt (3:1). The titled compound was obtained aspale brown needles (22.1 g, 58.7%), and4,5-dihydro-6-thia-1,7a-diazaindene-3-carboxylic acid ethylester wasobtained as pale brown crystals (12.7 g, 33.9%).

[0632] 4,5-Dihydro-6-thia-1,7a-diazaindene-2-carboxylic acid ethylester¹H NMR (CDCl₃) δ 1.39 (t, 3H, J=7.1 Hz), 2.98 (t, 2H, J=6.1 Hz), 3.21(t, 2H, J=6.1 Hz), 4.40 (q, 2H, J=7.1 Hz), 5.17 (s, 2H), 6.60 (s, 1H).

[0633] 4,5-dihydro-6-thia-1,7a-diazaindene-3-carboxylic acid ethylester:¹H NMR (CDCl₃) δ 1.34 (t, 3H, J=7.1 Hz), 2.99 (t, 2H, J=6.1 Hz), 3.45(t, 2H, J=6.1 Hz), 4.28 (q, 2H, J=7.1 Hz), 5.11 (s, 2H), 7.85 (s, 1H).

[0634] Step 4: 4,5-Dihydro-6-thia-1,7a-diazaindene-2-carbaldehyde

[0635] To a 22.1 gram (0.10 mol) of4,5-dihydro-6-thia-1,7a-diazaindene-2-carboxylic acid ethylester in 520mL of dry THF was added LiAlH₄ (3.95 g, 0.10 mol) under a nitrogenatmosphere at 0° C., and then stirred for 45 min. The mixture wasquenched with water (20 mL) and the precipitate was filtered through apad of Celite and the pad was washed with water (100 mL) and THF (250mL). The filtrate was concentrated under reduced pressure, and thenwater (300 mL) was added. The aqueous layer was extracted with CH₂Cl₂(6×500 mL). The organic layer was dried (MgSO₄) and filtered. Thefiltrate was concentrated under reduced pressure and crude was obtainedas pale yellow crystals (17.2 g).

[0636] To a 17.2 gram of the crude(4,5-dihydro-6-thia-1,7a-diazainden-2-yl) methanol in 520 mL of CHCl₃was added activated MnO₂ (88.0 g) under a nitrogen atmosphere at roomtemperature, and then refluxed for 2 h. The mixture was filtered througha pad of Celite and the filtrate was concentrated under reducedpressure. The residue was applied to silicagel column chromatography,and then the column was eluted with hexane-AcOEt (2:1). The titledcompound was obtained as yellow crystals (13.0 g, 74.5%)

[0637]¹H NMR (CDCl₃) δ 3.00 (t, 2H, J=6.0 Hz), 3.23 (t, 2H, J=6.0 Hz),5.18 (s, 2H), 6.58 (s, 1H), 9.92 (s, 1H).

[0638] Step 5:(5R)(6Z)-6-(4,5-Dihydro-6-thia-1,7a-diazainden-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicAcid, Sodium Salt

[0639] The dry acetonitrile (11 mL) solution of4,5-dihydro-6-thia-1,7a-diazaindene-2-carbaldehyde (1.70 g, 10.1 mmol)was added to the dry acetinitrile (60 mL) solution of MgBr₂ (2.03 g,11.0 mmol) under a nitrogen atmosphere at room temperature, and then themixture was stirred for 10 min. The dry THF (71 mL) solution ofp-nitrobenzyl (5R, 6S)-6-bromopenem-3-carboxylate (3.55 g, 9.2 mmol) wasadded and the mixture was cooled to −20° C., and then triethylamine (3.1mL, 22.2 mmol) was added in one portion. The reaction vessel was coveredwith foil to exclude light. The reaction mixture was stirred for 3 h at−20° C. and treated with 4-dimethylamino pyridine (0.11 g, 0.9 mmol) andacetic anhydride (1.8 mL, 18.6 mmol) in one portion. The reactionmixture was warmed to 0° C. and stirred for 15 h at 0° C. Ethyl acetate(280 mL) and 1 mol/L citric acid aqueous solution (140 mL) was added tothe reaction mixture and separated. The organic layer was washed withsaturated sodium hydrogen carbonate and brine, dried (MgSO₄) andfiltered. The filtrate was concentrated under reduced pressure and crude(5R)-6-[acetoxy-(4,5-dihydro-6-thia-1,7a-diazainden-2-yl)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid p-nitrobenzyl ester was obtained as brown amorphous solid.

[0640] Freshly activated Zn dust (21.4 g) was added rapidly with 0.5mol/L phosphate buffer (pH 6.5, 112 mL) to the THF (76 mL) andacetonitrile (36 mL) solution of crude(5R)-6-[acetoxy-(4,5-dihydro-6-thia-1,7a-diazainden-2-yl)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid p-nitrobenzyl ester. The reaction vessel was covered with foil toexclude light. The reaction mixture was vigorously stirred for 1.5 h atroom temperature. The reaction solution was cooled at 0° C., and thenthe pH was adjusted to 8.0. Ethyl acetate (56 mL) was added to themixture and filtered through a pad of Celite. The pad was washed withwater (150 mL). The aqueous layer was separated and then the organiclayer was extracted with 0.5 mol/L phosphate buffer (pH 6.5, 2×30 mL).The combined aqueous layers were cooled at 0° C., and then the pH wasadjusted to 8.0. The mixture was concentrated to 236 g, and then appliedto Diaion HP-21 resin (480 mL, Mitsubishi Kasei Co. Ltd.) columnchromatography. After adsorbing, the column was eluted with water (960mL) and then acetonitrile aqueous solution (5%; 960 mL, 10%; 960 mL,20%; 960 mL). The combined active fractions were concentrated under highvacuum at 35° C. and lyophilized to give the titled compound as a yellowamorphous solid (1.28 g, 40.5%, pH 7.45).

[0641] Mp 200° C. (dec); ¹H NMR (D₂O) δ 2.95 (t, 2H, J=6.1 Hz), 3.12 (t,2H, J=6.1 Hz), 5.08 (s, 2H), 6.23 (s, 1H), 6.46 (s, 1H), 6.97 (s, 1H),7.01 (s, 1H); IR (KBr) 3382, 1752, 1684, 1597, 1554 cm 1; λ^(max) (H₂O)366, 292, 197 nm.

Example 29 Preparation of(5R),(6Z)-6-(6,6-Dimethyl-5,6,7,8-tetrahydroimidazo[1.2-a]pyrizin-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicAcid, Sodium Salt

[0642] Step 1: Preparation of 5,5-Dimethyl-2-piperidone

[0643] 5-5-Dimethyl-2-piperadinone (1) was prepared in the method ofNagasawa (J. Med. Chem., 23, 1176 (1977)).

[0644] Step 2: Preparation of3,3-Dimethyl-6-methoxy-2,3,4,5-tetrahydropyridine

[0645] Trimethyloxonium tetrafluoroborate (97%, 11.9 g, 78 mmol) wasadded to the dry dichloromethane (156 mL) solution of5,5-dimethyl-2-piperidone (9.93 g, 78 mmol) at room temperature andstirred for 14 h. The reaction mixture was neutralized with 10% sodiumhydrogen carbonate aqueous solution, and the organic layer wasseparated. The aqueous layer was extracted with ethyl acetate (3×120mL), then the combined organic layer was washed with 10% sodium hydrogencarbonate aqueous solution and brine. The organic layer was dried(MgSO₄) and filtered. The filtrate was concentrated under reducedpressure and the titled compound was obtained as pale yellow oil (9.0 g,82.0%).

[0646]¹H NMR (CDCl₃) δ 0.92 (s, 6H), 1.49 (t, 2H, J=7.0 Hz), 2.18 (t,2H, J=7.0 Hz), 3.19 (s, 2H), 3.63 (s, 3H).

[0647] Step 3: 5,5-Dimethylpiperidine-2-ylideneamine Monohydrochloride

[0648] The mixture of 3,3-dimethyl-6-methoxy-2,3,4,5-tetrahydropyridine(9.0 g, 64 mmol) and ammonium chloride (3.4 g, 64 mmol) in dry ethanol(160 mL) was heated to reflux for 2 h. The reaction mixture was thenconcentrated under reduced pressure and the titled compound was obtainedas a white solid (9.9 g, 94.6%).

[0649]¹H NMR (DMSO-d⁶) δ 0.95 (s, 6H), 1.52 (t, 2H, J=6.9 Hz), 2.55 (t,2H, J=6.9 Hz), 2.99 (d, 2H, J=2.1 Hz).

[0650] Step 4:6,6-Dimethyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carbaldehyde &6,6-Dimethyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-3-carbaldehyde

[0651] The mixture of 2-bromo-3-hydroxypropenal (10.1 g, 67 mmol),p-toluenesulfonic acid monohydrate (0.13 g, 0.6 mmol) and 2-propanol(12.6 mL, 165 mmol) in cyclohexane (100 mL) was azeotroped until thevaper temperature over 80° C. The reaction mixture was concentratedunder reduced pressure. The residue was dissolved in dry EtOH (200 mL).The dry EtOH (350 mL) solution of 5,5-dimethylpiperidine-2-ylideneaminemonohydrochloride (9.9 g, 61 mmol) and the dry EtOH (50 mL) solution ofNaOMe (28%, 11.7 g, 61 mmol) were added at room temperature. Thereaction mixture was stirred at room temperature for 2 h, and then thereaction solution was removed in vacuo. The residue was dissolved inCHCl₃ (300 mL) and triethylamine (8.5 mL, 61 mmol) was added, and thenthe reaction mixture was heated to reflux for 2 h. The reaction mixturewas cooled to room temperature, and then the reaction solution wasremoved in vacuo. The residue was dissolved in CH₂H₁₂ (600 mL) andwashed with 50% K₂CO₃ aqueous solution (2×200 mL). The combined aqueoussolution was extracted with CH₂Cl₂ (2×200 mL). The combined organiclayer was dried (MgSO₄) and filtered. The filtrate was concentratedunder reduced pressure. The residue was applied to silica gel columnchromatography, eluted with CHCl₃-methanol (50:1), and the titledcompound6,6-Dimethyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carbaldehyde(brown solid, 4.4 g, 40.7%) and6,6-Dimethyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-3-carbaldehyde(orange solid, 1.7 g, 15.8%) were obtained.

[0652]6,6-Dimethyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carbaldehyde: ¹HNMR (CDCl₃) δ 1.10 (s, 6H), 1.78 (t, 2H, J=6.9 Hz), 2.95 (t, 2H, J=6.9Hz), 3.71 (s, 2H), 7.46 (s, 1H), 9.83 (s, 1H).

[0653]6,6-Dimethyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-3-carbaldehyde: ¹HNMR (CDCl₃) δ 1.09 (s, 6H), 1.74 (t, 2H, J=6.8 Hz), 2.97 (t, 2H, J=6.8Hz), 4.05 (s, 2H), 7.74 (s, 1H), 9.64 (s, 1H).

[0654] Step 5:(5R),(6Z)-6-(6,6-Dimethyl-5,6,7,8-tetrahydroimidazor[,2-a]pyrizin-2-ylmethylene)-7-oxo4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt

[0655] The dry acetonitrile (28 mL) solution of6,6-dimethyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carbaldehyde(4.55 g, 26 mmol) was added to the dry acetinitrile (152 mL) solution ofMgBr₂ (5.22 g, 28 mmol) under a nitrogen atmosphere at room temperature,and then the mixture was stirred for 10 min. The dry THF (180 mL)solution of p-nitrobenzyl (5R, 6S)-6-bromopenem-3-carboxylate (8.94 g,23 mmol) was added and the mixture was cooled to −20° C., and thentriethylamine (7.8 mL, 56 mmol) was added in one portion. The reactionvessel was covered with foil to exclude light. The reaction mixture wasstirred for 3 h at −20° C. and treated with 4-dimethylamino pyridine(0.29 g, 2.4 mmol) and acetic anhydride (4.4 mL, 47 mmol) in oneportion. The reaction mixture was warmed to 0° C. and stirred for 16 hat 0° C. Ethyl acetate (715 mL) was added to the reaction mixture, andthen the organic layer was washed with 1 mol/L Citric acid aqueoussolution, saturated sodium hydrogen carbonate and brine. The organiclayer was dried (MgSO₄) and filtered. The filtrate was concentratedunder reduced pressure and crude(5R)-6-[acetoxy-(6,6-dimethyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid p-nitrobenzyl ester was obtained as brown amorphous solid.

[0656] Freshly activated Zn dust (53.6 g) was added rapidly with 0.5mol/L phosphate buffer (pH 6.5, 282 mL) to the THF (192 mL) andacetonitrile (90 mL) solution of(5R)-6-[acetoxy-(6,6-dimethyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid p-nitrobenzyl ester. The reaction vessel was covered with foil toexclude light. The reaction mixture was vigorously stirred for 1.5 h atroom temperature. The reaction mixture was cooled at 0° C., and then thepH was adjusted to 7.6. Ethyl acetate (140 mL) was added to the reactionmixture, and then the mixture was filtered through a pad of Celite andthe pad was washed with water (200 mL). The aqueous layer was separatedand then the organic layer was extracted with 0.5 mol/L phosphate buffer(pH 6.5, 2×50 mL). The pH of the combined aqueous layer was adjusted to8.1 and the mixture was concentrated to 584 g. 1 mol/L NaOH was added toadjust pH to 8.2 and applied to Diaion HP-21 resin (420 mL, MitsubishiKasei Co. Ltd.) column chromatography. After adsorbing, the column waseluted with 2.5% (2 bed volume), 5% (2 bed volume), 10% (1 bed volume)and 20% acetonitrile aqueous solution. The combined active fractionswere concentrated under high vacuum at 35° C. and lyophilized to givethe crude(5R),(6Z)-6-(6,6-Dimethyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrizin-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt as a yellow amorphous solid (1.19 g).

[0657] The crude(5R),(6Z)-6-(6,6-Dimethyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrizin-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt was purified by the preparative HPLC (Mightysil RP-18GP (5 □m), Kanto Chemical Co. Inc., 35×250 mm, 0.05 mol/L phosphatebuffer (pH 7.2): CH₃CN=70:30, 20 mL/min.). The purified product wasdesalted by Diaion HP-21 resin (50 mL) column chromatography and thetitle compound was obtained 230 mg (2.8%) as a yellow amorphous solid.

[0658] Mp 210° C. (dec); ¹H NMR (D₂O) δ; 0.91 (s, 3H), 0.93 (s, 3H),1.63 (t, 2H, J=6.8 Hz), 2.72 (t, 2H, J=6.8 Hz), 3.60 (s, 2H), 6.44 (s,1H), 6.90 (s, 1H), 6.91 (s, 1H), 7.19 (s, 1H).

Example 30 Preparation of (5R),(6Z)-6-(5,6-Dihydro-8-H-imidazo[2,1-c]1,4]thiazin-3-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicAcid

[0659] The dry acetonitrile (40 mL) solution of5,6-dihydro-8H-imidazo[2,1-c][1,4]thiazine-3-carbardehyde (813 mg) wasadded to the dry acetinitrile (40 mL) solution of MgBr₂ (2.2 g) under anitrogen atmosphere at room temperature then the mixture was stirred for10 min. The dry THF (80 mL) solution of p-nitrobenzyl (5R,6S)-6-bromopenem-3-carboxylate (2.1 g) was added, the mixture was cooledto −20° C. then triethylamine (1.7 mL) was added in one portion. Thereaction vessel was covered with foil to exclude light. The reactionmixture was stirred for 3.5 h at −20° C. and treated with4,4-dimethylamino pyridine (64 mg) and acetic anhydride (0.9 mL) in oneportion. The reaction mixture was warmed to 0° C. and stirred for 14 hat 0° C. 10% Citric acid aqueous solution (500 mL) was added to thereaction mixture and the aqueous layer was extracted with ethyl acetate(3×200 mL). The organic layer was washed with water, saturated sodiumhydrogen carbonate and brine, dried (MgSO₄) and filtered. The filtratewas concentrated under reduced pressure. The residue was applied tosilica gel column chromatography and eluted with CH₂Cl₂-acetone (20:1)to obtain crude(5R)-6-[acetoxy-(5,6-dihydro-8H-imidazo[2,1-c][1,4]thiazin-3-yl)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid p-nitrobenzyl ester as a brown solid.

[0660] The solid obtained above chromatography was dissolved in THF (11mL). Freshly activated Zn dust (1.4 g) was added rapidly with 0.5 mol/Lphosphate buffer (pH 6.5, 11 mL). The reaction vessel was covered withfoil to exclude light. The reaction mixture was vigorously stirred for 2h at room temperature. The reaction solution was filterd through a padof Celite and the pad was washed with water (26 mL) and n-butanol (26mL). The aqueous layer was separated and then the organic layer wasextracted with 0.5 mol/L phosphate buffer (pH 6.5, 2×5 mL). The combinedaqueous layer was concentrated to 18 g, 1 mol/L NaOH was added to adjustpH to 7.3 and applied to Diaion HP-21 resin (20 mL, Mitsubishi Kasei Co.Ltd.) column chromatography. After adsorbing, the column was eluted withwater and then 5% acetonitrile aqueous solution. The combined activefractions was concentrated under high vacuum at 35° C. and lyophilizedto give the title compound as a yellow amorphous solid (81 mg).

[0661] Mp 145° C. (dec); ¹H NMR (D₂O) δ 3.05-3.08 (m, 1H), 3.83 (s, 1H),4.13-4.16 (m, 1H), 6.37 (s, 1H), 6.91 (s, 1H), 7.01 (s, 1H), 7.04 (s,1H); IR (KBr) 3371, 1770, 1672, 1613 cm⁻¹; max (H₂O) 314 nm.

Example 31 Preparation of(5R)(6Z)-7-Oxo-6-(4H-5-thia-1,6a-diazapentalen-2-ylmethylene)-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicAcid. Sodium Salt

[0662] Step 1: Preparation of 3-Oxo-3a, 4-dihydro-3H,6H-2-oxa-5-thia-1-aza-6a-azonio-3a-pentalenide

[0663] Conc. HCl (15 mL) and NaNO₂ (16.6 g) were added to the H₂O (166mL) solution of L-thioproline (24.3 g) under a nitrogen atmosphere at 0°C. and stirred for 2 h. The solution was extracted with CH₂Cl₂, organiclayer was dried over MgSO₄ and concentrated under reduced pressure toafford the crude N-nitroso compound as a yellow solid.

[0664] Trifluoroacetic anhydride (5.0 mL) was added to the THF (350 mL)solution of crude N-nitroso thioproline under a nitrogen atmosphere at0° C. and stirred for 5 h at 0° C. The solution was concentrated underreduced pressure. The residue was applied to silica gel columnchromatography, then the column was eluted with n-hexane -AcOEt (1:1).The titled compound was obtained as a pale brown solid (4.0 g, 15.1%).

[0665]¹H NMR (CDCl₃) δ:4.04 (t, 2H, J=1.7 Hz), 5.40 (t, 2H, J=1.7 Hz).

[0666] Step 2: Preparation of 4H-5-Thia-16a-diazapentalen-2-carboxylicAcid Ethylester

[0667] Ethyl propiolate (3.1 mL) was added to the o-xylene (130 mL)solution of 3-oxo-3a, 4-dihydro-3H,6H-2-oxa-5-thia-1-aza-6a-azonio-3a-pentalenide (4.0 g) under a nitrogenatmosphere and refluxed for 19 h. The solution was cooled to roomtemperature and concentrated under reduced pressure. The residue wasapplied to silica gel column chromatography, then the column was elutedwith n-hexane -AcOEt (4:1). The titled compound was obtained as a yellowsolid (2.7 g, 49.3%), and 4H-5-thia-1,6a-diazapentalen-3-carboxylic acidethylester was obtained as pale yellow crystals (1.2 g, 21.7%).

[0668]¹H NMR (CDCl₃) δ 1.40 (t, 3H, J=7.1 Hz), 4.11 (d, 2H, J=2.1 Hz),4.40 (q, 2H, J=7.1 Hz), 5.24 (t, 2H, J=1.6 Hz), 6.61 (s, 1H).

[0669] Step 3: Preparation of(4H-5-Thia-1,6a-diazapentalen-2-yl)methanol

[0670] LiBH₄ (cont. 90%) (459 mg) was added to the ether (126 mL)solution of 4H-5-thia-1,6a-diazapentalen-2-carboxylic acid ethylester(2.5 g) and MeOH (0.77 mL) under a nitrogen atmosphere at roomtemperature, then refluxed for 1.5 h. The mixture was quenched with 1mol/L HCl (25 mL) and stirred for 1 h at room temperature. The mixturewas neutralized by saturated sodium hydrogen carbonate solution andseparated. The aqueous layer was extracted with dichloromethane (10×25mL). The organic layer was dried (MgSO₄) and filtered. The filtrate wasconcentrated under reduced pressure. The residue was applied to silicagel column chromatography, then the column was eluted with AcOEt. Thetitled compound was obtained as a pale yellow solid (1.7 g, 87.9%).

[0671]¹H NMR (CDCl₃):δ 2.95 (t, 1H, J=5.6 Hz), 4.07 (s, 2H), 4.62 (d,2H, J=5.1 Hz), 5.13 (t, 1H, J=1.6 Hz), 6.04 (s, 1H).

[0672] Step 4: Preparation of4H-5-Thia-1,6a-diazapentalen-2-carbaldehyde

[0673] The dry dichloromethane (8 mL) solution of dimethylsulfoxide (2.2mL) was added dropwise to the dry dichloromethane (110 mL) solution ofoxalyl chloride (2.0 mL) at −78° C. The reaction mixture was stirred for15 min at the same temperature. The dry dichloromethane (40 mL) solutionof (4H-5-thia-1,6a-diazapentalen-2-yl)methanol (1.7 g) was addeddropwise to the reaction mixture at −78° C., and stirring was continuedfor an additional 15 min. The reaction mixture was allowed to warm to−45° C. and stirred for 1 h. Triethylamine (11.3 mL) was added dropwiseand the reaction mixture was allowed to warm to 0° C. After 20 min,saturated ammonium chloride solution (50 mL) and water (100 mL) wereadded and separated. The aqueous layer was extracted with AcOEt (3×150mL). The combined organic layers were washed with water (200 mL) andbrine (200 mL), dried (MgSO₄) and filtered. The filtrate wasconcentrated under reduced pressure. The residue was applied to silicagel column chromatography, then the column was eluted with hexane-AcOEt(1:1). The titled compound was obtained as a yellow solid (1.7 g,quant.).

[0674]¹H NMR (CDCl₃) δ 4.13 (s, 2H), 5.26 (d, 2H, J=1.4 Hz), 6.59 (s,1H), 9.90 (s, 1H).

[0675] Step 5: Preparation of(5R)(6Z)-7-Oxo-6-(4H-5-thia-1,6a-diazapentalen-2-ylmethylene)-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicAcid, Sodium Salt

[0676] The dry acetonitrile (92 mL) solution of4H-5-thia-1,6a-diazapentalen-2-carbaldehyde (1.7 g) was added to the dryacetinitrile (92 mL) solution of MgBr₂ (5.0 g) under a nitrogenatmosphere at room temperature then the mixture was stirred for 10 min.The dry THF (184 mL) solution of p-nitrobenzyl (5R,6S)-6-bromopenem-3-carboxylate (4.3 g) was added and the mixture wascooled to −20° C. then triethylamine (7.4 mL) was added in one portion.The reaction vessel was covered with foil to exclude light. The reactionmixture was stirred for 3 h at −20° C. and treated with 4-dimethylaminopyridine (138 mg) and acetic anhydride (2.1 mL) in one portion. Thereaction mixture was warmed to 0° C. and stirred for 15 h at 0° C. The 1mol/L Citric acid aqueous solution (1000 mL) was added to the reactionmixture and the aqueous layer was extracted with ethyl acetate (3×400mL). The combined organic layers were washed with water, saturatedsodium hydrogen carbonate and brine, dried (MgSO₄) and filtered. Thefiltrate was concentrated under reduced pressure and crude(5R)-6-[acetoxy-(4H-5-thia-1,6a-diazapentalen-2-yl)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid p-nitrobenzyl ester was obtained asa brown amorphous.

[0677] Freshly activated Zn dust (19.3 g) was added rapidly with 0.5mol/L phosphate buffer (pH 6.5, 100 mL) to the THF (100 mL) solution ofcrude(5R)-6-[acetoxy-(4H-5-thia-1,6a-diazapentalen-2-yl)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid p-nitrobenzyl ester. The reactionvessel was covered with foil to exclude light. The reaction mixture wasvigorously stirred for 2.5 h at room temperature. The reaction solutionwas filtered through a pad of Celite and the pad was washed with water(200 mL) and n-butanol (200 mL). The aqueous layer was separated andthen the organic layer was extracted with 0.5 mol/L phosphate buffer (pH6.5, 2×50 mL). The combined aqueous layers were concentrated to 90 g, 1mol/L NaOH was added to adjust pH to 8.0 and applied to Diaion HP-21resin (180 mL, Mitsubishi Kasei Co. Ltd.) column chromatography. Afteradsorbing, the column was eluted with water and then 15% acetonitrileaqueous solution. The combined active fractions were concentrated underhigh vacuum at 35° C. and lyophilized to give the title compound as ayellow amorphous solid (634 mg, 17.4%, pH 7.25).

[0678] Mp 150° C. (dec); ¹H NMR (D₂O) 64.00 (s, 2H), 5.09 (s, 2H), 6.14(s, 1H), 6.36 (s, 1H), 6.91 (s, 1H), 6.92 (s, 1H); IR (KBr) 3381, 1752,1683, 1600, 1558 cm⁻¹; λ^(max) (H₂O) 292, 196 nm.

Example 32 Preparation of(5R)(6Z)-6-(2,3-Dihydropyrazolo[5,1-b]thiazol-6-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt

[0679] Step 1: Preparation of 3-Oxo-3a, 4-dihydro-3H,6H-2-oxa-4-thia-1-aza-6a-azonio-3a-pentalenide

[0680] To a suspension of thiazolidine-2-carboxylic acid (39.9 g, 0.30mol) in 1,000 ml of acetic acid was added a solution of 31.0 g (0.45mol) of sodium nitrite in 500 ml of water over 13 minutes at roomtemperature and stirred for 5 hours. The reaction solution wasconcentrated under reduced pressure. Acetone (500 ml) was added to theresidue and the precipitate was filtered through a pad of Celite. Thepad was washed with acetone (500 ml). The filtrate was concentratedunder reduced pressure to dryness and crude3-nitrosothiazolidin-2-carboxylic acid was obtained as a yellow solid.

[0681] To a solution of crude 3-nitrosothiazolidin-2-carboxylic acid in600 ml of dry tetrahydrofuran was added trifluoroacetic anhydride (189.6g, 0.90 mol) over 20 minutes under a nitrogen atmosphere at 0° C. andstirred for 19 hours at 0° C. The solution was concentrated underreduced pressure. The residue was applied to a silica-gel columnchromatography, and then the column was eluted with n-hexane-ethylacetate (1:1). The titled compound was obtained as a pale brown crystal(19.2 g, 44.5%).

[0682]¹H NMR (CDCl₃) δ 3.98 (t, 2H, J=7.7 Hz), 4.65 (t, 2H, J=7.7 Hz).

[0683] Step 2: Preparation of2,3-Dihydropyrazolo[5,1-b]thiazol-6-carboxylic acid ethyl ester and2,3-dihydropyrazolo[5,1-b]thiazol-7-carboxylic Acid Ethyl Ester

[0684] Ethyl propiolate (20.3 ml, 0.20 mol) was added to an o-xylene(600 ml) solution of 3-oxo-3a, 4-dihydro-3H,6H-2-oxa-4-thia-1-aza-6a-azonio-3a-pentalenide (19.2 g, 0.13 mol) undera nitrogen atmosphere and refluxed for 21 hours. The solution was cooledto room temperature and concentrated under reduced pressure. The residuewas applied to a silica gel column chromatography, and then the columnwas eluted with n-hexane-ethyl acetate (2:21 to 1:1). The mixture of2,3-Dihydropyrazolo[5,1-b]thiazol-6-carboxylic acid ethyl ester and2,3-dihydropyrazolo[5,1-b]thiazol-7-carboxylic acid ethyl ester wasobtained as a brown oil in the ratio of 1:1.5 respectively. (21.2 g,Yield: 80.0%).

[0685] 2,3-Dihydropyrazolo[5,1-b]thiazol-6-carboxylic acid ethyl ester;¹H NMR (CDCl₃) δ1.39 (t, 3H, J=7.1 Hz), 3.82 (t, 2H, J=7.5 Hz), 4.39 (q,2H, J=7.1 Hz), 4.42 (t, 2H, J=7.5 Hz), 6.52 (s, 1H).

[0686] 2,3-dihydropyrazolo[5,1-b]thiazol-7-carboxylic acid ethyl ester;¹H NMR (CDCl₃) δ1.34 (t, 3H, J=7.1 Hz), 3.85 (t, 2H, J=7.8 Hz), 4.28 (q,2H, J=7.1 Hz), 4.39 (t, 2H, J=7.8 Hz), 7.87 (s, 1H).

[0687] Step 3: 2,3-Dihydropyrazolo[5,1-b]thiazol-6-carbaldehyde and2,3-dihydro-pyrazolo[5,1-b]thiazol-7-carbaldehyde

[0688] To the mixture [21.2 g (0.11 mol)] of2,3-dihydropyrazolo[5,1-b]thiazol-6-carboxylic acid ethyl ester and2,3-dihydropyrazolo[5,1-b]thiazol-7-carboxylic acid ethyl ester in 540ml of dry tetrahydrofuran was added LiAlH₄ (4.05 g, 0.11 mol) under anitrogen atmosphere at 0° C., and then stirred for 2.5 hours at roomtemperature. The mixture was quenched with water (15 ml) and theprecipitate was filtered through a pad of Celite. The pad was washedwith water (100 ml) and tetrahydrofuran (500 ml). The filtrate wasconcentrated under reduced pressure, and then water (150 ml) was added.The aqueous layer was extracted with dichloromethane (15×250 ml). Thecombined organic layers were dried (MgSO₄) and filtered. The filtratewas concentrated under reduced pressure and a mixture of(2,3-dihydropyrazolo[5,1-b]thiazol-6-yl) methanol and(2,3-dihydropyrazolo[5,1-b]thiazol-7-yl) methanol was obtained as palebrown oil (15.5 g).

[0689] To the mixture [15.5 g (0.10 mol)] of(2,3-dihydropyrazolo[5,1-b]thiazol-6-yl) methanol and(2,3-dihydropyrazolo[5,1-b]thiazol-7-yl) methanol in 500 ml ofchloroform was added activated MnO₂ (77.7 g) under a nitrogen atmosphereat room temperature, and then refluxed for 3 hours. The mixture wasfiltered through a pad of Celite and the filtrate was concentrated underreduced pressure. The residue was applied to a silica gel columnchromatography, and then the column was eluted with hexane-ethyl acetate(2:1 to 1:1). The titled compound2,3-Dihydropyrazolo[5,1-b]thiazol-6-carbaldehyde was obtained as ayellow crystal (2.50 g, 15.2%) and2,3-dihydro-pyrazolo[5,1-b]thiazol-7-carbaldehyde was obtained as a palebrown solid (5.57 g, 33.8)2,3-Dihydropyrazolo[5,1-b]thiazol-6-carbaldehyde; ¹H NMR (CDCl₃) δ 3.86(t, 2H, J=7.5 Hz), 4.45 (t, 2H, J=7.5 Hz), 6.50 (s, 1H), 9.83 (s, 1H).2,3-dihydro-pyrazolo[5,1-b]thiazol-7-carbaldehyde; ¹H NMR (CDCl₃) δ 3.92(t, 2H, J=7.9 Hz), 4.40 (t, 2H, J=7.9 Hz), 7.91 (s, 1H), 9.76 (s, 1H).

[0690] Step 4: Preparation of(5R)(6Z)-6-(2,3-Dihydropyrazolo[5,1-b]thiazol-6-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicAcid, Sodium Salt

[0691] A dry acetonitrile (19 ml) solution of2,3-dihydropyrazolo[5,1-b]thiazol-6-carbaldehyde (2.50 g, 16.2 mmol) wasadded to a dry acetinitrile (106 ml) solution of MgBr₂ (3.67 g, 19.9mmol) under a nitrogen atmosphere at room temperature then the mixturewas stirred for 10 minutes. A dry tetrahydrofuran (125 ml) solution ofp-nitrobenzyl (5R, 6S)-6-bromopenem-3-carboxylate (6.23 g, 16.2 mmol)was added and the mixture was cooled to −20° C. then triethylamine (5.4ml, 38.7 mmol) was added in one portion. The reaction vessel was coveredwith foil to exclude light. The reaction mixture was stirred for 3 hoursat −20° C. and treated with 4-dimethylamino pyridine (198 mg, 1.62 mmol)and acetic anhydride (3.1 ml, 32.9 mmol) in one portion. The reactionmixture was warmed to 0° C. and stirred for 16 hours at 0° C. Ethylacetate (500 ml) was added to the reaction mixture and then the organiclayer was washed with 1 mol/l citric acid aqueous solution, saturatedsodium hydrogen carbonate and brine. The organic layer was dried (MgSO₄)and filtered. The filtrate was concentrated under reduced pressure andthe crude (5R)-6-[acetoxy-(2,3-dihydropyrazolo[5,1-b]thiazol-6-yl)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid p-nitrobenzyl ester was obtained as a brown amorphous solid.

[0692] Freshly activated Zn dust (37.4 g) was added rapidly with 0.5mol/l phosphate buffer (pH 6.5, 196 ml) to tetrahydrofuran (134 ml) andacetonitrile (62 ml) solution of (5R)-6-[acetoxy-(2,3-dihydropyrazolo[5,1-b]thiazol-6-yl)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid p-nitrobenzyl ester. The reaction vessel was covered with foil toexclude light. The reaction mixture was vigorously stirred for 1.5 hoursat room temperature. The reaction mixture was cooled at 0° C., and thenthe pH was adjusted to 8.0. Ethyl acetate (100 ml) was added to thereaction mixture. The mixture was filtered through a pad of Celite andthe pad was washed with water (300 ml). The aqueous layer was separatedand then the organic layer was extracted with 0.5 mol/l phosphate buffer(pH 6.5, 2×50 ml). The pH of the combined aqueous layer was adjusted to8.0 and the mixture was concentrated to 426 g. The concentrate wasadjust pH to 8.0 and applied to Diaion HP-21 resin (540 ml, MitsubishiKasei Co. Ltd.) column chromatography. After adsorbing, the column waseluted with water (1 bed volume) and then 5% (2 bed volume), 10% (2 bedvolume) and 20% acetonitrile aqueous solution. The combined activefractions were concentrated under high vacuum at 35° C. and lyophilizedto give the title compound as a orange amorphous solid (2.09 g, 39.2%,pH 7.10).

[0693] Mp 150° C. (dec); ¹H NMR (D₂O) δ 3.75 (t, 2H, J=7.5 Hz), 4.27 (t,2H, J=7.5 Hz), 6.00 (s, 1H), 6.34 (s, 1H), 6.85 (s, 1H), 6.94 (s, 1H);IR (KBr) 3392, 1755, 1596, 1554 cm⁻¹; λ^(max)(H₂O) 290, 223 nm.

Example 33 Preparation of(5R)(6Z)-6-(2,3-Dihydropyrazolo[5,1-b]oxazol-6-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicAcid, Sodium Salt

[0694] Step 1: Preparation of ethyl2,3-dihydropyrazolo[5,1-b][1,3]oxazole-6-carboxylate:

[0695] To the stirred suspension of ethyl5-hydroxy-1H-pyrazole-3-carboxylate (10.34 g, 0.66 mol) and 36.62 g ofpotassium carbonate in 500 ml of acetonitrile was added 13.68 g of1,2-dibromoethane, and refluxed for 16 hours. The reaction mixture wasallowed to cool to room temperature, then filtered, the solid was washedwith acetonitrile. The filtrate was concentrated to an oil. The residuewas dissolved in ethyl acetate and extracted with water. The organicphase was dried over MgSO₄ and evaporated to dryness. 5.80 g of thedesired product was obtained (48%).

[0696] Step 2: Preparation of2,3-dihydropyrazolo[5,1-b][1,3]oxazole-6-methanol:

[0697] To the stirred solution ofethyl2,3-dihydropyrazolo[5,1-b][1,3]oxazole-6-carboxylate (5.47 g, 35mmol) of in 100 ml of THF was added 1.05 g of lithium borohydride and1.54 g of methanol. The solution was heated at 40° C. for 2.5 hour. Thereaction was quenched by 1 N HCl, and adjusted to pH 1.3 and stirred atroom temperature for 1 hour. The reaction mixture was adjusted pH to 8with k₂CO₃. The reaction mixture was extracted with ethyl acetate. Theorganic layer was dried over MgSO₄, and concentrated to an oil andcolumn chromatographyed to give 2.68 g of the desired product (65%).

[0698] Step 3: Preparation of 2,3-dihydropyrazolo[5,1-b][1,3]oxazole-6-carbaldehyde:

[0699] To the stirred solution of2,3-dihydropyrazolo[5,1-b][1,3]oxazole-6-methanol (2.60 g, 18.5 mmol) in60 ml of CH₃Cl was added 12.9 g of MnO₂. Th suspension was refluxed for1.5 hour under a nitrogen atmosphere. The reaction mixture was filteredthrough a pad of Celite. The filtrate was concentrated to give yellowoil. The product was purified by chromatography. 2.15 g of the productwas obtained (84.3%).

[0700] Step 4: 4-Nitrobenzy(5R)-6-[(acetyloxy)(2,3-dihydropyrazolo[5,1-b][1,3]oxazol-0.6-yl)-)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate:

[0701] 2,3-dihydropyrazolo[5,1-b][1,3]oxazole-6-carbaldehyde (607 mg,4.3 mmol) and the dry THF solution (20 mL) of (5R,6S)-6-bromo-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid 4-nitro-benzyl ester (1.54 g, 4.6 mmol) were added successively tothe dry acetonitrile (15 mL) solution of anhydrous MgBr₂: O(Et)₂ (2.21g, 8.5 mmol)under an argon atmosphere at room temperature. After coolingto −20° C., Et₃N (2.0 mL) was added in one portion. The reaction vesselwas covered with foil to exclude light. The reaction mixture was stirredfor 2 h at −20° C. and treated with acetic anhydride (1.04 mL) in oneportion. The reaction mixture was warmed to 0° C. and stirred for 15 hat 0° C. The mixture was diluted with ethyl acetate and washed with 5%citric acid aqueous solution, saturated sodium hydrogen carbonate, andbrine. The organic layer was dried (MgSO₄) and filtered through a pad ofCelite. The pad was washed with ethyl acetate. The filtrate wasconcentrated under reduced pressure. The residue was applied to silicagel column chromatography, then the column was eluted with ethylacetate:hexane (1:1). Collected fractions were concentrated underreduced pressure and the mixture of diastereo isomers were taken to nextstep. Pale yellow amorphous solid; Yield: 1.9 g, 81%; M+H 566.

[0702] H-NMR(CDCl₃) 8.24(2H, d, J=6.6 Hz), 7.60(2H, d, J=6.6 Hz),7.44(1H, s), 6.34(1H, s), 6.23(1H, s), 5.56(1H, s), 5.44(1H, d, J=10.2Hz), 5.27(1H, d J=10.2 Hz), 5.04(2H, m), 4.30(2H, m), 2.10(3H, s).

[0703] Anal.Calcd. for C₂₁H₁₇BrN₄O₈S: C, 44.61, H, 3.03, N, 9.91

[0704] Found: C, 45.00, H, 3.14, N, 9.53

[0705] Step-5:(5R,6Z)-6-(2,3-dihydropyrazolo[5,1-b][1,3]oxazol-6-ylmethylene}-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicAcid Sodium Salt:

[0706]4-Nitrobenzy-6-[(acetyloxy)(2,3-dihydropyrazolo[5,1-b][1,3]oxazol-6-yl)-)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate(700 mg, 1.2 mmol) was dissolved in THF (20 mL), acetonitrile (10 mL)and 0.5 M phosphate buffer (pH 6.5, 28 mL) and hydrogenated over 10%Pd/C at 40 psi pressure. After 4 hrs the reaction mixture was filtered,cooled to 3° C., and 0.1 M NaOH was added to adjust pH to 8.5. Thefiltrate was washed with ethyl acetate and the aqueous layer wasseparated. The aqueous layer was concentrated under high vacuum at 35°C. to give yellow precipitate. The product was purified by HP21 resinreverse phase column chromatography. Initially the column was elutedwith deionized water (2 lits) and latter with 10% acetonitrile: Water.The fractions containing the product were collected and concentrated atreduced pressure at room temperature. The yellow solid was washed withacetone and filtered. Dried. Yield: 276 mg, 73%; as yellow amorphoussolid; (M+H+Na)314.

[0707]¹H-NMR(D₂O); δ 6.97(1H, s), 6.95(1H, s), 6.46(1H, s), 5.56(1H, s)5.07(2H, d, J=6.3 Hz), 4.30(2H, t, J=6.3 Hz).

Example 34 Preparation of(5R,6Z)-6-[(5-acetyl-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)methylene-9-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicAcid (E+Z Isomers Mixture,Sodium Salt)

[0708] Step 1:5-acetyl-4,5,6,7-tetrahydrothieno[3,2-c]pyridine-2-carbaldehyde:

[0709] To a cold (0° C.) suspension of 1.5 g.(7.4 mmol) of4,5,6,7-tetrahydrothieno[3,2-c]pyridine-2-carbaldehyde hydrochloride in50 mL methylene chloride, under N₂ atm., dry conditions, was addeddropwise under stirring 2.6 mL (2.5 eqs) of triethylamine. RM stirredfor 30 min at 0°C. and a solution of 0.7 g.(8.1 mmol,1.1 eqs) of acetylchloride in 15 mL methylene chloride was dropwise added, RM allowed toreach RT and stirred for 3 hours. Filtered trough a celite pad, filtratewashed with 3×50 mL water, dried, evaporated, gave 1.1 g.(71.4%) of thetitle compound, viscous oil, (M+H)⁺210.3.

[0710] Step 2: Preparation of4-nitrobenzyl(5R)-6-[(acetyloxy)(5-acetyl-4,5,6,7-tetrahydrotieno[3,2-c]pyridin-2-yl)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0.]hept-2-ene-2-carboxylate

[0711] 5-acetyl-4,5,6,7-tetrahydrothieno[3,2-c]pyridine-2-carbaldehyde(540 mg, 2.57 mmol) and the dry THF solution (20 mL) of (5R,6S)-6-bromo-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid 4-nitro-benzyl ester (950 mg, 2.5 mmol) were added successively tothe dry acetonitrile (15 mL) solution of anhydrous MgBr₂: O(Et)₂ (2.21g, 8.5 mmol)under an argon atmosphere at room temperature. After coolingto −20° C., Et₃N (2.0 mL) was added in one portion. The reaction vesselwas covered with foil to exclude light. The reaction mixture was stirredfor 2 h at −20° C. and treated with acetic anhydride (1.04 mL) in oneportion. The reaction mixture was warmed to 0° C. and stirred for 15 hat 0° C. The mixture was diluted with ethyl acetate and washed with 5%citric acid aqueous solution, saturated sodium hydrogen carbonate, andbrine. The organic layer was dried (MgSO₄) and filtered through a pad ofCelite. The pad was washed with ethyl acetate. The filtrate wasconcentrated under reduced pressure. The residue was applied to silicagel column chromatography, then the column was eluted with ethylacetate:hexane (1:1). Collected fractions were concentrated underreduced pressure and the mixture of diastereo isomers were taken to nextstep. Pale yellow amorphous solid; Yield: 870 mg, 53%; m.p. 46-48° C.;(M+H)+637.6.

[0712] 1 HNMR(CDCl₃): δ 2.15(t,6H); 2.8-3.0(m, 2H);3.7-3.9(m,2H);4.58-4.68(m, 2H);5.30-5.45(dd, 2H);5.85(d, 1H);6.71 (s, 1H);6.95(s,1H);7.35-7.45(d, 1H); 7.60(dd, 2H); 8.25(dd, 2H).

[0713] Step 3:(5R,6Z)-6-[(5-acetyl-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)methylene]-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid (E+Z Isomers Mixture,Sodium Salt)

[0714] A solution of 0.77 g.(1.21 mmol,4-nitrobenzyl(5R)-6-[(acetyloxy)(5-acetyl-4,5,6,7-tetrahydrotieno[3,2-c]pyridin-2-yl)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0.]hept-2-ene-2-carboxylatein 40 mL THF and 40 mL phosphate buffer solution (pH=6.36) washydrogenated at 40 psi for 3 hours in the presence of 0.4 g. Palladiumon Carbon 10% catalyst. Reaction mixture was filtrated through celitepad, filtrate adjusted to pH=8.0, concentrated in vacuo, residuepurified on a reverse-phase column (amberlite), using 5%.10% ACN/watermixture as solvent, gave 0.107 g.(23%) of the title compound, reddishcrystals, m.p.362.4° C., (M+H)⁺409.5.

[0715] 1H NMR:δ 2.08 (s, 3H);2.80-2.95 (m, 1H);3.74(m, 2H);3.98-4.06(d,2H)6.32-6.42 (s, 1H); 6.50-6.60(s, 1H);6.98-7.20 (s, 1H);7.30-7.40 (s,1H).

Example 35 Preparation of(5R,6Z)-6-(6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid

[0716] Step 1: 4-Nitrosomorpholine-3-carboxylic Acid

[0717] To a solution of morpholine-3-carboxylic acid (6.96 g, 52 mmol)in water (20 ml), at 0° C. under nitrogen, was added concentratedhydrochloric acid (4 ml), followed by sodium nitrite (5.0 g, 72 mmol) insmall portions. The mixture was stirred at 0° C. for 1 hr, and thenconcentrated under vacuum at 30 to 35° C. The residue was stirred with200 ml of acetone and filtered. The filtrate was evaporated and theresidue treated with 50 ml of THF and concentrated. The process wasrepeated with 2×50 ml of THF to give 11.87 g of light yellow foam; MS(ESI) m/z 159.2 (M−H).

[0718] Step 2:6,7-Dihydro-4H-[1,2,3]oxadiazolo[4,3-c][1,4]oxazin-8-ium-3-olate

[0719] The crude 4-nitrosomorpholine-3-carboxylic acid (11.0 g) fromstep 1 was dissolved in THF (250 ml) and cooled to 0° C. A solution oftrifluoroacetic anhydride (7.4 ml, 52 mmol) in THF (20 ml) was addedwith stirring over 10 min. The resulting mixture was stirred at 0° C.for 5 hr, and warmed to room temperature for 16 hr. The solvent wasevaporated and the residue was diluted with 250 ml of ethyl acetate andstirred with 30 g of anhydrous potassium carbonate. The mixture wasfiltered through a pad of silica gel and the filtrate evaporated. Theresidue was washed with a mixture of ethyl acetate-ether to give 3.80 gof a white solid; mp 132-133° C.; MS (ESI) m/z 143.1 (M+H).

[0720] Step 3: Ethyl6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazine-2-carboxylate

[0721] To a partial solution of6,7-dihydro-4H-[1,2,3]oxadiazolo[4,3-c][1,4]oxazin-8-ium-3-olate (3.41g, 24 mmol) in o-xylene (80 ml), was added ethyl propiolate (2.7 ml, 26mmol). The mixture was stirred at 140° C. for 3 hr. An additional 2.0 ml(19 mmol) of ethyl propiolate was then added and the mixture was stirredat reflux for 18 hr. The final solution was evaporated under vacuum, andthe residue was dissolved in a mixture of methylene chloride and hexanes(1:5). The solution was passed through a pad of silica gel and thefilter pad was eluted with methylene chloride-hexanes, followed by ethylacetate. The ethyl acetate eluent was evaporated and the residue washedwith hexanes to give 4.10 g of a white solid; mp 63° C.; MS (ESI) m/z197.1 (M+H).

[0722] Step 4: 6,7-Dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-2-ylmethanol

[0723] To a solution of ethyl6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazine-2-carboxylate (1.57 g, 8.0mmol) in methylene chloride (30 ml) was added 24 ml of a 1.0 M solutionof diisobutylaluminum hydride in methylene chloride at 0° C., undernitrogen. After stirring for 0.5 hr at 0° C., the mixture was warmed toroom temperature for 2 hr. It was then treated with 30 ml of saturatedammonium chloride solution and extracted with ethyl acetate. The organicsolution was washed with brine, dried over anhydrous sodium sulfate,filtered and evaporated to give 1.27 g of a colorless oil; MS (ESI) m/z155.3 (M+H).

[0724] Step 5: 6,7-Dihydro-4H-pyrazolo[5,1-c][1,4]oxazine-2-carbaldehyde

[0725] To a solution of6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-2-ylmethanol (1.08 g, 7.0mmol) in 1,2-dichloroethane (30 ml) was added 5.4 g of activatedmanganese dioxide at room temperature with stirring. The mixture washeated to 60° C. for 1 hr and then stirred at room temperature for 16hr. The final mixture was filtered through a column of silica gel toppedwith celite. The filter pad was eluted with methylene chloride, followedby ethyl acetate. The ethyl acetate eluent was evaporated and theresidue triturated with to give 0.81 g of a white solid; mp 91° C.; MS(ESI) m/z 153.2 (M+H).

[0726] Step 6: 4-Nitrobenzyl(5R)-6-[(acetyloxy)(6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-2-yl)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate

[0727] To a solution of MgBr₂ (0.94 g, 5.1 mmol) in acetonitrile (25 ml)under nitrogen was added6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazine-2-carbaldehyde (0.26 g, 1.7mmol) at room temperature with stirring. A solution of(5R,6S)-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid 4-nitrobenzyl ester (0.58 g, 1.5 mmol) in THF (25 ml) was thenadded, and the mixture was cooled to −20° C. Triethylamine (0.71 ml, 5.1mmol) was introduced, and the mixture was stirred at −20° C. in the darkfor 5 hr. It was then treated with acetic anhydride (0.6 ml, 6.0 mmol),and 4-N,N-dimethylaminopyridine (24 mg, 0.2 mmol), and kept at 0° C. for18 hr. The mixture was concentrated and the residue was dissolved inethyl acetate. The ethyl acetate solution was washed with 5% citricacid, saturated sodium bicarbonate solution, and brine, dried overanhydrous sodium sulfate, and evaporated. The crude material waschromatographed with silica gel (EtOAc-CH₂Cl₂/1:5) to give 0.77 g of awhite foam; MS (ESI) m/z 578.9 (M+H).

[0728] Step 7:(5R,6Z)-6-(6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicAcid

[0729] To a solution of 4-nitrobenzyl(5R)-6-[(acetyloxy)(6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-2-yl)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate(0.35 g, 0.6 mmol) in THF (20 ml), under nitrogen, was added 20 ml of aphosphate buffer solution (0.5M, pH 6.5), and 120 mg of 10% Pd/C. Themixture was hydrogenated at 40-50 psi for 3 hr, and then filteredthrough Celite. The filter pad was washed with THF, and the filtrate wasextracted with ethyl acetate. The organic extract was dried overanhydrous magnesium sulfate and evaporated. The residue was washed withether to give; 0.09 g of a yellow solid; HRMS: calcd for C₁₃HN₁₃O₄S,305.0470; found (ESI+), 306.05434; ¹H NMR (DMSO-d₆) δ 4.07-4.09 (t, 2H),4.13-4.17 (t, 2H), 4.82 (s, 2H), 6.36 (s, 1H), 6.55 (s, 1H), 7.17 (s,1H), 7.55 (s, 1H), 12.80 (bs, 1H).

Example 36 Preparation of(5R)(6Z)-6-(6,7-5H-Dihydropyrazolo[5,1-b]oxazin-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicAcid, Sodium Salt

[0730] Step 1: Preparation of ethyl6,7-dihydro-5H-pyrazolo[5,1][1,3]oxazine-2-carboxylate:

[0731] To the stirred suspension of ethyl5-hydroxy-1H-pyrazole-3-carboxylate (10.34 g, 0.66 mol) and 36.62 g ofpotassium carbonate in 500 ml of acetonitrile was added 14.7 g of1,3-dibromopropane, and refluxed for 16 hours. The reaction mixture wasallowed to cool to room temperature, then filtered, the solid was washedwith acetonitrile. The filtrate was concentrated to an oil. The residuewas dissolved in ethyl acetate and extracted with water. The organicphase was dried over MgSO₄ and evaporated to dryness. 8.80 g of thedesired product was obtained (68%), m.p. 44-46° C. (M+H)+197.1.

[0732] Step 2: Preparation of2,3-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-2-yl-methanol:

[0733] To the stirred solution of6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxylate: (4.0 g, 20mmol) of in 100 ml of THF was added 0.71 g of lithium borohydride and1.03 g of methanol. The solution was heated at 40° C. for 2.5 hour. Thereaction was quenched by 1 N HCl, and adjusted to pH 1.3 and stirred atroom temperature for 1 hour. The reaction mixture was adjusted pH to 8with k₂CO₃. The reaction mixture was extracted with ethyl acetate. Theorganic layer was dried over MgSO₄, and concentrated to an oil andcolumn chromatographyed to give 2.08 g of the desired product (67%);(M+H) 155.

[0734] Step 3: Preparation of6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carbaldehyde:

[0735] To the stirred solution of2,3-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-2-yl-methano (2.08 g, 13.5mmol) in 60 ml of CH₃CI was added 9.38 g of MnO₂. Th suspension wasrefluxed for 2 hour under a nitrogen atmosphere. The reaction mixturewas filtered through a pad of Celite. The filtrate was concentrated togive yellow oil. The product was purified by chromatography. 2.15 g ofthe product was obtained (78%).

[0736] Step 4:4-Nitrobenzy(5R)-6-[(acetyloxy)(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-2-yl)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate:

[0737] 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carbaldehyde (330mg, 2 mmol) and the dry THF solution (20 mL) of (5R,6S)-6-bromo-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid 4-nitro-benzyl ester (0.794 g, 2.2 mmol) were added successively tothe dry acetonitrile (15 mL) solution of anhydrous MgBr₂: O(Et)₂ (1.2g)under an argon atmosphere at room temperature. After cooling to −20°C., Et₃N (2.0 mL) was added in one portion. The reaction vessel wascovered with foil to exclude light. The reaction mixture was stirred for2 h at −20° C. and treated with acetic anhydride (1.04 mL) in oneportion. The reaction mixture was warmed to 0° C. and stirred for 15 hat 0° C. The mixture was diluted with ethyl acetate and washed with 5%citric acid aqueous solution, saturated sodium hydrogen carbonate, andbrine. The organic layer was dried (MgSO₄) and filtered through a pad ofCelite. The pad was washed with ethyl acetate. The filtrate wasconcentrated under reduced pressure. The residue was applied to silicagel column chromatography, then the column was eluted with ethylacetate:hexane (1:1). Collected fractions were concentrated underreduced pressure and the mixture of diastereo isomers were taken to nextstep. Pale yellow amorphous solid; Yield: 0.76 g, 65%; M+H 579.

[0738] Step-5:(5R)(6Z)-6-(6,7-5H—Dihydropyrazolo[5,1-b]oxazin-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicAcid, Sodium Salt

[0739]4-Nitrobenzy(5R)-6-[(acetyloxy)(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-2-yl)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate(350 mg, 0.6 mmol) was dissolved in THF (20 mL), acetonitrile (10 mL)and 0.5 M phosphate buffer (pH 6.5, 28 mL) and hydrogenated over 10%Pd/C at 40 psi pressure. After 4 hrs the reaction mixture was filtered,cooled to 3° C., and 0.1 M NaOH was added to adjust pH to 8.5. Thefiltrate was washed with ethyl acetate and the aqueous layer wasseparated. The aqueous layer was concentrated under high vacuum at: 35°C. to give yellow precipitate. The product was purified by HP21 resinreverse phase column chromatography. Initially the column was elutedwith deionized water (2 lits) and latter with 10% acetonitrile: Water.The fractions containing the product were collected and concentrated atreduced pressure at room temperature. The yellow solid was washed withacetone and filtered. Dried. Yield: 103 mg, 52%; as yellow amorphoussolid; (M+H+Na)327.

[0740]¹H-NMR(D₂O); δ 6.97(1H, s), 6.93(1H, s), 6.47(1H, s), 5.65(1H, s)4.28(2H, m), 4.10(2H, m), 2.21 (2H, m).

Example 37 Preparation of(5R),(6Z)-6-[5-(3-carboxypropionyl)-4,5,6,7-tetrahydropyrazolo[15-a]pyrazin-2-ylmethylene]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-carboxylicAcid,Disodium Salt

[0741] The above mentioned compound was prepared by the proceduresoutlined in all the above examples. Starting from(5R),(6Z)-6-{5-[3-(4-itrobenzyloxycarbonyl)propionyl]-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylmethylene}-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid sodium salt (467 mg) and hydrogenating it over Pd/C (10%), 276 mgof (74%) of(5R),(6Z)-6-[5-(3-carboxypropionyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylmethylene]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-carboxylicacid,disodium salt was isolated as yellow amorphous solid. Mp. 180° C.(Dec); ¹H NMR (D₂O) □ 2.41 (t, 2H), 2.42 (t, 2H), 2.67 (t, 2H), 2.72 (t,2H), 3.95-4.09 (m, 2H), 4.18 (t, 2H), 4.28 (t, 2H), 4.75 (s, 2H), 4.87(s, 2H), 6.33 (s, 1H), 6.34 (s, 1H), 6.53 (s, 1H), 7.00 (s, 1H), 7.09(s, 1H).

Example 38 Preparation of(5R),(6Z)-6-[5-(2-methoxyacetyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylmethylene1-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-carboxylicAcid,Sodium Salt

[0742] (5R),(6Z)-7-Oxo-6-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylmethylene)-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt (Example 25)

[0743] To the THF (64 mL) and H₂O (64 mL) solution of(5R),(6Z)-7-Oxo-6-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylmethylene)-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt (Example 25) (638 mg) was added 0.1 M NaOH aq slowlyto adjust pH to 12.5 at 0° C. To the mixture was added methoxyacetyl-chloride (0.28 mL) over 5 min. The mixture was stirred for 0.5 h at 0°C. and methoxyacetylchloride (0.09 mL) was added to the mixture. Afterstirring the mixture for 0.5 h at the same temperature, 0.1 M NaOH aqwas added to adjust pH to 8.05. The mixture was concentrated under highvacuum at 35° C. The concentrate was applied to Diaion HP-21 (78 mL,Mitsubishi Kasei Co. Ltd.) resin column chromatography. After adsorbing,the column was eluted with H₂O-MeCN (1:0 to 9:1). The combined fractionswere concentrated under high vacuum at 35° C. and lyophilized to givethe title compound as a yellow amorphous solid (509 mg, 65%, pH 7.58).

[0744] Mp 170° C. (dec); ¹H NMR (D₂O) □3.28 (s, 3H×½), 3.29 (s, 3H×½),3.78 (t, 2H×½, J=5.4 Hz), 3.89-3.93 (m, 2H×½), 4.09 (t, 2H×½, J=5.4 Hz),4.14 (t, 2H×½, J=5.4 Hz), 4.20 (s, 2H×½), 4.25 (s, 2H×1/2), 4.61 (s,2H×½), 4.66 (s, 2H×½), 6.19 (s, 1H×½), 6.22 (s, 1H×½), 6.37 (s, 1H×½),6.372 (s, 1H×½), 6.87 (s, 1H), 6.93 (s, 1H)

Example 39 Preparation of(5R),(6Z)-6-[5-(2-methoxyacetyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylmethylene]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-carboxylicAcid,Sodium Salt

[0745] (4,5,6,7-Tetrahydropyrazolo[1,5-a]pyrazin-2-yl)-methanol

[0746] Methanol (150 ml) was added to the mixture of2-hydroxymethyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylic acid4-nitrobenzyl ester (Example 25) (2.38 g) and 10% Pd-C (50% wet, 1.19g). The reaction mixture was stirred for 2 hours under a hydrogenatmosphere. The mixture was filtered and concentrated under reducedpressure. The residue was applied to silica-gel column chromatography,then the column was eluted with 50% methanol in chloroform. The titledcompound was obtained as a white solid (1.08 g, 98%).

[0747]¹H NMR (400 MHz, CD₃OD)□3.22-3.25 (m, 2H), 3.99 (s, 2H), 4.03-4.06(m, 2H), 4.52 (s, 2H), 6.06 (s, 1H).[5-(4,5-Dihydrothiazol-2-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl]-methanol

[0748] Hydrogen chloride (2 mol/l) solution in diethyl ether (0.7 ml)was added to the methanol (20 ml) solution of(4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl)-methanol (1.08 g) and2-methylsulfanyl-4,5-dihydrothiazole (1.03 g). The reaction mixture wasrefluxed for 4 days. The mixture was quenched with small amount ofsaturated potassium carbonate solution, dried (MgSO₄) and filtered. Thefiltrate was concentrated under reduced pressure. The residue wasapplied to silica-gel column chromatography, then the column was elutedwith 10% methanol in chloroform. The titled compound was obtained as awhite solid (1.49 g, 89%).

[0749]¹H NMR (400 MHz, CDCl₃) □ 2.04 (brs, 1H), 3.39 (t, 2H, J=7.5 Hz),3.90 (t, 2H, J=5.3 Hz), 4.06 (t, 2H, J=7.5 Hz), 4.21 (t, 2H, J=5.3 Hz),4.66 (s, 2H), 4.69 (s, 2H), 6.07 (s, 1H).

[0750] (5R),(6Z)-6-[5-(4,5-Dihydrothiazol-2-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylmethylene]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicAcid Sodium Salt

[0751] The activated manganese (IV) oxide (16.75 g) was added to themixture of chloroform (180 ml) solution of[5-(4,5-dihydrothiazol-2-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl]-methanol(3.35 g) at room temperature. The reaction mixture was refluxed for 1hour. After refluxing, the mixture was filtered through a pad of Celiteand the filtrate was concentrated under reduced pressure. The residuewas dried in vacuo and the crude5-(4,5-dihydrothiazol-2-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-carbaldehydewas obtained as a colorless solid. The crude aldehyde thus obtained(2.56g) was added to a dry acetonitrile (200 ml) solution of MgBr₂ (7.36 g)under a nitrogen atmosphere at room temperature then the mixture wasstirred for 10 minutes. A dry THF (200 ml) solution of WLJ 20,014 (4.16g) was added and the mixture was cooled to −20° C. Then triethylamine(11.3 ml) was added in one portion. The reaction vessel was covered withfoil to exclude light. The reaction mixture was stirred for 1.5 hours at−20° C. and treated with 4-dimethylaminopyridine (132 mg) and aceticanhydride (4.2 ml) in one portion. The reaction mixture was warmed to 0°C. and stirred for 20 hours at 0° C. The mixture was diluted with ethylacetate and washed with 5% citric acid aqueous solution, saturatedsodium hydrogen carbonate, and brine. The organic layer was dried(MgSO₄) and filtered. The filtrate was concentrated under reducedpressure. The residue was applied to silica gel column chromatography,then eluted with n-hexane-AcOEt (1:2) and chloroform-methanol (9:1). The(5R,6RS)-6-{(RS)-acetoxy-[5-(4,5-dihydrothiazol-2-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl]-methyl}-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid 4-nitrobenzyl ester was obtained (5.41 g, 75.4%).

[0752] The(5R,6RS)-6-{(RS)-acetoxy-[5-(4,5-dihydrothiazol-2-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl]-methyl}-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid 4-nitrobenzyl ester (5.41 g) was dissolved in THF (76 ml) andacetonitrile (35 ml). Freshly activated Zn dust (21.6 g) and 0.5 mol/lphosphate buffer (pH 6.5, 111 ml) were added to the mixture. Thereaction vessel was covered with foil to exclude light. The reactionmixture was vigorously stirred for 2 hours at 30 to 35° C. The reactionmixture was cooled at 0° C., and then the pH was adjusted to 7.6. Ethylacetate was added to the reaction mixture and filtered through a pad ofCelite. The pad was washed with water and the aqueous layer wasseparated. The aqueous layer was concentrated under high vacuum at 35°C. The concentrate was applied to Diaion HP-21 (170 ml, Mitsubishi KaseiCo. Ltd.) resin column chromatography. After adsorbing, the column waseluted with water and then with 5% to 15% acetonitrile aqueous solution.The combined active fractions was concentrated under high vacuum at 35°C. and lyophilized to give the titled compound as a crude yellowamorphous solid (1.60 g).

[0753] The crude compound was purified by preparative HPLC (MightysilRP-18GP, KANTO CHEMICAL CO., INC., 35×250 mm, 0.05 mol/I phosphatebuffer (pH 7.1): acetonitrile=80:20, 25 ml/min) followed by desaltationon Diaion HP-21 resin (150 ml, Mitsubishi Kasei Co. Ltd.) to give thetitled compound as a yellow amorphous solid (1.06 g, y. 31.5%, pH 8.33).

[0754] Mp 100° C. (dec); ¹H NMR (D₂O) □ 3.18 (t, 2H, J=7.6 Hz), 3.60 (t,2H, J=5.3 Hz), 3.73 (t, 2H, J=7.6 Hz), 3.94 (t, 2H, J=5.3 Hz), 4.37 (s,2H), 6.01 (s, 1H), 6.21 (s, 1H), 6.77 (s, 1H), 6.78 (s, 1H); IR (KBr)3381, 1752, 1606 cm⁻¹; □^(max) (H₂O) 369, 291, 208 nm.

Example 40 Preparation of(5R),(6Z)-6-[5-(2-methoxyacetyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylmethylene]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-carboxylicAcid,Sodium Salt

[0755] Preparation of Ethyl2-[(acetyloxy)((5R)-6-bromo-2-{[(4-nitrobenzyl)oxy]carbonyl}-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-en-6-yl)methyl]-4,7-dihydrofuro[2,3-c]pyridine-6(5H)-carboxylate

[0756] The titled compound was prepared from 0.669 grams of methyl2-formyl-4,7-dihydrofuro[2,3-c]pyridine-6(5H)-carboxylate and 1.155grams of 4-nitrobenzyl(5R)-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylateyielded 1.65 grams of product (84%), which was used directly for thenext step. MS: 652.2(M+H)

[0757] Preparation of(5R,6Z)-6-{[6-(ethoxycarbonyl)-4,5,6,7-tetrahydrofuro[2,3-c]pyridin-2-yl]methylene}-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicAcid

[0758] The title compound was prepared from 1.65 g of ethyl2-[(acetyloxy)((5R)-6-bromo-2-{[(4-nitrobenzyl)oxy]carbonyl}-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-en-6-yl)methyl]-4,7-dihydrofuro[2,3-c]pyridine-6(5H)-carboxylate,yielded 0.386 grams of product (41%). MP: decomposed at 175° C. MS:375.0 (M−H). H-NMR(D20): □ 6.91 (s, 1H), 6.84(s, 1H), 6.62(s, 1H),6.39(s, 1H), 4.41(b, 2H), 4.04 (q, 2H, J=5 Hz), 3.52(b, 2H), 2.42(b,2H), 1.14 (t, 3H, J=5 Hz),

What is claimed is:
 1. A compound of formula I:

wherein: one of A and B is hydrogen and the other is an optionallysubstituted fused bicyclic heteroaryl group; X is O or S; R₅ is H, C1-C6alkyl, C5-C6 cycloalkyl, or CHR₃OCOC1-C6alkyl; and R₃ is hydrogen, C1-C6alkyl, C5-C6 cycloalkyl, optionally substituted aryl, or optionallysubstituted heteroaryl; or a pharmaceutically acceptable salt thereof.2. The compound according to claim 1 wherein the bicyclic heteroarylgroup is

wherein Z1, Z2 and Z3 are independently CR₂, N, O, S or N—R₁, providedone of Z1-Z3 is carbon and is bonded to the remainder of the molecule;W₁, W₂ and W₃ are independently CR₄R₄, S, SO, SO₂, O, or N—R₁; with theproviso that no S—S or O—O or S-Obond formation can occur to form thesaturated ring system; t=1 to 4; R₁ is H, optionally substituted C1-C6alkyl, optionally substituted aryl, optionally substituted heteroaryl ormono or bicyclic saturated heterocycles, optionally substituted C5-C7cycloalkyl, optionally substituted C3-C6 alkenyl, optionally substitutedC3-C6 alkynyl with the proviso that neither the double bond nor thetriple bond should be present at the carbon atom which is directlylinked to N; optionally substituted C1-C6 perfluoroalkyl, —S(O)_(p)optionally substituted alkyl or aryl where p is 0-2, optionallysubstituted —C═Oheteroaryl, optionally substituted —C═Oaryl, optionallysubstituted —C═O(C1-C6) alkyl, optionally substituted—C═O(C5-C6)cycloalkyl, optionally substituted —C═O mono or bicyclicsaturated heterocycles, optionally substituted C1-C6 alkylaryl,optionally substituted C1-C6 alkyl heteroaryl, optionally substitutedaryl-C1-C6 alkyl, optionally substituted heteroaryl-C1-C6 alkyl,optionally substituted C1-C6 alkyl mono or bicyclic saturatedheterocycles, optionally substituted arylalkenyl of 8 to 16 carbonatoms, —CONR₆R₇, —SO₂NR₆R₇, optionally substituted arylalkyloxyalkyl,optionally substituted-alkyl-O-alkyl-aryl, optionallysubstituted-alkyl-O-alkyl-heteroaryl, optionally substitutedaryloxyalkyl, optionally substituted heteroaryloxyalkyl, optionallysubstituted aryloxyaryl, optionally substituted aryloxyheteroaryl,optionally substituted C1-C6alkylaryloxyaryl, optionally substitutedC1-C6 alkylaryloxyheteroaryl, optionally substitutedalkylaryloxyalkylamines, optionally substituted alkoxycarbonyl,optionally substituted aryloxycarbonyl, or optionally substitutedheteroaryloxy carbonyl; R₂ is hydrogen, optionally substituted C1-C6alkyl, optionally substituted C2-C6 alkenyl, optionally substitutedC2-C6 alkynyl, halogen, cyano, N—R₆R₇, optionally substituted C1-C6alkoxy, hydroxy; optionally substituted aryl, optionally substitutedheteroaryl, COOR₆, optionally substituted alkyl aryloxy alkylamines,optionally substituted aryloxy, optionally substituted heteroaryloxy,optionally substituted C3-C6 alkenyloxy, optionally substituted C3-C6alkynyloxy, C1-C6 alkylamino-C1-C6 alkoxy, alkylene dioxy, optionallysubstituted aryloxy-C1-C6 alkyl amine, C1-C₆ perfluoro alkyl,S(O)_(q)-optionally substituted C1-C6 akyl, S(O)_(q)-optionallysubstituted aryl where q is 0, 1 or 2, CONR₆R₇, guanidino or cyclicguanidino, optionally substituted C1-C6 alkylaryl, optionallysubstituted arylalkyl, optionally substituted C1-C6 alkylheteroaryl,optionally substituted heteroaryl-C1-C6 alkyl, optionally substitutedC1-C6 alkyl mono or bicyclic saturated heterocycles, optionallysubstituted arylalkenyl of 8 to 16 carbon atoms, SO₂NR₆R₇, optionallysubstituted arylalkyloxyalkyl, optionally substituted aryloxyalkyl,optionally substituted heteroaryloxyalkyl, optionally substitutedaryloxyaryl, optionally substituted aryloxyheteroaryl, substitutedheteroaryloxyaryl, optionally substituted C1-C6alkyl aryloxyaryl,optionally substituted C1-C6 alkylaryloxyheteroaryl, optionallysubstituted aryloxyalkyl, optionally substituted heteroaryloxyalkyl, oroptionally substituted alkylaryloxyalkylamine; R₄ is H, optionallysubstituted C1-C6 alkyl, one of R₄ is OH, C₁-C₆ alkoxy, —S—C1-C6 alkyl,COOR₆, —NR₆R₇, —CONR₆R₇; or R₄R₄ may together be ═O or R₄R₄ togetherwith the carbon to which they are attached may form a spiro system offive to eight members with or without the presence of heteroatomsselected from N, O, S═(O)nl (where n=0 to 2), and N—R₁; and R₆ and R₇are independently H, optionally substituted C1-C6 alkyl, optionallysubstituted aryl, optionally substituted heteroaryl, optionallysubstituted C1-C6 alkylaryl, optionally substituted arylalkyl,optionally substituted heteroarylalkyl, optionally substituted C1-C6alkylheteroaryl, or R₆ and R₇ can be together to form a 3-7 memberedsaturated ring system optionally having one or two heteroatoms selectedfrom N, O, or S.
 3. The compound according to claim 1 wherein thebicyclic heteroaryl group is

wherein Z1, Z2 and Z3 are independently CR₂, N, O, S or N—R₁ providedone of Z1-Z3 is carbon and is bonded to the remainder of the molecule;W₁, W₂ and W₃ are independently CR₄R₄, S, SO, SO₂, O, or N—R₁; t=1 to 4;Y₁ and Y₂ are independently N or C; with the proviso that if thearomatic ring portion of the bicyclic heteroaryl group is imidazole, thenonaromatic ring portion may not contain a S adjacent to the bridgeheadcarbon; R₁ is H, optionally substituted C1-C6 alkyl, optionallysubstituted aryl, optionally substituted heteroaryl or mono or bicyclicsaturated heterocycles, optionally substituted C5-C7 cycloalkyl,optionally substituted C3-C6 alkenyl, optionally substituted C3-C6alkynyl with the proviso that neither the double bond nor the triplebond should be present at the carbon atom which is directly linked to N;optionally substituted C1-C6 perfluoroalkyl, —S(O)_(p) optionallysubstituted alkyl or aryl where p is 0-2, optionally substituted—C=Oheteroaryl, optionally substituted —C=Oaryl, optionally substituted—C═O(C1-C6) alkyl, optionally substituted —C═O(C5-C6)cycloalkyl,optionally substituted —C═O mono or bicyclic saturated heterocycles,optionally substituted C1-C6 alkylaryl, optionally substituted C1-C6alkyl heteroaryl, optionally substituted aryl-C1-C6 alkyl, optionallysubstituted heteroaryl-C1-C6 alkyl, optionally substituted C1-C6 alkylmono or bicyclic saturated heterocycles, optionally substitutedarylalkenyl of 8 to 16 carbon atoms, —CONR₆R₇, —SO₂NR₆R₇, optionallysubstituted arylalkyloxyalkyl, optionally substituted-alkyl-O-alkyl-aryl, optionally substituted -alkyl-O-alkyl-heteroaryl,optionally substituted aryloxyalkyl, optionally substitutedheteroaryloxyalkyl, optionally substituted aryloxyaryl, optionallysubstituted aryloxyheteroaryl, optionally substitutedC1-C6alkylaryloxyaryl, optionally substituted C1-C6alkylaryloxyheteroaryl, optionally substituted alkylaryloxyalkylamines,optionally substituted alkoxycarbonyl, optionally substitutedaryloxycarbonyl, or optionally substituted heteroaryloxy carbonyl; R2 ishydrogen, optionally substituted C1-C6 alkyl, optionally substitutedC2-C6 alkenyl, optionally substituted C2-C6 alkynyl, halogen, cyano,N—R₆R₇, optionally substituted C1-C6 alkoxy, hydroxy; optionallysubstituted aryl, optionally substituted heteroaryl, COOR₆, optionallysubstituted alkyl aryloxy alkylamines, optionally substituted aryloxy,optionally substituted heteroaryloxy, optionally substituted C3-C6alkenyloxy, optionally substituted C3-C6 alkynyloxy, C1-C6alkylamino-C1-C6 alkoxy, alkylene dioxy, optionally substitutedaryloxy-C1-C6 alkyl amine, C1-C6 perfluoro alkyl, S(O)_(q)-optionallysubstituted C1-C6 akyl, S(O)_(q)-optionally substituted aryl where q is0, 1 or 2, CONR₆R₇, guanidino or cyclic guanidino, optionallysubstituted C1-C6 alkylaryl, optionally substituted arylalkyl,optionally substituted C1-C6 alkylheteroaryl, optionally substitutedheteroaryl-C1-C6 alkyl, optionally substituted C1-C6 alkyl mono orbicyclic saturated heterocycles, optionally substituted arylalkenyl of 8to 16 carbon atoms, SO₂NR₆R₇, optionally substituted arylalkyloxyalkyl,optionally substituted aryloxyalkyl, optionally substitutedheteroaryloxyalkyl, optionally substituted aryloxyaryl, optionallysubstituted aryloxyheteroaryl, substituted heteroaryloxyaryl, optionallysubstituted C₁-C₆alkyl aryloxyaryl, optionally substituted C₁-C₆alkylaryloxyheteroaryl, optionally substituted aryloxyalkyl, optionallysubstituted heteroaryloxyalkyl, or optionally substitutedalkylaryloxyalkylamine; R₄ is H, optionally substituted C1-C6 alkyl, oneof R₄ is OH, C1-C6 alkoxy, —S—C1-C6 alkyl, COOR₆, —NR₆R₇, —CONR₆R₇; orR₄R₄ may together be ═O or R₄R₄ together with the carbon to which theyare attached may form a spiro system of five to eight members with orwithout the presence of heteroatoms selected from N, O, S═(O)nl (wheren=0 to 2), and N—R₁; and R₆ and R₇ are independently H, optionallysubstituted C1-C6 alkyl, optionally substituted aryl, optionallysubstituted heteroaryl, optionally substituted C1-C6 alkylaryl,optionally substituted arylalkyl, optionally substitutedheteroarylalkyl, optionally substituted C1-C6 alkylheteroaryl, or R₆ andR₇ can be together to form a 3-7 membered saturated ring systemoptionally having one or two heteroatoms selected from N, O, or S. 4.The compound according to claim 1 wherein the bicyclic heteroaryl groupis

wherein Z1, Z2, Z3 and Z4 are independently CR₂ or N provided one ofZ1-Z4 is carbon and is bonded to the remainder of the molecule; W₁, W₂and W₃ are independently CR₄R₄, S, SO, SO₂, O, or N—R₁; with the provisothat no S—S or O—O or S—O bond formation can occur to form the saturatedring system; t=1 to 4; Y₁ and Y₂ are independently C or N; R₁ is H,optionally substituted C1-C6 alkyl, optionally substituted aryl,optionally substituted heteroaryl or mono or bicyclic saturatedheterocycles, optionally substituted C5-C7 cycloalkyl, optionallysubstituted C3-C6 alkenyl, optionally substituted C3-C6 alkynyl with theproviso that neither the double bond nor the triple bond should bepresent at the carbon atom which is directly linked to N; optionallysubstituted C1-C6 perfluoroalkyl, —S(O)_(p) optionally substituted alkylor aryl where p is 0-2, optionally substituted —C=Oheteroaryl,optionally substituted —C=Oaryl, optionally substituted —C═O(C1-C6)alkyl, optionally substituted —C═O(C5-C6)cycloalkyl, optionallysubstituted —C═O mono or bicyclic saturated heterocycles, optionallysubstituted C1-C6 alkylaryl, optionally substituted C1-C6 alkylheteroaryl, optionally substituted aryl-C1-C6 alkyl, optionallysubstituted heteroaryl-C1-C6 alkyl, optionally substituted C1-C6 alkylmono or bicyclic saturated heterocycles, optionally substitutedarylalkenyl of 8 to 16 carbon atoms, —CONR₆R₇, —SO₂NR₆R₇, optionallysubstituted arylalkyloxyalkyl, optionally substituted-alkyl-O-alkyl-aryl, optionally substituted -alkyl-O-alkyl-heteroaryl,optionally substituted aryloxyalkyl, optionally substitutedheteroaryloxyalkyl, optionally substituted aryloxyaryl, optionallysubstituted aryloxyheteroaryl, optionally substitutedC1-C6alkylaryloxyaryl, optionally substituted C1-C6alkylaryloxyheteroaryl, optionally substituted alkylaryloxyalkylamines,optionally substituted alkoxycarbonyl, optionally substitutedaryloxycarbonyl, or optionally substituted heteroaryloxy carbonyl; R₂ ishydrogen, optionally substituted C1-C6 alkyl, optionally substitutedC2-C6 alkenyl, optionally substituted C2-C6 alkynyl, halogen, cyano,N—R₆R₇, optionally substituted C1-C6 alkoxy, hydroxy; optionallysubstituted aryl, optionally substituted heteroaryl, COOR₆, optionallysubstituted alkyl aryloxy alkylamines, optionally substituted aryloxy,optionally substituted heteroaryloxy, optionally substituted C3-C6alkenyloxy, optionally substituted C3-C6 alkynyloxy, C1-C6alkylamino-C1-C6 alkoxy, alkylene dioxy, optionally substitutedaryloxy-C1-C6 alkyl amine, C1-C6 perfluoro alkyl, S(O)_(q)-optionallysubstituted C1-C6 akyl, S(O)_(q)-optionally substituted aryl where q is0, 1 or 2, CONR₆R₇, guanidino or cyclic guanidino, optionallysubstituted C1-C6 alkylaryl, optionally substituted arylalkyl,optionally substituted C1-C6 alkylheteroaryl, optionally substitutedheteroaryl-C1-C6 alkyl, optionally substituted C1-C6 alkyl mono orbicyclic saturated heterocycles, optionally substituted arylalkenyl of 8to 16 carbon atoms, SO₂NR₆R₇, optionally substituted arylalkyloxyalkyl,optionally substituted aryloxyalkyl, optionally substitutedheteroaryloxyalkyl, optionally substituted aryloxyaryl, optionallysubstituted aryloxyheteroaryl, substituted heteroaryloxyaryl, optionallysubstituted C1-C6alkyl aryloxyaryl, optionally substituted C1-C6alkylaryloxyheteroaryl, optionally substituted aryloxyalkyl, optionallysubstituted heteroaryloxyalkyl, or optionally substitutedalkylaryloxyalkylamine; R₄ is H, optionally substituted C1-C6 alkyl, oneof R₄ is OH, C1-C6 alkoxy, —S—C1-C6 alkyl, COOR₆, —NR₆R₇, —CONR₆R₇; orR₄R₄ may together be=0 or R₄R₄ together, with the carbon to which theyare attached may form a spiro system of five to eight members with orwithout the presence of heteroatoms selected from N, O, S═(O)_(n) (wheren=0 to 2), and N—R₁; and R₆ and R₇ are independently H, optionallysubstituted C1-C6 alkyl, optionally substituted aryl, optionallysubstituted heteroaryl, optionally substituted C1-C6 alkylaryl,optionally substituted arylalkyl, optionally substitutedheteroarylalkyl, optionally substituted C1-C6 alkylheteroaryl, or R₆ andR₇ can be together to form a 3-7 membered saturated ring systemoptionally having one or two heteroatoms selected from N, O, or S. 5.The compound according to claim 2 wherein one of Z1-Z3 is CR₂.
 6. Thecompound according to claim 2 wherein one of Z2 or Z3 is N, O, or S. 7.The compound according to claim 5 wherein one of Z2 or Z3 is N, O, or S.8. The compound according to claim 2 wherein at least one of W₁, W₂ andW₃ is CR₄R₄.
 9. The compound according to claim 8 wherein W₁, W₂ and W₃are independently CR₄R₄.
 10. The compound according to claim 2 whereint=1-3.
 11. The compound according to claim 3 wherein t=3.
 12. Thecompound according to claim 3 wherein at least two of Z₁, Z₂, Z₃, Y₁,and Y₂ are N.
 13. The compound according to claim 12 wherein three ofZ₁, Z₂, Z₃, Y₁, and Y₂ are N.
 14. The compound according to claim 3wherein two of W₁, W₂, and W₃ are independently CR₄R₄.
 15. The compoundaccording to claim 14 wherein R₄ is H.
 16. The compound according toclaim 3 wherein one of Y₁ and Y₂ is C and the other is N.
 17. Thecompound according to claim 3 wherein two of Z₁, Z₂, and Z₃ areindependently CR₂.
 18. The compound according to claim 4 wherein threeof Z₁-Z₄ are independently CR₂ and the other is C.
 19. The compoundaccording to claim 4 wherein at least one of Z₁-Z₄ is N.
 20. Thecompound according to claim 19 wherein Z₁ is N.
 21. The compoundaccording to claim 19 wherein two of Z₁-Z₄ are N.
 22. The compoundaccording to claim 19 wherein three of Z₁-Z₄ are N.
 23. The compoundaccording to claim 1 selected from the group consisting of a.(5R,6Z)-6-[(5-benzyl-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)methylene]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid; b. (5R),(6Z)-6-(7-Methyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazin-2-ylmethylene)-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt; c. (5R),(6Z)-7-Oxo-6-(5,6,7,8-tetrahydroimidazo[1,2-a]pyrazin-2-ylmethylene)-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt; d.(5R,6Z)-6-{[5-(4-methoxybenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)]methylene}-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt; e. (5R),(6Z)-6-(5,6-dihydro-8H-imidazo[2,1-c][1,4]thiazin-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt; f. (5R),(6Z)-6-(6,7-Dihydro-5H-pyrrolo[1,2-a]imidazol-2-ylmethylene)-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt; g. (5R),(6Z)-6-(5,6-Dihydro-8H-imidazo[2,1-c][1,4]oxazin-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt; h.(5R),(6Z)-6-(5,6-Dihydro-4H-pyrrolo[1,2-b]pyrazol-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt; i.(5R)(6Z)-7-Oxo-6-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-2-ylmethylene)-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt; j. (5R),(6Z)-6-(7-Methyl-6-oxo-5,6,7,8-tetrahydro-imidazo[1,2-a]pyrazin-2-ylmethylene)-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid sodium salt; k.(5R)(6Z)-6-(6,7-Dihydro-4H-pyrazolo[5,1-c][1,4]thiazin-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt; l.(5R)(6Z)-7-Oxo-6-(4H-5-thia-1,6a-diazapentalen-2-ylmethylene)-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt; m.(5R)(6Z)-6-(7H-Imidazo[1,2-c]thiazol-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt; n.(5R,6Z)-7-oxo-6-[(4-oxo-6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-2-yl)methylene]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid; o.6-(6,7-Dihydro-4H-thieno[3,2-c]pyran-2-ylmethylene)-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid; p.6-(6,7-Dihydro-4H-thieno[3,2-c]thiopyran-2-ylmethylene)-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid; q.6-(5-Methyl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-2-ylmethylene)-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid; r.2-(2-Carboxy-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-en-6-ylidenemethyl)-6,7-dihydro-4H-thieno[3,2-c]pyridine-5-carboxylicacid ethyl ester; s.7-Oxo-6-(6,7,8,9-tetrahydro-5H-imidazo[1,2-a]azepin-2-ylmethylene)-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid; t. (5R), (6Z)-6-(7-Benzyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazin-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid; u.(5R,6Z)-7-oxo-6-{[5-(pyridin-3-ylmethyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)]methylene}-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid; v.(5R,6Z)-7-oxo-6-{[5-(pyridin-3-ylcarbonyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)]methylene}-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid; w. (5R,6Z)-7-oxo-6-{[5-(phenylacetyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)]methylene}-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid; x. (5R),(6Z)-6-(5,5-Dioxo-4,5,6,7-tetrahydro-5λ⁶-pyrazolo[5,1-c][1,4]thiazin-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt; y. (5R),(6Z)-7-Oxo-6-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylmethylene)-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt; z.(5R)(6Z)-6-(5,5-Dimethyl-4H-1,6a-diazapentalen-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt 5,5-Dimethyl-2-piperidone; aa.(5R),(6Z)-6-(5,6-Dihydro-4H-cyclopenta[b]furan-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt; bb.(5R)(6Z)-6-(4,5-Dihydro-6-thia-1,7a-diazainden-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt; cc. (5R),(6Z)-6-(6,6-Dimethyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrizin-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt; dd. (5R),(6Z)-6-(5,6-Dihydro-8-H-imidazo[2,1-c][1,4]thiazin-3-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid; ee.(5R)(6Z)-7-Oxo-6-(4H-5-thia-1,6a-diazapentalen-2-ylmethylene)-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt; ff.(5R)(6Z)-6-(2,3-Dihydropyrazolo[5,1-b]thiazol-6-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt; gg.(5R)(6Z)-6-(2,3-Dihydropyrazolo[5,1-b]oxazol-6-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt; hh.(5R,6Z)-6-[(5-acetyl-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)methylene]-oxo-4-thia-1-azabicyclo[3.2.0.]hept-2-ene-2-carboxylicacid (E+Z Isomers mixture,Sodium salt); ii.(5R,6Z)-6-(6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid; jj. (5R)(6Z)-6-(6,7-5H-Dihydropyrazolo[5,1-b]oxazin-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt; kk. (5R), (6Z)-6-[5-(3-carboxypropionyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylmethylene]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-carboxylicacid,disodium salt; ll. (5R),(6Z)-6-[5-(2-methoxyacetyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylmethylene]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-carboxylicacid,sodium salt; mm.(5R),(6Z)-6-[5-(2-methoxyacetyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylmethylene]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-carboxylicacid,sodium salt; and nn. (5R),(6Z)-6-[5-(2-methoxyacetyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylmethylene]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-carboxylicacid,sodium salt.
 24. The compound according to claim 23 selected fromthe group consisting of i. (5R),(6Z)-6-(5,6-dihydro-8H-imidazo[2,1-c][1,4]thiazin-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt; ii. (5R),(6Z)-6-(6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-ylmethylene)-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt; iii. (5R),(6Z)-6-(5,6-dihydro-8H-imidazo[2,1-c][1,4]oxazin-2-ylmethylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt; and iv.(5R)(6Z)-7-Oxo-6-(4H-5-thia-1,6a-diazapentalen-2-ylmethylene)-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt.
 25. The compound according to claim 24: (5R),(6Z)-6-(6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-ylmethylene)-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylicacid, sodium salt.
 26. A method for the treatment of bacterial infectionor disease in a patient in need thereof which comprises providing tosaid patient an effective amount of a compound of formula I:

wherein: one of A and B is hydrogen and the other is an optionallysubstituted fused bicyclic heteroaryl group; X is O or S; R₅ is H, C1-C6alkyl, C5-C6 cycloalkyl, CHR₃OCOC1-C6alkyl; and R₃ is hydrogen, C1-C6alkyl, C5-C6 cycloalkyl, optionally substituted aryl, optionallysubstituted heteroaryl; or a pharmaceutically acceptable salt thereof.27. The method according to claim 26 wherein the compound isco-administered with a betalactam antibiotic.
 28. The method accordingto claim 27 wherein the ratio of β-lactam antibiotic to the compound isin a range from about 1:1 to 100:1.
 29. The method according to claim 28wherein the ratio of the β-lactam antibiotic to the compound is lessthan 10:1.
 30. The method according to claim 28 wherein the bicyclicheteroaryl group is

wherein Z1, Z2 and Z3 are independently CR₂, N, O, S or N—R₁ providedone of Z1-Z3 is carbon and is bonded to the remainder of the molecule;W₁, W₂ and W₃ are independently CR₄R₄, S, SO, SO₂, O, or N—R₁; with theproviso that no S—S or O—O or S—O bond formation can occur to form thesaturated ring system; t=1 to 4; R1 is H, optionally substituted C1-C6alkyl, optionally substituted aryl, optionally substituted heteroaryl ormono or bicyclic saturated heterocycles, optionally substituted C5-C7cycloalkyl, optionally substituted C3-C6 alkenyl, optionally substitutedC3-C6 alkynyl with the proviso that neither the double bond nor thetriple bond should be present at the carbon atom which is directlylinked to N; optionally substituted C1-C6 perfluoroalkyl, —S(O)_(p)optionally substituted alkyl or aryl where p is 0-2, optionallysubstituted —C=Oheteroaryl, optionally substituted —C=Oaryl, optionallysubstituted —C═O(C1-C6) alkyl, optionally substituted—C═O(C5-C6)cycloalkyl, optionally substituted —C═O mono or bicyclicsaturated heterocycles, optionally substituted C1-C6 alkylaryl,optionally substituted C1-C6 alkyl heteroaryl, optionally substitutedaryl-C1-C6 alkyl, optionally substituted heteroaryl-C1-C6 alkyl,optionally substituted C1-C6 alkyl mono or bicyclic saturatedheterocycles, optionally substituted arylalkenyl of 8 to 16 carbonatoms, —CONR₆R₇, —SO₂NR₆R₇, optionally substituted arylalkyloxyalkyl,optionally substituted -alkyl-O-alkyl-aryl, optionally substituted-alkyl-O-alkyl-heteroaryl, optionally substituted aryloxyalkyl,optionally substituted heteroaryloxyalkyl, optionally substitutedaryloxyaryl, optionally substituted aryloxyheteroaryl, optionallysubstituted C1-C6alkylaryloxyaryl, optionally substituted C1-C6alkylaryloxyheteroaryl, optionally substituted alkylaryloxyalkylamines,optionally substituted alkoxycarbonyl, optionally substitutedaryloxycarbonyl, or optionally substituted heteroaryloxy carbonyl; R₂ ishydrogen, optionally substituted C1-C6 alkyl, optionally substitutedC2-C6 alkenyl, optionally substituted C2-C6 alkynyl, halogen, cyano,N—R₆R₇, optionally substituted C1-C6 alkoxy, hydroxy; optionallysubstituted aryl, optionally substituted heteroaryl, COOR₆, optionallysubstituted alkyl aryloxy alkylamines, optionally substituted aryloxy,optionally substituted heteroaryloxy, optionally substituted C3-C6alkenyloxy, optionally substituted C3-C6 alkynyloxy, C1-C6alkylamino-C1-C6 alkoxy, alkylene dioxy, optionally substitutedaryloxy-C1-C6 alkyl amine, C1-C6 perfluoro alkyl, S(O)_(q)-optionallysubstituted C1-C6 akyl, S(O)_(q)-optionally substituted aryl where q is0, 1 or 2, CONR₆R₇, guanidino or cyclic guanidino, optionallysubstituted C1-C6 alkylaryl, optionally substituted arylalkyl,optionally substituted C1-C6 alkylheteroaryl, optionally substitutedheteroaryl-C1-C6 alkyl, optionally substituted C1-C6 alkyl mono orbicyclic saturated heterocycles, optionally substituted arylalkenyl of 8to 16 carbon atoms, SO₂NR₆R₇, optionally substituted arylalkyloxyalkyl,optionally substituted aryloxyalkyl, optionally substitutedheteroaryloxyalkyl, optionally substituted aryloxyaryl, optionallysubstituted aryloxyheteroaryl, substituted heteroaryloxyaryl, optionallysubstituted C1-C6alkyl aryloxyaryl, optionally substituted C1-C6alkylaryloxyheteroaryl, optionally substituted aryloxyalkyl, optionallysubstituted heteroaryloxyalkyl, or optionally substitutedalkylaryloxyalkylamine; R4 is H, optionally substituted C1-C6 alkyl, oneof R₄ is OH, C1-C6 alkoxy, —S—C1-C6 alkyl, COOR₆, —NR₆R₇, —CONR₆R₇; orR₄R₄ may together be=0 or R₄R₄ together with the carbon to which theyare attached may form a spiro system of five to eight members with orwithout the presence of heteroatoms selected from N, O, S═(O)_(n) (wheren=0 to 2), and N—R₁; and R₆ and R₇ are independently H, optionallysubstituted C1-C6 alkyl, optionally substituted aryl, optionallysubstituted heteroaryl, optionally substituted C1-C6 alkylaryl,optionally substituted arylalkyl, optionally substitutedheteroarylalkyl, optionally substituted C1-C6 alkylheteroaryl, or R₆ andR₇ can be together to form a 3-7 membered saturated ring systemoptionally having one or two heteroatoms selected from N, O, or S. 31.The method according to claim 27 wherein the bicyclic heteroaryl groupis

wherein Z1, Z2 and Z3 are independently CR₂, N, O, S or N—R₁ providedone of Z1-Z3 is carbon and is bonded to the remainder of the molecule;W₁, W₂ and W₃ are independently CR₄R₄, S, SO, SO₂, O, or N—R₁; t=1 to 4;Y₁ and Y₂ are independently N or C; with the proviso that if thearomatic ring portion of the bicyclic heteroaryl group is imidazole, thenonaromatic ring portion may not contain a S adjacent to the bridgeheadcarbon; R₁ is H, optionally substituted C1-C6 alkyl, optionallysubstituted aryl, optionally substituted heteroaryl or mono or bicyclicsaturated heterocycles, optionally substituted C5-C7 cycloalkyl,optionally substituted C3-C6 alkenyl, optionally substituted C3-C6alkynyl with the proviso that neither the double bond nor the triplebond should be present at the carbon atom which is directly linked to N;optionally substituted C1-C6 perfluoroalkyl, —S(O)_(p) optionallysubstituted alkyl or aryl where p is 0-2, optionally substituted—C=Oheteroaryl, optionally substituted —C=Oaryl, optionally substituted—C═O(C1-C6) alkyl, optionally substituted —C═O(C5-C6)cycloalkyl,optionally substituted —C═O mono or bicyclic saturated heterocycles,optionally substituted C1-C6 alkylaryl, optionally substituted C1-C6alkyl heteroaryl, optionally substituted aryl-C1-C6 alkyl, optionallysubstituted heteroaryl-C1-C6 alkyl, optionally substituted C1-C6 alkylmono or bicyclic saturated heterocycles, optionally substitutedarylalkenyl of 8 to 16 carbon atoms, —CONR₆R₇, —SO₂NR₆R₇, optionallysubstituted arylalkyloxyalkyl, optionally substituted-alkyl-O-alkyl-aryl, optionally substituted -alkyl-O-alkyl-heteroaryl,optionally substituted aryloxyalkyl, optionally substitutedheteroaryloxyalkyl, optionally substituted aryloxyaryl, optionallysubstituted aryloxyheteroaryl, optionally substitutedC1-C6alkylaryloxyaryl, optionally substituted C1-C6alkylaryloxyheteroaryl, optionally substituted alkylaryloxyalkylamines,optionally substituted alkoxycarbonyl, optionally substitutedaryloxycarbonyl, or optionally substituted heteroaryloxy carbonyl; R₂ ishydrogen, optionally substituted C1-C6 alkyl, optionally substitutedC2-C6 alkenyl, optionally substituted C2-C6 alkynyl, halogen, cyano,N—R₆R₇, optionally substituted C1-C6 alkoxy, hydroxy; optionallysubstituted aryl, optionally substituted heteroaryl, COOR₆, optionallysubstituted alkyl aryloxy alkylamines, optionally substituted aryloxy,optionally substituted heteroaryloxy, optionally substituted C3-C6alkenyloxy, optionally substituted C3-C6 alkynyloxy, C1-C6alkylamino-C1-C6 alkoxy, alkylene dioxy, optionally substitutedaryloxy-C1-C6 alkyl amine, C1-C6 perfluoro alkyl, S(O)_(q)-optionallysubstituted C1-C6 akyl, S(O)_(q)-optionally substituted aryl where q is0, 1 or 2, CONR₆R₇, guanidino or cyclic guanidino, optionallysubstituted C1-C6 alkylaryl, optionally substituted arylalkyl,optionally substituted C1-C6 alkylheteroaryl, optionally substitutedheteroaryl-C1-C6 alkyl, optionally substituted C1-C6 alkyl mono orbicyclic saturated heterocycles, optionally substituted arylalkenyl of 8to 16 carbon atoms, SO₂NR₆R₇, optionally substituted arylalkyloxyalkyl,optionally substituted aryloxyalkyl, optionally substitutedheteroaryloxyalkyl, optionally substituted aryloxyaryl, optionallysubstituted aryloxyheteroaryl, substituted heteroaryloxyaryl, optionallysubstituted C1-C6alkyl aryloxyaryl, optionally substituted C1-C6alkylaryloxyheteroaryl , optionally substituted aryloxyalkyl, optionallysubstituted heteroaryloxyalkyl, or optionally substitutedalkylaryloxyalkylamine; R₄ is H, optionally substituted C1-C6 alkyl, oneof R₄ is OH, C1-C6 alkoxy, —S—C1-C6 alkyl, COOR₆, —NR₆R₇, —CONR₆R₇; orR₄R₄ may together be=0 or R₄R₄ together with the carbon to which theyare attached may form a spiro system of five to eight members with orwithout the presence of heteroatoms selected from N, O, S═(O)n (wheren=0 to 2), and N—R₁; and R₆ and R₇ are independently H, optionallysubstituted C1-C6 alkyl, optionally substituted aryl, optionallysubstituted heteroaryl, optionally substituted C1-C6 alkylaryl,optionally substituted arylalkyl, optionally substitutedheteroarylalkyl, optionally substituted C1-C6 alkylheteroaryl, or R₆ andR₇ can be together to form a 3-7 membered saturated ring systemoptionally having one or two heteroatoms selected from N, O, or S. 32.The method according to claim 27 wherein the bicyclic heteroaryl groupis

wherein Z1, Z2, Z3 and Z4 are independently CR₂ or N provided one ofZ1-Z4 is carbon and is bonded to the remainder of the molecule; W₁, W₂and W₃ are independently CR₄R₄, S, SO, SO₂, O, or N—R₁; with the provisothat no S—S or O—O or S-0 bond formation can occur to form the saturatedring system; t=1 to 4; Y₁ and Y₂ are independently C or N; R₁ is H,optionally substituted C1-C6 alkyl, optionally substituted aryl,optionally substituted heteroaryl or mono or bicyclic saturatedheterocycles, optionally substituted C5-C7 cycloalkyl, optionallysubstituted C3-C6 alkenyl, optionally substituted C3-C6 alkynyl with theproviso that neither the double bond nor the triple bond should bepresent at the carbon atom which is directly linked to N; optionallysubstituted C1-C6 perfluoroalkyl, —S(O)_(p) optionally substituted alkylor aryl where p is 0-2, optionally substituted —C=Oheteroaryl,optionally substituted —C=Oaryl, optionally substituted —C═O(C1-C6)alkyl, optionally substituted —C═O(C5-C6)cycloalkyl, optionallysubstituted. —C═O mono or bicyclic saturated heterocycles, optionallysubstituted C1-C6 alkylaryl, optionally substituted C1-C6 alkylheteroaryl, optionally substituted aryl-C1-C6 alkyl, optionallysubstituted heteroaryl-C1-C6 alkyl, optionally substituted C1-C6 alkylmono or bicyclic saturated heterocycles, optionally substitutedarylalkenyl of 8 to 16 carbon atoms, —CONR₆R₇, —SO₂NR₆R₇, optionallysubstituted arylalkyloxyalkyl, optionally substituted-alkyl-O-alkyl-aryl, optionally substituted -alkyl-O-alkyl-heteroaryl,optionally substituted aryloxyalkyl, optionally substitutedheteroaryloxyalkyl, optionally substituted aryloxyaryl, optionallysubstituted aryloxyheteroaryl, optionally substitutedC1-C6alkylaryloxyaryl, optionally substituted C1-C6alkylaryloxyheteroaryl, optionally substituted alkylaryloxyalkylamines,optionally substituted alkoxycarbonyl, optionally substitutedaryloxycarbonyl, or optionally substituted heteroaryloxy carbonyl; R₂ ishydrogen, optionally substituted C1-C6 alkyl, optionally substitutedC2-C6 alkenyl, optionally substituted C2-C6 alkynyl, halogen, cyano,N—R₆R₇, optionally substituted C1-C6 alkoxy, hydroxy; optionallysubstituted aryl, optionally substituted heteroaryl, COOR₆, optionallysubstituted alkyl aryloxy alkylamines, optionally substituted aryloxy,optionally substituted heteroaryloxy, optionally substituted C3-C6alkenyloxy, optionally substituted C3-C6 alkynyloxy, C1-C6alkylamino-C1-C6 alkoxy, alkylene dioxy, optionally substitutedaryloxy-C1-C6 alkyl amine, C1-C6 perfluoro alkyl, S(O)_(q)-optionallysubstituted C1-C6 akyl, S(O)_(q)-optionally substituted aryl where q is0, 1 or 2, CONR₆R₇, guanidino or cyclic guanidino, optionallysubstituted C1-C6 alkylaryl, optionally substituted arylalkyl,optionally substituted C1-C6 alkylheteroaryl, optionally substitutedheteroaryl-C1-C6 alkyl, optionally substituted C1-C6 alkyl mono orbicyclic saturated heterocycles, optionally substituted arylalkenyl of 8to 16 carbon atoms, SO₂NR₆R₇, optionally substituted arylalkyloxyalkyl,optionally substituted aryloxyalkyl, optionally substitutedheteroaryloxyalkyl, optionally substituted aryloxyaryl, optionallysubstituted aryloxyheteroaryl, substituted heteroaryloxyaryl, optionallysubstituted C1-C6alkyl aryloxyaryl, optionally substituted C1-C6alkylaryloxyheteroaryl, optionally substituted aryloxyalkyl, optionallysubstituted heteroaryloxyalkyl, or optionally substitutedalkylaryloxyalkylamine; R₄ is H, optionally substituted C1-C6 alkyl, oneof R₄ is OH, C1-C6 alkoxy, —S—C1-C6 alkyl, COOR₆, —NR₆R₇, —CONR₆R₇; orR₄R₄ may together be=0 or R₄R₄ together with the carbon to which theyare attached may form a spiro system of five to eight members with orwithout the presence of heteroatoms selected from N, O, S═(O)n (wheren=0 to 2), and N—R₁; and R₆ and R₇ are independently H, optionallysubstituted C1-C6 alkyl, optionally substituted aryl, optionallysubstituted heteroaryl, optionally substituted C1-C6 alkylaryl,optionally substituted arylalkyl, optionally substitutedheteroarylalkyl, optionally substituted C1-C6 alkylheteroaryl, or R₆ andR₇ can be together to form a 3-7 membered saturated ring systemoptionally having one or two heteroatoms selected from N, O, or S. 33.The method according to claim 27 wherein the betalactam antibiotic isselected from the group consisting of a penicillin antibiotic and acephalosporin antibiotic.
 34. The method according to claim 33 whereinthe betalactam antibiotic is selected from the group consisting ofpiperacillin, amoxycillin, ticarcillin, benzylpenicillins, ampicillin,sulbenicillin, cefatrizine, cephaloridine, cephalothin, cefazolin,cephalexin, cephradine, aztreonam, and latamoxef.
 35. The methodaccording to claim 34 wherein the betalactam antibiotic is piperacillinor amoxycillin.
 36. The method according to claim 35 wherein thebetalactam antibiotic is piperacillin and is provided to the patientintravenously.
 37. The method according to claim 35 wherein thebetalactam antibiotic is amoxycillin and is provided to the patientorally.
 38. A pharmaceutical composition which comprises apharmaceutically acceptable carrier and an effective amount of acompound of formula I:

wherein: one of A and B is hydrogen and the other is an optionallysubstituted fused bicyclic heteroaryl group; X is O or S; R₅ is H, C1-C6alkyl, C5-C6 cycloalkyl, CHR₃OCOC1-C6alkyl; and R₃ is hydrogen, C1-C6alkyl, C5-C6 cycloalkyl, optionally substituted aryl, optionallysubstituted heteroaryl; or a pharmaceutically acceptable salt thereof.39. The composition according to claim 36 further comprising abetalactam antibiotic.